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In recent years, Stenotrophomonas maltophilia has not only gained importance 
due to its increasing prevalence in human disease around the world but because of its 
intrinsic multidrug resistance, which makes this bacterium an interesting model to study 
mechanisms of drug resistance while informing rational drug design and changes to 
chemotherapy protocols.  
Here, we aimed to identify novel mechanisms of resistance to ceftazidime, 
amikacin, levofloxacin, and minocycline. Overexpression of the chromosomally 
encoded serine-β-lactamase (SBL), L2, and metallo- β-lactamase (MBL), L1, is known 
to confer resistance to β-lactams, including ceftazidime. However, the mechanisms 
behind β-lactamase hyperproduction are not completely understood. Here, a new 
mechanism responsible for L1/L2 hyperproduction has been characterised: loss of 
function mutations in mpl which likely lead to accumulation of activator ligand for 
AmpR, the transcriptional regulator of L2 and L1. Additionally, for the first time a TonB 
energy-dependent mechanism is proposed for ceftazidime uptake where the alteration 
of a proline-rich region, deactivating TonB, is responsible for ceftazidime resistance in 
non-β-lactamase hyper-producers.  
Although reduced antimicrobial permeability in S. maltophilia due to 
upregulation of efflux-pumps is well known, little is known about their regulation. Here 
evidence is provided to associate SmeYZ aminoglycoside efflux pump upregulation 
with ribosomal damage caused by mutations in the rplA gene, encoding a ribosomal 
subunit target of aminoglycosides and by ribosomal-acting agents such as gentamicin. 
Alterations in genes involved in lipid trafficking were found to be associated with 
SmeDEF efflux pump upregulation. Two novel ABC transporters were shown to be 
involved in levofloxacin resistance and reduced minocycline susceptibility; each is 
locally regulated by a two-component system. Minocycline was found to be the most 
promising therapeutic agent and resistant mutants or clinical isolates could not be 
found. 
In addition to characterise last-line antimicrobials, the potential of non-classical 
β-lactamase inhibitors to restore β-lactam activity was studied. It was found that the 
diazabicyclooctane avibactam and the new bicyclic boronate 2 have potential to 
combat β-lactam resistance in S. maltophilia when compared to the traditional β-lactam 
based inhibitor, clavulanic acid based on microbiological, kinetic and structural 




antimicrobial activity (e.g. with ceftazidime) new combinations strategies 
(aztreonam/avibactam or aztreonam/bicyclic boronate 2) or new inhibitors (MBL 
inhibitors in combination with meropenem) showed significant promise. In addition, the 
sideromimic modification of γ-lactam antibiotic, lactivicin (LTV-17) was found tp 
increase its antimicrobial activity 1000-fold against S. maltophilia. Although LTV-17 
induces L1//L2 production, lactivicin is only slowly hydrolysed by β-lactamases. 
Therefore, LTV-17 antimicrobial activity is still strong against β-lactamase and efflux 
pump hyper-producing mutants, and extensively-drug resistant clinical isolates. 
Mutants with reduced LTV-17 susceptibility were identified, and were found to have the 
same loss of the TonB energy-transducer seen in ceftazidime resistant mutants. This 
work has given insight into the mechanisms of resistance in S. maltophilia to assist the 
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1.1 Origin of antibiotics 
 
Amongst the natural roles of secondary metabolites, the ecological role is only 
one explanation for their vast distribution (1). Secondary metabolites produced by 
microorganisms can be used to shape population density in a dynamic way. When 
secondary metabolites are antibiotics –natural products that eliminate other 
microorganisms- producers can prevent overgrowth of the community whilst non-
secondary-metabolite producers may have mechanisms to avoid the antibiotic 
meaning that the mixed population reaches an equilibrium (2, 3). The human body also 
produces antimicrobial chemicals (part of the innate immune system) which are active 
against bacteria, viruses, archaea, and lower eukaryotic cells that humans may come 
into contact with (4, 5). Yet despite the existence of a potent innate immune system, 
humans are susceptible to microbes as a cause of disease. This might be through 
excessive growth of indigenous (also known as commensal) microbes which has been 
associated with cardiovascular diseases, cancer and even neurodegenerative 
diseases (6-8). However, the most notorious impact of microbes on human health 
throughout history, is the presence and/or the disproportional growth of exogenous 
microorganisms that are pathogenic, and so can cause specific diseases. Given that 
the adaptive immune system is frequently insufficient at dealing with this exogenous 
threat, it is unsurprising that human have turned to technology to regain some sort of 
control over pathogenic microorganisms. To do this, humans have, pursued antibiotics 
obtained from a natural environments and used them to ‘tame’ the microbial 
populations that live within them, and can attack them, and so doing they have 
extended human lifespan.  
Alleviation of man’s ailments empirically started in Nature, even before humans 
associated the detrimental effects of infections with microorganisms. The earliest 
applications of natural extracts are described in Mesopotamian records, which are still 
used today to treat coughs and parasitic infections (9). However, infection outbreaks, 
during history, quickly demonstrated that humans needed to be more proactive to tilt 
the balance. Although adoptions of public health measures like vaccination, 
quarantine, or pasteurization clearly reduced the rate of infections, it was observation 
of the antibiosis phenomenon that accelerated this process (10). Observation of 
antibioses gave rise to the term ‘antibiotic’ to dsecribe those substances that alter 




kill the bacterial cell (bactericidal) (11). Interest in the isolation of antibiotics increased 
and with it the scrutiny of natural sources, methods of chemical synthesis and more 
recently bioengineered systems. 
Traditionally, natural compounds have constituted the platform for development 
of antibiotics. It is estimated that over the period 1981-2014, nearly 60% of the 
identified chemical entities with antimicrobial properties had a natural origin or were 
derived from a natural scaffold structures (12). It was Sir Alexander Fleming’s and 
Selman Waksman’s observations that pointed out fungi and bacteria as sources of 
antibiotics. In fact, these observations established the ‘golden era’ of antibiotic 
discovery (1940s-1960s) (Figure 1.1). The enormous success of soil-streptomycetes 
and soil-actinomycetes- antibiotics, against bacterial infections, quickly started to 
decline in the 1990s due to the rise and spread of antibiotic resistance (13). Nowadays, 
natural product discovery platforms are being enriched by exploring new environments, 
which in the past were not considered due to the limitations of recreating the growth 
conditions in the laboratory. Lichens, sponges, seaweed, corals and marine plants are 
providing interesting evidence for the next-generation of antibiotic scaffolds (14). 
The first successful compound with antimicrobial activity in clinical use was 
chemically obtained. Paul Ehrlich whose interest in understanding how substances 
were being up-taken by organisms led to explore the antimicrobial activity of 
arsenicals. Ehrlich obtained a bioactive compound, Salvarsan that killed the causing 
agent of syphilis (Treponema pallidum). Later, Salvarsan was known as the ‘magic 
bullet’ due to the killing effect it had on the target pathogen but not on the patient’s 
healthy tissue. Following the same line of discovery, Prontosil was tested by Gerhard 
Domagk and Ernest Fourneau’s groups and finally determined that the sulphonamide 
group in it was enough for the killing activity (15). Since then, research with synthetic 
antimicrobials has been carried out as an alternative way of generating innovative 
chemical skeletons after it became clear that searching for natural products led to 
continuous rediscovery of old molecules from natural platforms. Despite its innovation, 
the effectiveness of chemically synthesized antimicrobials has been limited due to the 
required chemical complexity of the molecules and with it restricted cell penetration 
properties. During the last 50 years only two successful classes of antibiotics have 






Figure 1.1 Timeline of Antibiotic Discovery 
Describes the introduction of different classes of antibiotics. 
Adapted from (12) 
 
 
Bioengineered systems have emerged as an approach to go beyond the 
limitations of natural and chemically synthesised antibiotics. In fact, combined efforts of 
synthetic biology and metabolic engineering have identified active biomolecules, with 
improved antimicrobial activity. The production of these secondary metabolites has 
been achieved due to the identification and manipulation of genetic elements that 
seem to be silent or cryptic, under specific conditions, and further tuning through 
manipulation of their respective regulatory elements in the biosynthetic pathways. The 
challenge remains to accurately identify these antibiotic biosynthetic genes (17).  
The ancient, natural origin of antibiotics shows that microbes have been in 
contact with antibiotics for many millions if not billions of years. Certainly, exposure to 
antibiotics did not start after the introduction of antibiotics into clinical practice. 
However, this contact did increase during the modern antibiotic era. The close 
relationship that humans have developed with antibiotics, during the last seven 
decades, has led to dramatic benefits for human health. But also has led to the 
selection of new, and pre-evolved resistance to antibiotics in bacteria. Our relationship 
with antibiotics is not over, but it will experience changes based on lessons learnt from 
the past and the rise of antibiotic resistance in the future. 
1.2 Use of antibiotics 
 
Antibiotics have found an application in many different human activities and are 




modern medicine. Surgical site infections have reduced after establishing guidelines 
for the prophylactic administration of antibiotics. Likewise, the successful outcome of 
other medical treatments such as cancer chemotherapy has been partially due to the 
prevention or cure of infections in those patients whose immune systems are 
compromised by chemotherapy (18). Even in those geographical areas where modern 
medicine has not reached its peak and sanitation systems are still poor, administration 
of antibiotics has controlled the spread and reduced the severity of communicable 
infections (19). Evidently, the use of antibiotics has reduced morbidity and mortality but 
most important has been a pivotal factor to increase life expectancy when combined 
with the virtues of medicine. 
The non-medical uses of antibiotics and synthetic antimicrobials include a wide 
range of activities from agriculture to domestic use. In animal husbandry, antibiotics 
have been used for growth promotion and as infection preventers where a large 
number of individuals are in contact. In plant agriculture, bacterial diseases are less 
prevalent; however, antibiotics are still used to protect the crops. In industries such as 
brewing production, the use of antibiotics increases starch fermentation by yeast by 
abolishing bacterial competition. In activities of daily living, numerous products that 
contain bioactive substances such as soap, shampoo, deodorants, facial cleaners, etc. 
kill potential harmful bacteria. The medley of anthropogenic activities represents a 
large fraction of the artificial presence of antibiotics in the ecosystem (20). 
Understanding the success of antibiotics throughout history has also revealed, 
at a slow pace, valuable reasons to explain their failure. The usefulness humans have 
found in antibiotics, has triggered their overuse. Thus, the constant exposure of 
bacteria to antibiotics has only accelerated the evolution of the natural mechanisms of 
antibiotic resistance in bacteria. By 1946, Fleming had already foreseen this 
phenomenon when he stated: ‘There is probably no chemotherapeutic drug to which in 
suitable circumstances the bacteria cannot react in some way acquiring fastness’. 
1.3 Antibiotics and their targets 
 
 Understanding bactericidal effect of antibiotics is focused on the study of the 
drug-target interactions that inhibit cellular functions. According to the cellular target, 
current antibiotics can be classified into three different types. Bacterial cell envelope is 
disrupted by, for example β-lactams, glycopeptides and polymyxins. Antibiotics that 




tetracyclines. Synthesis of nucleic acids is inhibited by quinolones, rifampicin, 
sulphonamides and trimethoprim (21).    
1.3.1 β-lactams 
 
1.3.1.1 Mechanism of action 
 
 The most prescribed antibiotics in clinics are β-lactams. β-lactams represent 
65% of the antibiotics market, comprising sales of US $15 billion per year (22, 23). 
Good activity against a wide range of Gram-positive and Gram-negative bacteria and 
good penetration in skin and soft tissues have made β-lactams a very popular choice in 
first-line therapy. β-lactams target, peptidoglycan (PG), a component present in the cell 
wall of Gram-positive and Gram-negative bacteria.  
PG is made of repeating subunits of a disaccharide N-acetyl glucosamine 
(NAG) and N-acetyl muramic acid (NAM) connected by oligopeptide stems. The PG 
unit is transported to the periplasm and joins to the end of extending glycan chain by 
the action of transglycosylases. The stem oligopeptides bound to NAM are cross-linked 
to the neighbouring stem oligopeptides by transpeptidases. Penicillin-binding-proteins 
(PBPs) are responsible for the polymerization and cross-linking of the peptidoglycan 
chains. As well as being transglycosylases, PBPs can have a DD-peptidase activity 
that includes DD-transpeptidase, DD-carboxypeptidase or DD-endo-peptidase activity. 
Some PBPs have dual activity. During transpeptidation; the double lysine-serine 
system, present in the active site of high-molecular weight PBPs such as PBP-1, 
PBP-2, PBP-3, is responsible for acylation and deacylation. Here, the penultimate 
D-Ala residue from the stem pentapeptide acylates the PBP obtaining an acyl-enzyme 
complex which leads to deacylation and removal of the terminal D-Ala residue, 
resulting in cross-linking of the reactive acyl-enzyme complex with the amino group of 
the third residue of the neighbouring stem oligopeptides. In Gram-negative bacteria the 
cross-linking is direct while in Gram-positives, such as Staphylococcus aureus, it 
occurs through a pentaglycine bridge or in the case of Enterobacterium faecium via a 
single D-Asp (24-27). 
β-lactams exert their bactericidal action on the transpeptidase PBPs anchored 
to the outer surface of the cytoplasmic membrane after entering into the cell via 
hydrophilic channels (porins) present in the outer membrane (Figure 1.2). The 
chemical structure of β-lactams mimics the D-alanyl-D-alanine terminus of the stem 
peptide that reacts with DD-peptidase PBPs (28). The main difference relates to the 




residue of the active site of PBPs which results in a stable acyl-enzyme complex which 
is no longer reactive. On its own, inhibition of cross-linking does not abolish cell wall 
biosynthesis but added to the active state of cell wall lytic transglycosylases, integrity 





Early work to obtain industrial quantities of penicillin showed that different 
producer strains grown at certain conditions produced different penicillin derivatives. 
Howard Florey’s group obtain 2-pentenylpenicillin from an English strain (Penicillium 
notatum) while in the United States, benzyl-penicillin was obtained from a different 
strain (Penicillium chrysogenum). However, the core structure in both types of penicillin 
was the β-lactam ring which results from the condensation of three amino acids (L-α-
aminoapidic acid, L-cysteine and L-valine) (28, 29). Based on these findings, chemists 
were interested on structure modifications to improve absorption in the human body 
but most important to increase the spectrum of antimicrobial activity (12, 30).  
1.3.1.3 Penicillins 
 
Penicillins contain a bicyclic ‘penam’ nucleus (Figure 1.3). This core results 
from the phusion of the rings of a β-lactam and a thiazolidine, and an acyl side-chain. 
In nature they are produced by some Penicillium and Aspergillus species (29). 
 
Figure 1.2 PBP-3 complexed with ceftazidime 





However, fermentation studies by workers at Beecham Pharmaceuticals in 1958-1960 
demonstrated that chemical synthesis of penicillin was not only possible but could also 
improve its antimicrobial activity (30, 31). A penicillin intermediate, 6-amino-penicillanic 
acid (6-APA), was obtained through fermentation from where different penicillin 
analogues could be obtained by its acylation with acid chlorides. The reasoning behind 
addition of different acyl side-chains to 6-APA was preventing β-lactam ring opening.  
The carbonyl group present in the ring can react with a neighbouring acyl group which 
ultimately renders an opened β-lactam ring (32). The strategy to prevent the opening is 
to add a bulky acyl side chain which gave place to the following penicillin derivatives: 
penicillinase-sensitive, penicillinase-resistant, aminopenicillins, antipseudomonal 
penicillins, and extended spectrum penicillins (33).  
 
Figure 1.3 Penicillin core 6-amino-penicillanic acid 
 
Penicillin G (benzylpenicillin) and penicillin V (phenoxymethyl-penicillin) belong 
to the penicillinase-sensitive group (Figure 1.4). β-lactamases, formerly known as 
penicillinases, are enzymes that can open the β-lactam ring which leads to its 
inactivation. The first penicillinase-resistant penicillin was methicillin which was 
obtained by the addition of a bulky acyl-side chain. Additional chemical modifications 
gave place to oxacillin, cloxacillin, dicloxacillin which offered a gamut of 
pharmacokinetic properties but with a narrow spectrum of activity. Aminopenicillins 
such as amoxicillin and ampicillin are not only effective against Gram-positive bacteria 
but also Gram-negatives, nevertheless they are still sensitive to β-lactamases. 
Carbenicillin and ticarcillin are resistant to some β-lactamases and possess a wider 
spectrum of activity against Gram-negative pathogens including Pseudomonas 
aeruginosa. The extended spectrum penicillins are not only effective against 95% of P. 







Figure 1.4 Representatives of penicillin groups 








Cephalosporin C was recovered from a fungus (Cephalosporin acremonium) 
found in sewer waters on the Sardininan Island in 1948.  Different from penicillins, the 
structure of cephalosporins include a six-membered dihydrothiazine ring, instead of a 
five-membered ring, fused to the β-lactam ring. Synthetic tailoring, to obtain 
cephalosporin analogues, was not an easy task since 7-ACA (7-amino-cephalosporin 
acid) could not be obtained by fermentation. Chemical modifications in 7-ACA were 
only possible, when 7-ACA was obtained in enough quantities as a result of a new 
method of chemical hydrolysis to eliminate the side chain of Cephalosporin C. Such 
modifications can occur in three different places: the carbon atom 7 or the acyl side 
chain of the β-lactam ring or the acetoxymethyl chain of the dihydrothiazine ring 
(carbon atom 3) (Figure 1.5) (32).  
 
Figure 1.5 Cephalosporins core 7-aminocephalosporin 
Cephalosporin C is the original cephalosporin that rendered 7-ACA to allow newer 
generations of cephalosporins. 
 
First-generation cephalosporins include cephalothin (2-thiopheneacetyl 
derivative), the first cephalosporin analogue, which was the result of a variation of the 
7-acylamino acid chain. In general, cephalothin has low affinity to PBPs of Gram-




bacilli but it is resistant to β-lactamases produced by Staphylococcus aureus. 
Cephaloridine instead, emerged from the substitution of the acetoxymethyl chain with a 
pyridinium group that increases activity against Gram-positive organisms. The methyl 
substitution at the same position with the appropriate 7-acylamino group gave place to 
cephalexin to increase the gut wall uptake but maintaining its antimicrobial activity (34, 
35).  
Second-generation cephalosporins include Cephamycin C which was the first 
β-lactam obtained from a bacterium (Streptomyces clavuligens). A methoxy variation at 
the carbon atom 7 with a variation of the side chain gave place to cefoxitin. Cefoxitin 
has an increased potency against Gram-positive and Gram-negative bacteria and 
reduced susceptibility to the hydrolytic activity of β-lactamases and mammalian 
esterases. Although the introduction of the α-oxymino group in the 7-acyl chain 
increases the affinity for PBP-3, e.g. to make cefuroxime; the antipseudomonal activity 
is still low (34, 35).  
Third-generation cephalosporins such as ceftazidime incorporated a new 
thiazolidine ring in the 7-acyl chain, which improved its bacterial penetration without 
compromising its target affinity. In Gram-negative organisms, low-dose ceftazidime 
leads to bacterial filamentation formation due to PBP-3 inhibition whereas at high 
concentrations inhibits PBP-1 and causes quick bacteriolysis (15, 36).  The 
appearance of β-lactamases capable of hydrolysing third-generation cephalosporins 
prompted a fourth generation of cephalosporins by maintaining the zwitterionic 
structure of the third-generation cephalosporins but adding an amino-thiazole side 
chain. Cefepime or BMY-28142 was more stable than other broad-spectrum 
cephalosporins against β-lactamases and had antipseudomonal activity (37, 38).  
Currently, use of fifth-generation cephalosporins such as ceftobiprole, is only approved 
in Europe. Ceftobiprole includes a vynilpyrrolidinone at carbon 3, which augments 
affinity for PBP-2 and explains its distinguished efficacy against methicillin-resistant S. 















Carbapenems include a β-lactam ring fused to a five-membered ring (pyrroline) 
but they differ from the penicillin and cephalosporin in three ways. In the 
five-membered ring, presence of a double bond between C2 and C3 and substitution of 
the traditional sulphur atom (in penicillins and cephalosporins) with a carbon atom, 
enhance the antimicrobial activity. Additionally to these changes, a hydroxyethyl group 
replaces the 7-acyl side chain, which is also responsible for the activity against multiple 
PBPs of Gram-Positive and Gram-negative bacteria, including P. aeruginosa and its 
slow hydrolysis in presence of β-lactamases (40). Thienamycin was the first 
carbapenem obtained from Streptomyces cattleya but it was chemically unstable. The 
first carbapenem analogue that did not have this instability was imipenem (41) which 
was obtained after the addition of a formamidine group at position C3. In general, 
imipenem has higher affinity for PBP-1a and works better against Gram-positive 
bacteria. Imipenem intravenous administration was successful therapeutically only 
when combined with the dehydropeptidase inhibitor cilastin, because imipenem is 
inactivated by renal dehydropeptidase DPH-1 (42), and cilastin inhibits this enzyme. 
Meropenem does not need to be administered with cilastin due to the presence of a 
methyl group in the pyrroline ring. The modification of the C2 side chain that includes a 
pyrrolidine group confers broad-spectrum activity, which is relative higher against 
Gram-negative pathogens when compared to imipenem (Figure 1.7) (43, 44). 
Doripenem does not require co-administration since it shares structural similarities with 
meropenem. When compared to imipenem, doripenem has a higher antipseudomonal 
activity due to its affinity to PBP-2 and PBP-3 in this particular species (45). Ertapenem 
instead has limited activity against P. aeruginosa but still effective against 
Gram-positive aerobic bacteria and Gram-negative enterobacteria producing β-
lactamase. Ertapenem only requires administration once a day and it is used as a 









Monobactams were discovered because of a screening that included soil 
bacteria such as: Acinetobacter, Agrobacterium, Chromobacterium, Pseudomonas. 
Chromobacterium violaceum was responsible of the production of the simplest form of 
monobactam 3-AMA (3-Aminomonobactamic acid) (Figure 1.8). Opposite to the 
previous structures of penicillins and cephalosporins, monobactams only have the 
β-lactam ring. Despite the weak activity, monobactams showed to have affinity for 
PBPs and surprisingly great stability in presence of β-lactamases. Aztreonam is the 
only monobactam commercially available and it is synthetic. The sulphur atom added 
to the β-lactam ring is responsible of its increased activity whilst the carbonyl and 
methyl groups in C4 confers resistance to β-lactamase activity (Figure 1.8). Finally, the 










1.3.2.1 Mechanism of action 
 
Over the past few decades, quinolones rose to become one of the most 
prescribed classes of antibacterial drugs after β-lactams (23, 50). Quinolones are 
based on the antimicrobial activity of a derivative from quinine production, which was 
initially considered a waste product (51). Further optimisation, lead to the first useful 
analogue, nalixidic acid, which prompted the synthesis of approximately 10000 
quinolones that over history have yielded more than 25 clinically approved 
compounds with broad spectrum activity (15). Quinolones target bacterial 
topoisomerases, responsible of modulating the separation of the DNA strands during 
replication and transcription (52). 
In E. coli, hydrophilic quinolones are up-taken through the porin OmpF (53) 
and have their action by the inhibition of topoisomerase II, also known as DNA 
gyrase; and topoisomerase IV (Figure 1.9). In an ATP-dependent process, DNA 
gyrase is responsible of generating negative supercoils in DNA. Negative supercoils, 
opposite to the direction of the DNA twist (54), alleviate the generated tension of the 
positive supercoils in the regions ahead and behind the replication fork during DNA 
synthesis (52, 55). DNA gyrase is a heterotetramer enzyme, which comprises two 
identical subunits (two GyrA and two GyrB). GyrA breaks the DNA to form a transitory 




is also responsible of re-sealing the 4-base pair gate whilst GyrB presents an ATPase 
activity. Although topoisomerase IV is also responsible for relaxing positive supercoils 
generated during DNA synthesis, its primary role is to unlink the resulting new DNA 
molecules at the end of replication. Topoisomerase IV is also a heterotetramer 
formed by ParC and ParE subunits. DNA gyrase and Topoisomerase IV form a 
complex with the DNA strands, between the tyrosine residues present in the active 
site and the 5’ end of the DNA break. Quinolones interact with the DNA-gyrase or 
DNA-topoisomerase IV complexes due to the presence of an Mg2+ ion. The water- 
Mg2+ ion bridges allow the interaction of quinolones and the serine and acidic 
residues of the complex. The quinolone-binding to GyrA changes the conformation of 
the enzyme to prevent the re-ligation of the broken DNA strands generated during the 
creation of the transient gate (52, 56), but ATP hydrolysis is not affected. In contrast, 
other topoisomerase-inhibitors such as the naturally occurring coumarins (novobiocin 




Figure 1.9 Topoisomerase IV-DNA –levofloxacin complex (PDB 3RAE) 








The quinolone group encompasses four generations of analogues. The first 
generation includes a naphthyridone, nalidixic acid, which presents a fused γ-
pyridone and benzene rings(58). Different from the original quinolone, isolated from 
antimalarial-drug production, naphthyridones possess a nitrogen atom in the benzene 
ring instead of the carbon atom C8 (51) (Figure 1.10). Initially, nalidixic acid had a 
limited use due to its narrow activity spectrum. Later, nalidixic acid became popular to 
treat urinary tract infections caused by enterobacteria, especially in cases of bacterial 
resistance to other antibiotics used at the time (59).  However, rapid emergence of 
resistance to nalidixic acid urged the synthesis of analogues (60). Both classes, 
naphthyridone and quinolones, were improved by the addition of a fluorine atom to 
the C6 position of the core structure. Improvement was evident by increased DNA 
gyrase inhibition and antimicrobial potency (51). However, quinolone classification 
tends to be restricted to fluoroquinolones since fluorinated naphthyridones are not 
common in developed countries (61, 62). The first fluoroquinolone obtained was 
flumequine. Flumequine preserved the good activity nalidixic acid had against Gram-
negative but offered the first approach to improve activity against  Gram-positive 
bacteria (60). The second generation of fluoroquinolones includes changes at 
position C7 and N1(51).  Piperazine at position C7 in norfloxacin improved 
antimicrobial activity against Gram-negative due to the direct interaction with 
topoisomerase II and IV(63). Norfloxacin was considered the first broad-spectrum 
fluoroquinolone. Nevertheless, its poor tissue penetration limited its use to 
genitourinary diseases(64). The addition of a cyclopropyl group to N1 position gave 
place to ciprofloxacin, which demonstrated to have an extended spectrum of activity, 
including anti-pseudomonal activity, better tissue penetration and thus improved 
activity outside the urinary tract (51, 64). Ofloxacin contains a methyl group in an 
oxazine ring that links N1 and C8. Interestingly, the S isomer has two-fold increased 
activity that the R isomer(53). The S-isomer of ofloxacin, levofloxacin, was assigned 
to the third-generation group since its activity against Gram-positive and Gram-
negative bacteria was higher which also implied the administration of a unique dosis 
per day (53, 62). Fourth-generation fluoroquinolones are mainly prescribed for 
respiratory infections since they present improved activity against Gram-positive 
bacteria and anaerobes (62). Moxifloxacin contains an azabicyclo at C7, a metoxy 






Figure 1.10 Quinolones core 
 







1.3.3.1 Mechanism of action 
 
Tetracycline use around the world is difficult to determine. In developing 
countries, consumption of tetracycline increases due to its low cost (23, 65). However, 
the underestimation of its use as a growth promoter for swine, poultry and in 
aquaculture alters the final values. This is particularly certain for countries like the 
United States, China and India, but not Europe where growth promoting uses of 
antibiotics are banned (66). In fact, in some European countries the general trend of 
antibiotic consumption has decreased such the case of Norway, Sweden and Finland 
(67). In 1947, the first member of the tetracycline group, chlortetracycline or 
aureomycin, was isolated from Streptomyces aureofaciens (68) whilst oxytetraycline or 
terramycin was obtained from Streptomyces rimous. Soon, these tetracyclines became 
very popular due to their broad-spectrum bacteriostatic effect on Gram-positive, 
Gram-negative, anaerobes, and intracellular pathogens. Whilst the typical mode of 
action of tetracyclines prevents elongation of the peptide chain by binding to the 30S 
ribosomal subunit  (32, 69), the atypical binding involves interaction with the bacterial 
cytoplasmic membrane (70).  
Tetracycline uptake in Gram-negative bacteria depends on porins and its 
lipophilic chemical structure, which allows its passage through the inner membrane of 
Gram-negative and Gram-positive bacteria. In Gram-negative bacteria, positively 
charged tetracycline-Mg2+ complexes traverse OmpF and OmpC porin channels and 
accumulate in the periplasm. Once in the periplasm the coordination complex releases 
the uncharged and lipophilic tetracycline, which crosses the cytoplasmic membrane by 
action of the proton motive force. Once in the cytoplasm, tetracycline is chelated by 
Mg2+ and the resulting complex is more likely to bind to the ribosome (71). Tetracycline 
binds to the S7 protein and the 16S rRNA, in the aminoacyl site (A-site) of the 30S 
ribosome (Figure 1.12). Here, the tetracycline binding prevents the association of the 
aminoacyl tRNA to the A-site of the ribosome. Tetracycline binding also inhibits the 
binding of release factors 1 and 2, which are responsible of the liberation of the 






Figure 1.12 30S ribosome complexed with tetracycline (PDB 1HNW) 




Tetracycline structure presents a basic core formed by naphthacene, four 
linearly fused aromatic rings (A, B, C, and D), where other functional groups have been 
attached to improve tetracycline antimicrobial activity (71). The minimal pharmacore is 





Figure 1.13 Tetracyclines core 
 
The first generation of tetracyclines include chlortetracycline, oxytetracycline, 
and tetracycline.  Chlortetracycline lacks a hydroxyl moiety at C5 in ring B but has a 
chlorine atom at C7 in ring D when compared to oxytetracycline. The simplest structure 
of the group is a chlortetracycline derivative that has lost its chlorine atom, tetracycline. 
In fact, chemical synthesis of tetracycline and posterior identification as a precursor of 
chlortetracycline during fermentation process confirm improved antimicrobial activity 
when compared to other members of the group. Second-generation tetracyclines 
include semi-synthetic tetracylines that emerged as an alternative to reduce toxicity 
and improve antimicrobial activity. Modification of the C-ring in oxytetracycline render 
methacycline, which was later used to obtained doxycycline. Other attempts to 
potentiate tetracycline involved manipulation of bioengineered strains from where 
demeclocycline was obtained and later used to produce a different intermediate, 
sancycline. Further modifications in C7, such as the addition of a dimethylamino group 
gave place to minocycline. Third-generation tetracycline includes complete synthetic 
analogues such as tigecycline. Tigecycline is minocycline derivative with a glycylamide 










1.3.4.1 Mechanism of action 
 
In 2014, the size of the global market for aminoglycosides was estimated to be 
USD 1.1 billion and it is expected to increase to USD 1.68 billion by 2022. 
Aminoglycosides are broad-spectrum antibiotics whose usage is likely to raise due to 
veterinary applications and administration for tuberculosis eradication (74). In 1944, 
streptomycin was the first aminoglycoside isolated obtained from Streptomyces 
griseus. Soon, streptomycin became the most important antibiotic after penicillin due to 




pseudo-oligosaccharides that alter protein synthesis by binding to the 30S ribosome 
(76).  
Aminoglycosides cannot cross the outer membrane through porins due to its 
size. Instead, aminoglycosides rely on its displacing action on Mg2+ bridges, between 
lipopolysaccharides, to traverse the outer membrane. Penetration through the 
cytoplasmic membrane implies an energy-dependent phase, EDP-I (77). Once in the 
cytosol, EDP-II allows aminoglycosides to bind to the conserved A-site present in 16S 
rRNA present in the small subunit 30S (Figure 1.15). Whilst the formation of the 
translation initiation complex remains intact, the proofreading process of the peptide 
chain changes. The aminoglycoside binding modifies the conformation of an internal 
loop in the A-site, which allows the integration of unrelated tRNA. Thus, 
aminoglycoside binding contributes to codon misread and inhibition of the translocation 
of the tRNA-mRNA complex from the A-site to the P-site, which alters the elongation of 
the peptide chain (77, 78). Later, these erratic proteins can be integrated into the 






Figure 1.15 30S complexed with paranomycin (1FJG) 




Natural and semi-synthetic aminoglycosides have a chemical core, which is 
neamine. Neamine is formed by a six-member aminocyclitol ring and a 
glucosaminopyranose (79). The aminocyclitol ring contains 2-deoxystreptamine 
(2-DOS), 1, 3 diamino groups and three or four hydroxyl groups to provide the link to 
aminosugars (Figure 1.16). In fact, the stereochemistry of the glycosidic bond between 
the neamine core and the carbohydrate is crucial for antibacterial activity of 





Figure 1.16 Aminoglycosides core 
 
 
According to the chemical modification on the neamine core, aminoglycosides 
can be grouped in three different classes: 4-monosubstituted, 4,5-disubstituted, and 
4,6-disubstituted (81). Apramycin represents monosubstituted aminoglycosides. In 
particular, apramycin has a veterinary application and it is the only aminoglycoside with 
a bicyclic ring linked to the neamine core. Neomicyn represents the group of 4, 
5-disubstituted aminoglycosides, but the group contains three subclasses according to 
the chemistry of their third ring additional modifications. Neomycin was originally 
isolated from Streptomyces fradiae. Administration of neomycin is not intravenous due 
to nephrotoxicity and ototoxicity. Kanamycin and tobramycin belong to one of the two 
subclasses of 4, 6-disubstituted aminoglycosides whilst gentamicin and amikacin 
belong to the other. Kanamycin was isolated from Streptomyces kanamyceticus, 
gentamicin from Micronospora purpurea, tobramycin from Streptomyces tenebrarius 
and amikacin is a semi-synthetic aminoglycosides derived from kanamycin. The 
difference between both groups responds to the chemistry of the third ring and the 
additional modifications. The third group of aminoglycosides is widely used in 
combination to treat infections caused by Gram-negative, Gram-positive and non-
typical mycobacterial infections including P. aeruginosa, Salmonella and Enterobacter 











1.4 Antibiotic Resistance 
 
As previously discussed, because antibiotics are or are derived from natural 
products, many bacteria have been exposed to antibiotics for millennia. This means 
that antibiotic resistance is also ancient. For example analysis of bacteria in ancient 
permafrosts has revealed collections of antibiotic resistance genes, which date back 
millennia (84). This ancient origin of antibiotic resistance means that it has been with 
us since the first use of these drugs.  At the end of the 1930s, sulfonamide resistance 
was reported in clinical practice as soon as it was introduced, the same mechanism 
that dominates 80 years later. In the 1940s, it was acknowledged that overuse of 
penicillin G promoted the selection of penicillinase producer strains. By the 1950s, 
common pathogens such as S. aureus had acquired resistance to all the available 
antibiotics of that time. A decade later, the introduction of semisynthetic versions of the 
previous failed antibiotics gave some hope. Shortly after introduction of new 
generations of antibiotics, new and improved mechanisms of resistance were reported 
(85) (Figure 1.18).  
 
Figure 1.18 First observed antibiotic resistance 
 
 
In the hospital setting where exposure to antibiotics is constant and bacterial 
population is numerous, a wide range of resistance mechanisms are seen. Hospital 
acquired (nosocomial) infections are responsible for 175000 deaths per year only in 
Europe, and as rates of resistance rise, death rates will also rise (86). In parallel, there 




to the rise of resistance few and far between. Pharmaceutical companies face high 
risks when investing in antibiotic discovery. Restricted antibiotic administration; when 
compared to neurological, cardiology or oncology products, translates into reduction of 
profits. Regulatory measures not only control the criteria used to test the efficacy of a 
new antibiotic but also its way of marketing. Changes adopted by FDA (Food and Drug 
Administration) or EMEA (European Agency for the Evaluation of Medicinal Products) 
have repercussions on costs and delays of clinical trials which ultimately can halt the 
development of a new antibiotic. Lastly, government institutions have only recognized 
the rising menace of antibiotic resistance during the last decade. Centers for Disease 
Control and Prevention (CDC), the World Health Organization (WHO) and the World 
Economic Forum accepted that the post-antibiotic era was no longer a distant future, 
but a worldwide reality that menaces public health (87). In 2014, the first global report 
by WHO revealed cases of resistance to ‘last resort’ antibiotic spread around the 
globe. Antibiotic resistance is a problem that affects directly or indirectly to every 
individual but being multifactorial requires concrete and multilateral approaches to be 
combated.  
If a threat is to be tackled then it must be first defined. The European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) defines antibiotic 
resistance as the result of having a surviving population of bacteria after antibiotic 
exposure whose phenotypic lack of susceptibility to the antibiotic in question renders a 
negative clinical outcome (88). Adopting standardized methods to identify antibiotic 
resistance has subsenquently contributed to resistance surveillance and ultimately 
prioritization of strategies against the more menacing resistant pathogens (89). In 
2017, the WHO priority pathogens list for research and development (R&D) of new 
antibiotics included three groups according to its level of resistance. In the critical level: 
Acinetobacter baumanii, P. aeruginosa, Mycobacterium tuberculosis, 
Enterobacteriaceae; in the high level: Enterococcus faecium, S. aureus, Helicobacter 
pylori, Campylobacter, Salmonella, Neisseria gonorrhoeae; and in the medium level: 
Streptococcus pneumoniae, Haemophilus influenzae, Shigella spp (90). These 
multidrug resistant bacteria (MDR), are often called ‘superbugs’ in the popular press, 
and belong to a larger classification separated in two groups. The first group includes 
those pathogens that belong to the normal human commensal flora but have acquired 
antibiotic resistance genes such as drug-resistant S. aureus and Escherichia coli. The 
second group includes those bacteria that only infect immunocompromised patients, 
also called opportunistic, such as P. aeruginosa, Stenotrophomonas maltophilia, 




Europe and also in the United States, approximately 25,000 people die each year 
because of a multidrug-resistant bacterial infection (91).  
1.4.1 Mechanisms of resistance- β-lactamase 
 
A penicillinase was the first β-lactamase identified in 1940. Since then more 
than 890 β-lactamases encoded by mobile genetic elements, plasmids and on 
chromosomes, have been documented. According to the amino acid sequence, the 
Ambler system groups these β-lactamases belong to four different classes: A, B, C, 
and D. Classes A, C and D are serine-β-lactamases (SBL) whose hydrolytic activity on 
β-lactams depends on the acylation of serine residue in the active site. Class B groups 
metallo-β-lactamases (MBL) whose hydrolytic activity involves the participation of zinc 
(92). 




Class A SBLs include penicillinases, extended spectrum β-lactamases (ESBLs) 
and carbapenemases. Penicillinases such as the sulfhydryl variant (SHV) in Klebsiella 
pneumoniae and the temoniera enzyme (TEM) in E. coli, H. influenza and 
N. gonorrheae are narrow spectrum and susceptible to long-established β-lactamase 
inhibitors such as clavulanic acid. Extended spectrum β-lactamases (ESBLs) were first 
identified as variants of SHV and TEM in E. coli and K. pneumoniae, but they have 
been extensively replaced by cefotaxime β-lactamases (CTX-M) in E. coli and 
Salmonella spp. ESBLs hydrolyze penicillins, cephalosporins, monobactams but not 
carbapenems. Class A carbapenamases comprise K. pneumoniae carbapenemase 
(KPC), and imipenem-hydrolyzing β-lactamases (IMI), Serratia marcescens enzyme 
(SME), Guiana extended-spectrum β-lactamase (GES), and non-metallo 
carbapenemase of class A (NMC-A). These carbapenamases have the ability to 
hydrolyze the last resort β-lactams (92, 93).  
Class C SBLs are predominantly cephalosporinases that 
hydrolyse, third-generation cephalosporins such as ceftazidime, cefotaxime and the 
cephamycin cefoxitin. Class C cephalosporinases are normally chromosomally 
encoded and produced at low basal levels; however, the presence of inducing agents 
such as amoxicillin or clavulanic acid raise the levels of production (in some species) 
and make them capable of conferring resistance to other β-lactams that they do not 




of a β-lactam inducer, carry stable regulatory mutations. Chromosomal class C 
cephalosporinases such as AmpC are present in Citrobacter freundii, E. coli, 
Enterobacter cloacae, Morganella morganii, Aeromonas species and P. aeruginosa. In 
enterobacteria, plasmid-encoded class C cephalosporinases can be present in strains 
with other types of β-lactamases and can also be inducible upon β-lactam challenge. 
An example of a plasmid-encoded class C cephalosporinase is cephamycinase (CMY), 
reported in enterobacteria (92, 94, 95).  
Class D SBLs are generally referred as OXA enzymes based on their ability to 
hydrolyze oxacillin. OXAs have been identified in A. baumani and P. aeruginosa, 
including those which have carbapenemase activity. Chromosomally encoded OXA 


















Figure 1.19 Classes of serine-β-lactamases and structural examples 
Penicillinases and examples (blue), cephaloporinases and examples (green), 
carbapenemases and examples (red). CTX-M-15 (PDB 4S2I chain A), AmpC 
(PDB 1FSY chain A), OXA-10 (PDB 5FQ9 chain A). Molecular visualization 
with NGL viewer from the set of tools from Galaxy platform 
(https://usegalaxy.org/) 
 
1.4.1.1.2 Mechanism of action of SBLs 
 
In general SBLs, hydrolyzes β-lactams in two steps. During the acylation step, 
the serine residue in the active site acts as a nucleophile to attack the β-lactam and 
form an enzyme-substrate acyl complex. During the deacylation reaction, a water 




opened β-lactam ring and the enzyme active site is regenerated. In the first step, a 
general base is needed to change the serine residue to a catalytic state. In the second 
step, a general base is required to deprotonate the water molecule during deacylation. 
Class A, C and D SBLs differ in the general bases they use for acylation and 
deacylation step (96). 
Class A SBLs use Lys73 and Glu166 as general bases for acylation and 
deacylation, respectively. Losing Lys73 stops the reaction whilst loss of Glu166 
decreases the kinetic rate. However, when the active site is at the apo-state, Lys73 is 
protonated and Glu166 deprotonated, which would make it unlikely for Lys73 to act on 
Ser70 to facilitae nucleophilic attack on the β-lactam. Quantum mechanics/molecular 
mechanics (QM/MM) have suggested that the mere binding of the enzyme in the apo-
state with the substrate leads to changes that deprotonate Lys73, but there is no 
experimental evidence. Additionally, it is not entirely elucidated how the general base 
changes from Lys73 to Glu166 during acylation and deacylation (96). In class C SBLs, 
Lys67 has the same role as Lys73 in acylation whilst Tyr150 executes the role of 
Glu166 in deacylation. A molecule that reduces the kinetic rate of deacylation can act 
as an inhibitor for class C SBLs (97). Class D SBLs distinguish themselves from other 
SBLs by the presence of a carboxylated lysine in charge of both stages, acylation and 
deacylation (98) .  




Class B β-lactamases group four subclases (B1, B2, B3 and B4), all of which 
are referred to as metallo-β-lactamases (MBLs) because of their use of zinc ion (s) in 
the active site (99).  Subclasses B1 and B3 MBLs have a broad spectrum of activity, 
which includes penicillins, cephalosporins and carbapenems. B2 MBLs only need one 
zinc atom in the active site. To date, the majority of MBLs identified are in subclass B1. 
These enzymes include imipenamase (IMP), Verona integron-encoded metallo- β-
lactamases (VIM), New Dehli metallo- β-lactamases (NDM) which are found in mobile 
elements (and are passed from bacterium to bacterium) in Enterobacteriaceae, 
P. aeruginosa, A. baumanii, E. coli, K. pneumoniae (73, 100).  
Subclass B2 MBLs have a narrower and deeper active site when compared to 
B1 and B3, which might explain their poor activity against penicillins and 
cephalosporins and almost exclusive activity against carbapenems. The most studied 




Aeromonas and Sfh-I in Serratia fonticola (101). Subclass B3 MBLsare also 
chromosomally encoded, the group includes enzymes such as L1 from S. maltophilia, 
GOB from Chryseobacterium meningosepticum, FEZ-1 from Legionella gormanii and 
the first identified mobile enzyme in the group Adelaide Imipenemase (AIM-1) in 
P. aeruginosa (101, 102) (Figure 1.20). Subclass B4 MBLs includes SPR-1 in Serratia 
proteamaculans which has a unique homologue in CSA-1 from Cronobacter sakazakii 
(103). Similarly to B1 and B3, B4 MBLs bind two zinc atoms in the active site (99). 
Within the group of β-lactams susceptible to the action of MBLs, monobactams such as 
aztreonam are excluded. 
 
Figure 1.20 Relevant classification of metallo-β-lactamases 
Metallo-carbapenamases and examples (red). NDM-1 (PDB 3SPU chainA), CphA 
(PDB 2GKL), L1 (PDB 1SML). Molecular visualization with NGL viewer from the set 
of tools from Galaxy platform (https://usegalaxy.org/) 
 
1.4.1.2.2 Mechanism of action of MBLs 
 
The presence of the zinc atom is essential for the hydrolytic activity of MBLs. In 




His118, His196) whilst Zn2 interacts with Asp120, Cys221, and His 263 (104, 105). In 
class B2 MBLs the binding of Zn1 to Asn 116, His118, His196 makes it catalytically 
active whilst the binding of Zn2 to Asp 120, Cys 221 and His263 inhibits the enzyme 
(105, 106). B3 enzymes have a similar 3H site except that His116 can also be Gly116, 
and Zn2 binds to Asp120, His 121 and His 262. 
In general, the hydrolytic mechanism of MBLs involves two steps: cleavage of 
the amide bond and protonation of the generated intermediate. With the substrate 
binding, the Michaelis complex (ES) is established and with it the positioning of the 
water/hydroxide molecule between the two zinc atoms. The bridging water, being a 
nucleophile, attacks the carbonyl carbon (C7) which leads to the cleavage of the C-N 
bond (an opened β-lactam ring) and formation of an anionic nitrogen intermediate 
stabilised by Zn atoms (EI).  The intermediate becomes protonated and an EP complex 
is formed before the product release (105, 107).  
1.4.2 β-lactamase inhibitors 
 
The search for β-lactamase inhibitors started in the 1970s. β-lactamase 
inhibitors can bind irreversibly or reversibly which implies covalent or non-covalent 
binding to the active site, respectively. During irreversible binding, covalent interactions 
with β-lactamases prevent a rapid dissociation of the inhibitor, in contrast to reversible 
inhibition (108, 109). Reversible inhibitors are poor substrates with high affinity but low 
hydrolysis rates. In general, irreversible inhibitors are considered better inhibitors since 
they inactivate the enzyme (110). 
1.4.2.1 β-lactam based inhibitors 
 
β-lactamase inhibitors were first conceived as irreversible that mimick the 
binding of a β-lactam in the active site of an SBL. The first of this class to be 
discovered was clavulanic acid which was originally obtained from Streptomyces 
clavuligerus. Clavulanic acid has a five-membered ring, fused to a β-lactam ring, where 
the sulfur atom has been replaced by an oxygen atom. An acylamino side chain is 
absent in the β-lactam ring. Clavulanic acid is considered a suicide irreversible inhibitor 
since its fragmentation (β-lactam ring opening by the catalytic action of a serine 
residue) produces an initial acyl-enzyme intermediate that reacts with a nucleophilic 
group to render a long lived transient intermediate that ultimately will proceed to 
inactive the enzyme (32). Clavulanic acid is particularly efficient against Ambler class A 




Other β-lactam based inhibitors are tazobactam and sulbactam which are 
penicillinate sulfones. Both conserve the sulfur atom in the ring attached to the β-
lactam ring, but tazobactam has an additional triazole group at C2 position. Sulbactam 
is slightly more active than clavulanic acid against cephalosporinases, but the triazole 
group in tazobactam improves its potency against class A and C β-lactamases. In fact, 
tazobactam inhibits P99 cephaloporinase from Enterobacter cloacae with less than 20 
turnovers of inhibitor per enzyme. The number of turnovers before the inactivation of 
the enzyme determines the potency (110). Additional experimental β-lactam based 
inhibitors include tazobactam analogues such as  AAI101, penam sulfones such as 
LN-1-255, sulbactam analogues such as BAL19764 and bridged monobactams such 
as BAL29880 (111).  
1.4.2.2 Non-β-lactam based inhibitors 
 
Diazabicyclooctanones (DBOs) non-β-lactam based inhibitors whose structures 
were inspired in anti-Bredt bicyclo γ-lactams which were originally obtained to inhibit β-
lactamases and PBPs but required structural optimisation (112, 113). Avibactam was 
the first of the series to be approved for use in clinics. What is particularly interesting 
about avibactam is its unique mode of binding, covalent reversible binding from where 
dissociation of the enzyme releases intact avibactam. Avibactam has nanomolar 
affinity for class A, C and some D SBLs and it has gained approval to be combined 
with ceftazidime, and soon with ceftaroline or aztreonam to restore antimicrobial 
activity against Gram-negative bacteria (Figure 1.21). Relebactam is an avibactam 
analogue that has an additional piperidine group in the DBO ring and similar activity 
against β-lactamases except for the class D carbapenemases OXA-48 (108, 114). 
Nacubactam has a carboxamide side chain which inhibits SBLs as well as PBP2. 
ETX2514 is still in pre-clinical development and contains a substitution in the piperidine 
ring which confers more reactivity and diffusion through the cell membrane (111).  
Boronic acid based compounds have been known as inhibitor for serine 
enzymes for decades. Acyclic boronates inhibit human serine hydrolases, however the 
active site of SBLs is wider and can accommodate cyclic boronates. Vaborbactam was 
the first in the series to be approved for clinical use for its nanomolar affinity towards 
Ambler class A, C and D SBLs. Optimisation to obtain a SBL/MBL inhibitor led to RPX-
7282, which exhibits good activity against all β-lactamases. Most recently, bicyclic 
boronates have been found to be another class of pan-β-lactamase inhibitors, which 




1.4.2.3 Zinc-binding inhibitors 
 
Sulfur based compounds provided the first hint to design MBL inhibitors since 
zinc binds to the sulphur atom. Thiomandelic acid was the first to show micromolar 
affinities for a broad range of MBLs (Figure 1.21). The azolythioacetamide provided a 
scaffold for triazolylthioacetamide that inhibit the important class B1 MBL, NDM-1. 
Thiol ester derivatives inhibit the class B3 MBL L1 and release mercaptoacetic acid 
which were the first inhibitors obtained based on the mechanism of inhibition and are 
active against NDM-1 and L1. L- and D- captopril contain thiol and carboxylate groups 
capable of forming coordination bonds with the zinc atoms in the binding site of all MBL 
subclasses. Thiazolidine derivatives such as bisthiazolidines share homology with β-
lactams and inhibit all MBL subclasses through different modes of binding (Figure 
1.21) (115).  
Other attempts to obtain zinc-binding inhibitors include carboxylate or 
phosphonate groups, derivatives from benzoic acid, dipicolinic acid, maleic acid, and 
more recently triazole (111).  
1.4.2.4 Zinc-chelating inhibitors 
 
An alternative form to design inhibitors is to hijack the zinc atom required for the 
mechanism of action of MBLs. EDTA is effective but unspecific, especially when 
considering that human metallo-enzymes often also require zinc. Aspergillomarasmine 
A derives has four carboxylate groups that sequester the zinc atoms. Similarly, spiro-
indoline-thiadiazole and macrocyles such as NOTA and DOTA have been shown to 
chelate zinc atoms to restore carbapenem activity against MBL producing bacteria 
(Figure 1.21) (111).  
1.4.2.5 Covalent inhibitors 
 
Covalent inhibition has been reported for urease activity in the presence of 
β-mercaptoethanol and 1, 4 benzoquinone. Ebselen is a selenium containing 
compound that binds with the class B1 MBL, NDM-1 due to the opening of the 
selenazol ring (Figure 1.21). 
The search of a universal β-lactamase inhibitor is limited due to tigh profile that 
these inhibitors need to fulfil such as cellular uptake, low cytotoxicity, in vitro efficacy, 











1.4.3 Mechanisms of resistance - Aminoglycoside modifying enzymes 
 
Aminoglycosides can be modified by the activity of acetyltransferases (AACs), 
aminoglycoside phosphotransferases (APHs), and nucleotidyltransferases (ANTs). 
AACs acetylate -NH2 groups in the 2-deoxystreptamine or the sugar groups by using 
acetyl coenzyme A (Figure 1.22). Acetylation can occur at positions: 1 [AAC (1)], 
2’ [AAC (2’)], 3[AAC(3)], or 6’[AAC(6’)] (116).  
 
Figure 1.22 AAC(6')-Ib in complex with CoA (PDB 2PRB) 
 














Aminoglycosides molecules can also be altered by APH phosphorylation. 
Depending on where the modification occurs, classes of APHs include: APH (4), APH 
(6), APH (9), APH (3’) (Figure 1.23). APH (2’’), APH (3’’) and APH (7’’) (116). 
 
Figure 1.23 APH(3') Ia complexed with kanamycin (PDB 4GKH) 
 
Structure displays seleno-methionene residues. Molecular visualization with NGL 
viewer from the set of tools from Galaxy platform (https://usegalaxy.org/) 
 
1.4.4 Mechanisms of resistance - reduced antibiotic penetration into cell  
 
The outer membrane of Gram-negative bacteria contains a bilayer of 
lipopolysaccharides and phospholipids where specific water-filled uptake channels 
named porins and ligand-gated porins are embedded. While alterations in the number 
or type of porins in the outer membrane can reduce the rate of entry of antibiotic, inner 
membrane multidrug efflux transporters, (including major facilitator superfamily 
transporters, resistance-nodulation division type efflux pumps, ATP-binding cassette or 
ABC transporters) can reduce the antibiotic concentration in the cell by their active 
expelling from the cytoplasm to the exterior (117).  
1.4.4.1 Major Facilitator Superfamily (MFS) efflux pumps 
  
Active antibiotic efflux by MFS antiporters is attributed to their capacity of using 
the potential energy stored in a chemical gradient across the cytoplasmic membrane 




transmembrane spanning segments (TMS), grouped in a N-terminal and C-terminal 
domain, and an aqueous cavity between the two domains (119) (Figure 1.24). Based 
on this structure, it has been determined that the substrate-binding site originally faces 
one side of the membrane but after binding the conformation of the site alters, to 
present it to the other side (120). In Gram-negative bacteria, MFS transporters work as 
a monomer or in association with membrane fusion proteins and, outer membrane 
proteins as a so-called ‘tripartite’ pump to transport antibiotics not only to the periplasm 
but to the exterior of the cell (121).   
 
Figure 1.24 Example of MFS efflux pump complexed with chloramphenicol 
Structural representation of MdfA MFS exporter in E. coli (PDB 4ZOW). Molecular 
visualization with NGL viewer from the set of tools from Galaxy platform 
(https://usegalaxy.org/) 
 
1.4.4.2 Resistance Nodulation Division (RND) type antibiotic efflux pumps 
 
RND efflux pumps are located in the inner membrane and their drug efflux 
function relies on the proton motive force. They are connected to a periplasmic protein 
adaptor, known as a membrane fusion protein (MFP) and so to an outer membrane 
protein (OMP). These three proteins work as a tripartite complex that spans the cell 





Figure 1.25 RND-Transporter 
 
Structural representation of AcrAB-TolC (PDB 5V5S) RND efflux pump. Molecular 
visualization with NGL viewer from the set of tools from Galaxy platform 
(https://usegalaxy.org/) 
 
1.4.4.3 ATP Binding Cassette Superfamily (ABC) efflux pumps 
 
ABC-type efflux pump proteins, contain two domains for ATP binding and two 
transmembrane domains (Figure 1.26). The ATP binding domains, signatures of ABC 
transporters, are well conserved in prokaryotes and eukaryotes. Key domains, Walker 
A and B, are involved in ATP hydrolysis and Mg2+ ion coordination. After ATP 
hydrolysis, conformational changes in the transmembrane domains allows transport 






Figure 1.26 ABC transporter 
 
Structural representation of MsbA ABC transporter in E. coli (PDB 6BPL). Molecular 
visualization with NGL viewer from the set of tools from Galaxy platform 
(https://usegalaxy.org/) 
 
1.4.5 Other mechanisms of resistance  
 
1.4.5.1 Target modification and protection 
 
Target site modification or protection is not as prevalent as mechanism that 
alter or prevent entry of the drug, but two good examples that reveal the complexity are 
aminoglycoside and tetracycline resistance. These antibiotic classes prevent protein 
synthesis by impeding the binding of tRNAs to the ribosome in the A-site. To 
compensate this effect, bacteria can either reduce influx, increase efflux, modify the 
antibiotic or overexpress the target (125). In fact, aminoglycoside resistance for 
example can arise from mutations occurring in the 16S rRNA where the 
aminoglycoside binding occurs or in ribosomal proteins, important for antibiotic 
interaction, such as rpsL. Alternatively overexpression of the 16S rRNA can hijack the 




be altered by methylation of the binding site due to the action of 16S ribosomal 
methyltransferases (126).  
Tetracycline resistance occurs due to the ribosomal assisted protection which 
include TetM and TetO that act on the ribosome-tetracycline complexes to remove the 
antibiotic (127, 128). Similarly, pentapeptide repeat proteins (PRPs) bind to 
quinolone-toporisomerase complex to release the antibiotic fron the binding site (129).  
  
1.5 Overview of S. maltophilia 
 
The ability of S. maltophilia to survive on humid surfaces increases its chances 
of colonising medical devices that breach the natural barriers of immunity in patients, 
such as ventilators, nebulizers, and catheters (130). Consequently, it is not surprising 
that S. maltophilia infections are mainly ventilator associated lower respiratory tract 
infections and catheter related, and bloodstream infections. It also causes, skin and 
soft tissue, bone and joint and urinary tract infections. S. maltophilia also causes an 
increasing number of infections but also in cystic fibrosis patients (130).  
The first record of the bacterium now known as S. maltophilia is attributed to a 
specimen isolated from pleural fluid in 1943 in the UK. Originally, the isolate was 
named ‘Bacterium bookeri NCTC 6572’ but further morphological, physiological and 
serological characterisation demonstrated that ‘Pseudomonas maltophilia’ was a better 
designation to describe a group of microorganisms that fulfil certain biochemical and 
physiological attributes such as strict aerobic growth, yellow pigmented colonies, 
maltose metabolism, and uni, bi or multi-flagellated (131). Later, comparative 
biochemical and molecular biological characterisation suggested a transfer of P. 
maltophilia to the genus Xanthomonas. However, results based on 16S RFLP led to 
Stenotrophomonas emerging as a completely new genus. The genus belongs to the 
Gammaproteobacteria class and includes eight species: S. maltophilia, S. 
nitritireducens, S. rhizophila, S. acidaminiphila, S. koreensis, S. chelatiphaga, S. terrae 
and S. humi. The only species known to be a human pathogen is S. maltophilia (132). 
In fact, S. maltophilia pathogenesis might respond to its environmental niche, which 
makes it a ubiquitous organism. 
1.5.1 Prevalence and clinical relevance 
 
The most susceptible population to S. maltophilia infections are debilitated 




malignancy, organ transplantation, HIV infection, cystic fibrosis, extended 
hospitalization, intensive care unit stay, mechanical ventilation, indwelling catheters, 
therapy with immunosuppresors and previous antibiotic therapy (131). However, S. 
maltophilia infections are not limited to hospitalized patients. Community infections 
were frequently associated with at least one of the risk factors mentioned above (133).  
The first report of S. maltophilia as a human pathogen was in 1980. Since that 
time, its isolation has become more frequent, especially in patients with neutropenia 
after exposure to chemotherapy and patients with indwelling catheters. In 1990, 
surveillance programs started to provide information about the prevalence of 
S. maltophilia. First locally such as the Canadian Ward Surveillance Study 
(CANWARD), the British Society for Antimicrobial Chemotherapy (BSAC) Resistance 
Surveillance Project, the Taiwan Surveillance of Antimicrobial Resistance  (TSAR) and 
then global surveillance programs such as the SENTRY Antimicrobial Surveillance 
Program launched in 1997 and the Study for Monitoring Antimicrobial Resistance 
Trends (SMART), in 2002 (134). However, the closest estimation of the actual 
prevalence of S. maltophilia as a cause of infection in the general population comes 
from comparison of large surveillance studies over time. From 1997-2003 the 
prevalence of S. maltophilia infection in the general population, globally, increased 
from 0.8-1.4% and from 1.3-1.68% during the period 2007-2012 (135, 136). It is not 
surprising that the prevalence in intensive care units is higher than in general 
population (1.4-3%) (134).  Until 2004, SENTRY reported 1.2% prevalence as a cause 
of infection in children ≤ 7 years and 1.4% in children ≤ 18 years. According to WHO S. 
maltophilia is classified as a leading multidrug-resistant organism in hospital settings 
(nosocomial infection) (137). Attributable mortality to S. maltophilia infections ranges 
from 21-69% that can reduce when the initial drug therapy is adequate (138, 139).  
Aside from bacteraemia and pneumonia, S. maltophilia is also associated with 
biliary sepsis, infections of the bones and joints, urinary tract and soft tissues, eye 
infections, endocarditis, meningitis, anatomic abnormalities and surgical manipulation 
(140). As stated before, S. maltophilia is a cystic fibrosis (CF) associated pathogen 
whose prevalence in CF patients increases with age. The CF Foundation Patient 
Registry (CFFPR) determined a remarkable increase in S. maltophilia prevalence from 
1988-2012. This can be attributable to an improved methodology in diagnosis and 
report in microbiology laboratories but also to the extended lifespan, long-term 
antimicrobial exposure, and possibly person-person transmission. However, S. 
maltophilia infections in CF patients seem to be acquired from 




exposure. Since S. maltophilia can be found in natural environments, it is advisable for 
CF patient to avoid prolonged exposure to soil, and not appropriately chlorinated pools 
or stagnant water. The healthcare sources associated to S. maltophilia in CF patients 
are not totally understood but in non-CF patients S. maltophilia infections have been 
linked to water sources (sink drains, faucets, potable water) and use of moisturizing 
lotion, instead of soap, by healthcare staff (141). 
1.5.2 Diagnosis 
 
Standard techniques allow diagnosis of S. maltophilia. However, culture based 
identification can be prone to error and is time consuming. For example, hematological 
diagnosis of S. maltophilia takes 4.5 days including the result from blood culture (142). 
When a patient has sepsis every hour of delay in the diagnosis represents a 7% 
increase in mortality (143). Since the determination of the genome sequence of 
S. maltophilia strain K279a faster and more accurate methods of diagnosis have been 
developed (144). A 5-plex real-time PCR nucleic acid diagnostics assay (NAD) was 
designed to identify and quantify the presence of S. maltophilia in water sources but 
demonstrated to be an assay applicable in clinics (145). A loop-mediated isothermal 
amplification (LAMP) method allowed to detect the L1 metallo-β-lactamase, with little 
amounts of DNA and within one hour (146). Target enriched multiplex PCR 
(TEM-PCRTM) can be used to detect S. maltophilia in a bloodstream infection. A 
peptide nucleic acid (PNA) probe allows S. maltophilia identification using fluorescence 
in situ hybridization (FISH) within 90 minutes with 100% sensitivity and specificity on 
pure culture and sputum samples from cystic fibrosis patients (147). Matrix-assisted 
laser desorption ionization-time-of-flight mass spectrometry (MALDI-ToF MS) has 
enabled identification of non-fermenting Gram-negative bacteria, including S. 
maltophilia (148). In fact in reference units  such as antimicrobial resistance and 
healthcare associated infections reference unit (AMRHAI) in the UK, MALDI-ToF MS 




S. maltophilia has gained its reputation due to the limited options in treatment. 
The combination of trimethoprim and sulfamethoxazole (TMP-SXT), co-trimoxazole, is 
frequently the first antibiotic choice against S. maltophilia infections. The course of 




synthesis of tetrahydrofolic acid, which is needed for the synthesis of thymidine, 
purines, and bacterial DNA. On the one hand, sulfamethoxazole, a para-aminobenzoic 
acid (PABA) analogue prevents the synthesis of one of the precursors of 
tetrahydrofolic acid, dihydropteroic acid by inhibition of dihydropteroate synthase. On 
the other hand, trimethoprim, a pteridine analogue, prevents the reduction of 
dihydrofolate to tetrahydrofolate by inhibition of dihydrofolate reductase. Abolishing two 
steps in one metabolic pathway leads to a bactericidal activity (150). However, side 
effects such as allergic reactions and concentration-dependent toxicity, and the 
presence of resistance mechanisms limit its use in S. maltophilia (151). 
The Clinical and Laboratory Standards Institute make available guidelines to 
test alternative antimicrobial agents against S. maltophilia using disc diffusion and 
microtitre both dilution (MIC methodology). Apart from co-trimoxazole, 
chemotherapeutic options against S. maltophilia infections include monotherapy or 
combination of the following drugs: ceftazidime, ticarcillin-clavulanate, minocycline, 
tigecycline, chloramphenicol, polymyxins, ciprofloxacin, and levofloxacin (135, 152). 
Although some of them exhibit good in vitro activity, reported success in clinical 
settings is limited (135). 
 
1.6 Antibiotic Resistance Mechanisms in S. maltophilia 
 
The sequenced genome of a representative Group A strain of S. maltophilia, 
K279a, identifies the presence of several elements to which intrinsic antimicrobial drug 
resistance is attributed. S. maltophilia phylogenetic Group A includes homogenous 
isolates in terms of their 16s rRNA and smeT-smeD intergenic region sequences (153). 
These resistance mechanisms include: limiting the entrance of antibiotic by 
permeability alterations in the cell envelope, active efflux of the antibiotic once it is in 
the cell, enzymatic mechanisms that destroy or modify the drug that prevents the 
action of the antibiotic (154). For example, the low overall outer-membrane 
permeability, due to the low abundance of porins, interferes with the drug cellular 
uptake. Likewise, the presence of nine RND-efflux pumps (most notably SmeDEF, 
SmeYZ and SmeIJK) confers resistance to fluoroquinolones, chloramphenicol, 
aminoglycosides and tetracycline due to drug extrusion, when these pumps are over-
produced following mutation. Modifying enzymes, such as the class B3 MBL L1 and 





1.6.1 β-lactam resistance in S. maltophilia 
 
1.6.1.1 β-lactamase production  
  
S. maltophilia has two chromosomally encoded β-lactamases. L2 is an SBL that 
belongs to the ESBL subclass of the Ambler class A (156). L1 is a tetrameric MBL that 
belongs to Ambler subclass B3 (157) . L1 and L2 both confer resistance to 
cephalosporins and penicillins, and uniquely to carbapenems in the case of L1 and 
monobactams in the case of L2 (158).  
In order to exert their hydrolytic activity on these β-lactams, mature 
β-lactamases must be translocated from the cytoplasm to the periplasm. The systems 
involved in this process are Sec and Tat. While the Sec system exports unfolded 
proteins, the Tat system transfers folded proteins. Before translocation, immature 
eproteins contain a signal peptide that contains 24 amino acids on average and once 
in the periplasm is cleaved. In S. matophilia, L2 is Tat dependent and L1 is exported by 
Sec system (159). Despite having different export systems, expression of both 
β-lactamases shares some regulatory elements, such as the transcriptional activator, 
AmpR, that belongs to the ampR-L2 module (160).  L1 and L1 production can be 
induced in the presence of a β-lactam or hyperproduced as a result of mutations in the 
regulatory circuit that controls induction. 
The major mechanisms involved in β-lactamase induction is the AmpG-AmpR-
AmpC pathway (26) (Figure 1.27). In S. maltophilia as in other Gram-negatives, during 
cell growth and division, lytic tranglycosylase enzymes (LT) cleave the glycan strand 
between NAM and NAG, and form an exposed anhydro-NAM and an endopeptidase 
breaks the cross-linking between stem oligopeptides. Then anhydro muropeptide 
monomers (NAG-anhydro-NAM-peptides) are liberated and transported into the 
cytoplasm through the inner membrane transporter AmpG where NAG is removed by 
the glycoside hydrolase NagZ. The final products, 1,6-anhydroNAM-oligopeptides, are 
transformed by a series of enzymes to UDP-NAM-pentapeptides which are PG 
precursors that can be recycled into the PG biosynthesis pathway, but also they can be 
sensed by the transcriptional regulator AmpR to induce the production of β-lactamase 
(26).β-lactams activate β-lactamase production by increasing the breakdown of PG, 
and so the abundance of the AmpR activatory ligand. A negative effector that reduces 
the expression of β-lactamase is the amidase AmpD which can remove stem peptides 
from anhydro-NAM thus reducing the concentration of the AmpR activator ligand 






Figure 1.27 β-lactamase production via AmpG-AmpR 
Muropeptides (GlcNAc-1, 6 -anhydroMurNac tri, tetra, and pentapeptides are recycled 
from the periplasm through AmpG where NagZ removes GlcNAc. Then, the NagZ-
processed product can induce β-lactamase (AmpC in Enterobacteria and P.aeruginosa or 
L2 in S. maltophilia) production by binding to AmpR, or be further processed by AmpD 
that excises the peptides from GlcNAc-1,6-anhydro-MurNAc and 1, 6-anhydroMurNac. 
PG degraded products will then be recycled as UDP-MurNAc peptides which act as 
repressor ligands of AmpR. Inactivation of the enzymes involved or β lactam exposure 
cause accumulation of degraded products that activate AmpR. 
 
 
As well as being more commonly attributed to an AmpR mediated mechanism, 
induction of β-lactamase production and so β-lactam resistance has also been 
attributed to the two-component regulatory system (TCRS) in some bacteria (26). 
Recently, proteomics analysis revealed the increase of two members of different TCRS 
in S. maltophilia after imipenem challenge: and integral membrane sensor histidine 
kinase (Smlt3765) and a GGDEF response regulator (Smlt4295) (161). However, the 





1.6.2 Quinolone resistance in S. maltophilia 
 
1.6.2.1 Smqnr gene 
 
Smqnr is a chromosomally-encoded pentapeptide repeat protein that is related 
to the Qnr proteins encoded on mobile genetic elements in Enterobacteriaceae (162-
164). Qnr proteins share some similarity to proteins involved in DNA-replication 
protection such as McbG and MfpA. These proteins are DNA mimics that bind to the 
DNA gyrase and topoisomerase IV. Similarly, it is believed that Qnr binds to the region 
of these topoisoemerases that are the quinolone target sites, thus protecting the 
targets from antimicrobial activity (64, 165).   
1.6.2.2 SmrA (ABC transporter) 
 
SmrA was the first ABC transporter identified in S. maltophilia. SmrA has been 
found to have 70.8 % similarity with VcaM from Vibrio cholerae. SmrA and VcaM are 
half-transporters since they have two fused homodimeric subunits. Although the 
regulator for SmrA is unknown, its role it quinolone resistance has been demonstrated 
by expression in a heterologous host, E. coli (164, 166). It is usual to find ABC 
transporters regulated by two-component systems (TCSs) which  are normally 
encoded contiguously to the transporter(167). 
1.6.2.3 SmeDEF (RND efflux pump) 
 
A major determinant for quinolone resistance in S. maltophilia is the 
overexproduction of the RND efflux pump, SmeDEF, which is encoded by an operon. 
SmeD is an AcrA homologue, found in E. coli which is an MFP whilst SmeE shows 
61% homology to the RND efflux protein AcrB (Figure 1.25), in E. coli. AcrA contains 
four domains: α-helical, lipoyl, β-barrel and membrane-proximal. SmeE is predicted to 
have 12 TMS as AcrB does, and two periplasmic loops (168). In AcrB, the periplasmic 
portion contains a porter and a funnel domains. The porter domain, closer to the inner 
membrane, contains two substrate-binding pockets composed of aromatic, polar and 
charged amino-acids that facilitates the interaction of a broad range of substrates. 
During substrate-binding, AcrB changes its conformation due to protonation of the 
structural repeats of the trans-membrane. Thus, only drug efflux is allowed and its 





1.6.3 Tetracycline resistance in S. maltophilia 
 
1.6.3.1 SmtcrA (MFS transporter) 
 
S. maltophilia posses a bicistronic operon that encodes SmqnrR (DeoR-type 
regulator) and SmtcrA (MFS transporter). This operon is located upstream of the 
Smqnr quinolone resistance gene. In some strains, deletion of the repressor regulator 
increases SmtcrA production, which is responsible for tetracycline resistance. 
However, the effect of the regulator deletion on quinolone resistance due to Smqnr 
expression might be strain-specific (170, 171). 
1.6.3.2 SmeDEF and SmeIJK (RND efflux pumps) 
 
Resistance to tetracycline is mainly attributed to tefflux by SmeDEF and 
SmeIJK. SmeIJK is particularly interesting since the MFP SmeI can form a complex 
with the RND transporters SmeJ or SmeK. While the overexpression of smeIJK 
confers tetracycline resistance, disruption of either smeJ or smeK restores 
susceptibility to some extent (172, 173).   
1.6.3.3 SmrA (ABC transporter) 
 
SmrA not only confers resistance to quinolones but also tetracyclines. 
However, the resistant phenotype has only been described for laboratory strains and 
not for clinical isolates. Later, expression of smrA was assessed in a collection of 450 
S. maltophilia isolates. Here, levels of smrA expression between tigecycline 
susceptible and non-susceptible strains did not reveal significant differences. Instead, 
tigecycline resistance was attributed to SmeDEF (174).  
1.6.4 Aminoglycoside resistance in S. maltophilia 
 
1.6.4.1 Aminoglycoside modifying enzymes 
 
In S. maltophilia, putative AAC (2’) and AAC (6’)-Iz are cromosomally encoded. 
In general, the AAC (6’)-I class is mainly active against amikacin but some variants can 
also act on gentamicin and quinolones. Despite low expression of AAC (6’)-Iz, this 
enzyme is capable of contributing to confer resistance to amikacin (175). Other 
variants such as AAC (6’)-Ib can accommodate structurally different substrates due to 
the plasticity of its active site (176, 177). S. maltophilia has a cromosomally encoded 





1.6.4.2 SmeIJK, SmeOP, SmeYZ (RND efflux pumps) 
 
Aminoglycosides are a substrate for many RND trasnporters including 
SmeABC, SmeIJK, SmeOP, and SmeYZ. SmeOP-TolCSm is regulated by the 
upstream located repressor, SmeRo. Disruption of smeOP or smeRo increase the level 
of susceptibility to aminoglycosides (179). Likewise, a role in aminoglycoside 
resistance has been attributed to SmeYZ overexpression. Again, regulation of smeYZ 
expression is controlled by a two-component system, SmeSyRy (180).  
1.6.4.3 MacABCsm (ABC transporter) 
 
The ABC transporter, MacABCsm, present in S. maltophilia contributes to 
aminoglycoside resistance. MacABCsm is constitutively expressed and besides its role 
in antimicrobial resistance posesses physiological roles related to cell protection during 
envelope and oxidative stress (181).   
1.6.5 Horizontal gene transfer 
 
Integrative and conjugative elements such as transposons, integrons, plasmids, 
and genomic islands contribute to the horizontal spread of acquired resistance  (182). 
In S. maltophilia, resistance to the TMP-SXT combination, which is the drug of choice 
is the result of a class 1 integron containing sul1 gene (130, 182). In addition, a 
high-level of ampicillin resistance has been attributed to the presence of the gene 
blaTEM in a Tn1/Tn3-type transposon in one clinical isolate (183). However, the low 
frequency of finding integrons and plasmids would suggest that they are not the major 
mechanisms for the dissemination of antibiotic resistance in S. maltophilia (184). 
Which, as discussed above, relies on intrinsic resistance mechanisms, and mutations 
that upregulate them for the few antimicrobials that have clinical efficacy.  
 
1.7 Aims of the project 
 
S. maltophilia is an emerging and relatively poorly studied pathogen, the overall 
am of the work reported in this thesis was to better characterise mechanisms of 
antibacterial drug resitance and to test the ability of novel antibacterials and inhibitors 




To follow up previous work from the groups that concluded that there are at 
least two uncharacterised mechanisms of ceftazidime resistance: one novel 
mechanism causing β-lactamase hyperproduction and one that does not involve 
β-lactamase hyperproduction. We set out to identify and characterise these 
mechanisms. 
To follow up on previous work from the group reporting SmeYZ efflux pump 
mediated aminoglycoside resistance and SmeDEF efflux pump mediated 
fluoroquinolone resistance by identifying the reasons for SmeYZ or SmeDEF 
overproduction in each case. Also to select and characterise the mechanisms used by 
mutants resitant to minocycline and levofloxacin since ther are considered valid 
therapies when co-trimoxazole cannot be administered. 
To evaluate the activity of various β-lactamase inhibitors in combination with 
various β-lactams against highly drug resistant S. maltophilia mutants and clinical 
isolates and to identify the spectrum and mode of activity of, and mechanisms of 
resitance to these combinations 
To evaluate the antimicrobial activity of chemically modified lactivicin antibiotics 
against a collection of S. maltophilia clinical isolates, and to evaluate mechanism of 















2 Materials and Methods 
 
2.1 Bacterial isolates and materials 
 
S. maltophilia clinical isolates here used originated from the SENTRY 
antimicrobial resistance survey and have been previously described (185, 186) or were 
isolated from patients being treated at the Bristol Oncology Centre (183). Isolates of 
other species were either obtained from type strain collections, or were clinical isolates 
collected by SENTRY and gifted by Dr Mark Toleman, Cardiff University, or have 
previously been described (187). The ceftazidime resistant, β-lactamase hyper-
producing mutants K CAZ 10 (188), KCAZ14 (188), KM11 (160), have previously been 
described. Mutants K AMI 8, K AMI 32, K MOX 2 and K MOX 8 were selected using 
K279a as parent strain as described previously (189). All growth media were from 
Oxoid. Chemicals were from Sigma, unless otherwise stated. LTV13 was re 
synthesized according to the literature protocol and kindly provided by Prof. C. 
Schofield, University of Oxford (190). LTV17 was kindly supplied by Pfizer. Avibactam 
was supplied by AstraZeneca whilst cyclic boronate 2 was synthesised according to 
published protocols (191) and provided by Prof. C. Schofield, University of Oxford. 
Likewise hydroxylcoumarin cephalosporin, FC5, (192) has been previously described 
and was provided by Prof. C. Schofield, University of Oxford. Synthesis of PMPC-1 
(3a) has been reported previously (193) and provided by Dr. Gary I. Dmitrienko, 
University of Waterloo. E. coli strains such as DH5α chemically competent cells 
(ThermoFisher) were used in DNA manipulation experiments while SoluBL21 (DE3) 
cells (Gentlantis) were used for protein expression. 
2.2 Primers and plasmids 
 
Primers used in this study are described in Table 2.1 Plasmid maps are 








Table 2.1 Primers used in this study 
Primer Sequence (5’-3’) Observation 
L2 Express F aag ttc tgt ttc agg gcc cgG CGG GCA AGG CCA 
C 
pOPINF-L2 
L2 Express R atg gtc tag aaa gct tta TCC GAT CAA CCG GTC 
GGC 
pOPINF-L2 
mpL_F1 ACCAGATCCAGGTACCGCC  
mpL_R1 GTGGCCGACTGATCGTCAA  
mpL_F2 CCAGTGCACATCGCCCATTG  
mpL_R2 TCTCACATCCCGTGTAGGACT  
rplA_F  GCGAAGGAACCGGATCTGA  
rplA_R  CGCCTGCGGTCTTTGAC  
rplAfull_NotI_F AAAGCGGCCGCATCCAGCTGTAGAGTCGAGC +NotI 
rplAfull_Not_I_R AAAGCGGCCGCCTGCGGTCTTTGACGGCTAC +NotI 
ampR (+) ATGTTGCACCCTACCCTG  
ampR (-) TGGTCTGCGATACCTACT  
Smlt_0009_F AAAGAATTCAGTAGGAATAACGCCTGAATGC +EcoRI 
Smlt_0009_R AAAGAATTCTGACGCTTACCTTTGTTGTGTG +EcoRI 




Smlt2644_F AAAGAATTCTTGGAGCCACTGTGGAGATTG +EcoRI 
Smlt2644_R AAAGAATTCGGTGGGTCGGGGGTAGAGT +EcoRI 
Smlt1636_F AAAGAATTCGAGGATGGCTGCGCATGAT +EcoRI 
Smlt1636_R AAAGAATTCCAGCAACATCGGCATCTGGA +EcoRI 
M13F GTAAAACGACGGCCAGT  
M13R AACAGCTATGACCATG  
* SmeZQ-F TGTCCAGCGTCAAGCACC   
*SmeZQ-R GCCGACCAGCATCAGGAAG   
*rDNA-F GACCTTGCGCGATTGAATG  ++rrnB 
* rDNA-R CGGATCGTCGCCTTGGT  ++rrnB 
*Primers used for RT-qPCR 
+Restriction site included in the primer sequence 





Figure 2.1 Map of pOPINF vector 
pOPIN contains an ampicillin selection marker AmpR, two important restriction sites 
KpnI and HindIII to linearize the vector since the 6X His (cyan) has been strategically 







Figure 2.2 Map of pBBR1MCS-5 
pBBR1MCS-5 is just one of a series of vectors designed for multiple hosts. 
pBBR1MCS-5 confers resistance to gentamicin. Multiple Cloning site (green) starts 
with KpnI and ends with SacI. Insertion of DNA can be confirmed using universals 
M13 primers. pBBR1MCS-1 confers resistance to chloramphenicol, pBBR1MCS-4 
confers resistance to ampicillin. 
 
2.3 Selection of resistant mutants 
 
K279a mutants were selected after exposure to ceftazidime discs on MHA by 
picking the colonies within the zone of inhibition after using a bacterial suspension that 
was 100-fold higher than the recommended value according to the CLSI 
guidelines(194). Lactivicin resistant mutants, minocycline resistant mutants, and 
levofloxacin resistant mutants were selected by plating 100 µL of an overnight culture 






2.4 Siderophore Detection 
 
100 µL of an overnight culture was used to set up a fresh subculture in 10 mL 
of MHB which was then incubated until the OD600 reached 0.5. Cells were centrifuged 
(4,000 x g, 10 min) and the resulting pellet was resuspended in 10 mL of PBS and 
centrifuged again (4,000 x g, 10 min). The supernatant was discarded and the pellet 
was again resuspended in fresh PBS (10mL) and centrifuged (4,000 x g, 10 min). 
Washed bacterial pellet was then diluted in PBS to prepare a bacterial suspension of 
OD600 0.2. Ten microliters of the bacterial suspension were spotted on Chrome Azurol 
S (CAS) agar. CAS agar was made up mixing up 90 mL of MHA and 10 mL of freshly 
made CAS solution. 100 mL of the CAS solution was made up based on the following 
description: 60.5 mg of CAS in 50 mL of water, 72.9 mg of hexadecyltrimethyl 
ammonium bromide HDTMA in 40 mL of water, and 10 mL of 1 mM FeCl3, 10 mM HCl) 
(195). CAS agar control included 100 µM FeCl3 where no colour change was expected. 
2.5 Determining minimal inhibitory concentrations (MICs) of antimicrobials and 
disc susceptibility testing 
 
The Clinical and Laboratory Standard Institute (CLSI) protocol was followed for 
disc-test susceptibility testing (196). The clearing zone was measured after 20 h of 
incubation and values reported as susceptible or resistant according to the CLSI 
published breakpoints (197). Reduced susceptibility is reported in comparison to a 
reference strain (K279a) when the difference between clearing zones strain was ≥ 5 
mm. 
MICs were determined using CLSI broth microtitre assays (194) and interpreted 
using published breakpoint (197). Briefly, a PBS bacterial suspension was prepared to 
obtain a stock of OD600=0.01. Antibiotic stocks were prepared considering the 
breakpoint value for resistance according to the CLSI guidelines and then diluted 
1:1000 to use it as the starting concentration from where the two-fold serial dilutions 
proceed. Final volume in the 96-well cell culture plates (Corning Costar) was 200 µL, 
obtained by combination of 180 µL of the antibiotic solution and 20 µL of the bacterial 
suspension. Bacterial growth was determined after 20 h of incubation by measuring 
OD600 values using a POLARstar Omega spectrophotometer (BMG Labtech). The well, 
corresponding to the antibiotic concentration, with an OD600 equivalent to a baseline 





2.6 β-lactamase production/induction assays 
 
To measure the amount of β-lactamase produced by bacteria in the absence or 
presence of different potential inducing agents, 100 µL of an overnight culture of 
bacteria was diluted in 10 mL of NB and grown at 37°C until OD600 was 0.4.  
Prospective inducer (s) were then added, or not, as necessary and incubation 
continued for 2 h before cell extracts were prepared.  
2.6.1 Preparation of cell extracts 
 
Cells from a 10 mL culture were pelleted by centrifugation (4,000 x g, 10 min) 
and pellets resuspended in 100 µL of BugBuster (Ambion. Pellets were transferred to 
1.5mL microtube (Eppendorf) before rocking at 70 rpm for 30 min at room temperature. 
Cell debris and unlysed cells were pelleted by centrifugation (13,000 x g, 5 min) and 
the supernatant retained as a source of crude cell protein. Protein cell extracts 
obtained from using the sonication and concentration method described in 2.11 were 
also used for some experiments. Protein concentrations in cell extracts were 
determined using the BioRad protein assay dye reagent concentrate. Briefly, 10 µL of 
cell extract was combined with 90 µL of the dye reagent and volume was made up to 1 
mL with water. OD599 was measured and Equation 1 used to calculate the protein 
concentration. The conversion factor was obtained based on a calibration curve using 







𝑂𝐷599 = 𝑜𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 
𝑥 = [𝑛𝑔. µ𝐿−1] 
 
2.7 β-lactamase activity assay 
 
β-lactamase activity in crude cell extracts was determined using a POLARstar 
Omega plate spectrophotometer (BMG Labtech). A meropenem (100 μM) or nitrocefin 
(40 μM) solution was used as a substrate, each prepared in filtered (0.2 µm) assay 




MgSO4·7H2O, 100 µM ZnCl2). Meropenem hydrolysis assay were performed using 
half-area 96-well UV-translucent plates (Greiner UV-Star. Bio-one), 90 µL of 100 μM 
meropenem was combined with 10 µL of the cell extract. Nitrocefin hydrolysis assays 
were performed in Corning Costar 96-well flat bottomed cell culture plates with a 
combination of 1 µL of cell extract and 179 µL of nitrocefin solution.  For meropenem, 
substrate depletion was followed at 300 nm for 10 min whilst for nitrocefin hydrolysis, 
product accumulation was measured at 482 nm for 5 min. Final β-lactamase activity 












𝐴∗ = 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑝𝑒𝑟 𝑚𝑖𝑛 
Calculated as the linear phase of the reaction in Omega Data Analysis 
 
𝑒 = 𝑒𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 (𝑀−1. 𝑐𝑚−1) 
9600 M-1cm-1 for meropenem, 17400 M-1cm-1  for nitrocefin 
 
𝑙 = 𝑝𝑎𝑡ℎ𝑙𝑒𝑛𝑔𝑡ℎ (𝑐𝑚) 
Pathlength for liquid in a well in a 96-well plate = 0.56 cm for nitrocefin and 
0.62cm for meropenem 
 
1000000 
Conversion to obtain activity in nmol.mL-1 
 
𝑣 = 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 (𝑚𝐿) 





𝑥 = 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛𝑔. µ𝐿−1) 
 
𝑣𝑝𝑜 = 𝑣𝑜𝑙𝑢𝑚𝑒𝑛 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑢𝑠𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑎𝑠𝑠𝑎𝑦 (µ𝐿) 
 
2.8 Steady-state kinetics and inhibitory concentration (IC50) measurement 
 
Recombinant L1 and L2 proteins were produced in E. coli and purified as 
described in (198) and (2.9). Steady state kinetics were determined by assaying 
enzyme activity using a POLARstar Omega (BMG Labtech) fluorescent plate reader 
using L1 assay buffer (50 mM HEPES pH 7.5, 10 µg/mL BSA, 10 µM ZnSO4  and 
0.01% v/v Triton X-100) or L2 assay buffer (50 mM Tris pH 7.5, 10 µg/mL BSA and 
0.01% v/v Triton X-100). Reactions were carried out as described in (192). Reactions 
were set up in black flat-bottomed 96-well plates (Greiner Bio-one, Stonehouse, UK) 
with a final volume of 100µL. Final reaction contained 50 pM enzyme and a series of 
two-fold serial dilutions of the fluorogenic substrate FC5, enabling to measure product 
accumulation at eight different concentrations at the excitation wavelength 380nm and 
emission wavelength at 460 nm. A similar process was used for chromogenic 
substrates meropenem, ceftazidime and aztreonam, but for these, spectrophotometric 
assay of substrate depletion was measured at 300 nm, 260 nm, 318 nm, respectively 
in half-area 96 well UV-translucent plates (Greiner UV-Star. Bio-one).  
 To determine IC50s of inhibitors against L1 and L2, assays were performed in 
black flat-bottomed 384-well plates with a final volume of 25 µL with enzyme 
concentration 50 pM, FC5 substrate concentration 5 µM, inhibitor concentration ranged 
from 1 nM-2.5 mM. Volumes of buffer, enzyme and substrate were dispensed using 
Multidrop Combi Reagent Dispenser (Thermo Scientific) whereas tested inhibitors 
were dispensed with Cybi-well (CyBio). Steady state kinetic data were analysed by 
curve fitting to the Michaelis-Menten equation using Prism software while IC50s curves 
corresponding to different inhibitor concentrations were logarithm-transformed and 
fitted by nonlinear regression to equation log(inhibitor) vs. response –(three 











𝑥 = 𝑙𝑜𝑔 𝑜𝑓 𝑖𝑛ℎ𝑏𝑖𝑡𝑜𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 
𝑦 = 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒, 𝑑𝑒𝑐𝑟𝑒𝑎𝑠𝑖𝑛𝑔 𝑎𝑠 𝑥 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒𝑠 
𝑇𝑜𝑝 𝑎𝑛𝑑 𝐵𝑜𝑡𝑡𝑜𝑚: 𝑝𝑙𝑎𝑡𝑒𝑢𝑠 𝑖𝑛 𝑠𝑎𝑚𝑒 𝑢𝑛𝑖𝑡𝑠 𝑎𝑠 𝑦 
𝑙𝑜𝑔𝐼𝐶50 = 𝑠𝑎𝑚𝑒 𝑢𝑛𝑖𝑡𝑠 𝑎𝑠 𝑥 
 
 
2.9 Expression and purification of L2 
 
For L2 protein expression the putative signal sequence (residues 1-27) was 
removed. Codons 82-912 of the L2 gene from S. maltophilia K279a genomic DNA 
were amplified with forward and reverse primers L2 express (Table 2.1). Primer 
sequences included extensions which allowed recombination into the pOPINF vector 
(199), resulting in an L2 construct containing an N-terminal His6 tag, with the tag 
cleavable with 3C protease. The resultant plasmid was designated pOPINF-L2Δ27. 
For protein overproduction, E. coli SoluBL21 (DE3) cells (Genlantis) bearing 
pOPINF-L2Δ27 were grown in six 2 L flasks with 500 mL 2xTY medium containing 
ampicillin (50µg/mL) and 5 mL overnight culture was added into each flask and grown 
at 37°C until reaching an OD600=0.9. Protein expression was induced with 1 mM IPTG 
at 18°C for 16 h. All subsequent purification steps were at 4°C. Cells were harvested 
by centrifugation (6500  × g, 10 mins) of the 3 L-culture and resuspended in 50 mM 
Tris pH 7.5, 150 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine TCEP) supplemented 
with EDTA-free protease inhibitor (Roche). Cells were lysed by two 30,000 psi 
passages through a cell disruptor. After centrifugation at 100,000 × g for 45 min, the 
supernatant was incubated for 1.5 h with Ni-NTA resin (Qiagen). Resin was washed 
with buffer A (50 mM Tris pH 7.5, 400 mM NaCl, 1 mM TCEP) plus 10 mM imidazole, 
then buffer A plus 0.1% Triton X-100, then buffer A plus 20 mM imidazole. Protein was 
eluted with 50mM Tris pH 7.5, 200 mM NaCl, 400 mM imidazole, 1 mM TCEP. 
Imidazole and NaCl concentrations were reduced to 5 mM and 150 mM, respectively, 
in an Amicon 10 kDa molecular weight cut-off (MWCO) concentrator and His tag 
removed by overnight incubation with his tagged 3C protease. The digestion mixture 




purified L2 was collected and concentrated to 30 mg/mL in an Amicon 10 kDa MWCO 
concentrator. 
2.10 Fluorescent Hoescht (H) 33342 dye accumulation assay  
 
Envelope permeability in living bacteria was tested using a standard dye 
accumulation assay protocol (200) where the dye only fluoresces if it crosses the entire 
envelope and interacts with DNA. Overnight cultures (in NB) at 37°C were used to 
prepare NB subcultures at 37°C to 0.6 OD600. Cells were pelleted by centrifugation 
(4000 rpm, 10 min) (ALC, PK121R) and resuspended in 500µL of PBS. The optical 
densities of all suspensions were adjusted to 0.1 OD600. Aliquots of 180 µL of cell 
suspension were transferred to a black flat-bottomed 96-well plate (Greiner Bio-one, 
Stonehouse, UK). Eight technical replicates, for each strain tested, were in each 
column of the plate. The plate was transferred to a POLARstar spectrophotometer 
(BMG Labtech) and incubated at 37°C.  Hoescht dye (H33342, 250 µM in water) was 
added to bacterial suspension of the plate using the plate-reader’s auto-injector to give 
a final concentration of 25 µM per well. Excitation and emission filters were set at 355 
nm and 460 nm respectively. Readings were taken in intervals (cycles) separated by 
150 s. 31 cycles were run in total. A gain multiplier of 1300 was used.  Results were 
expressed as absolute values of fluorescence versus time.   
2.11 Proteomics 
 
500 µL of an overnight culture were transferred to 50 mL NB and cells were 
grown at 37˚C to 0.6 OD600. Cells were pelleted by centrifugation (10 min, 4,000 ×g, 
4°C) and resuspended in 20 mL of 30 mM Tris-HCl, pH 8 and broken by sonication 
using a cycle of 1 s on, 0.5 s off for 3 min at amplitude of 63% using a Sonics Vibracell 
VC-505TM (Sonics and Materials Inc., Newton, Connecticut, USA). The sonicated 
samples were centrifuged at 8,000 rpm (Sorval RC5B PLUS using an SS-34 rotor) for 
15 min at 4°C to pellet intact cells and large cell debris; the supernatant was removed 
and concentrated (Amicon 3 kDa cutoff filter) for analysis of total cell protein. 
Alternatively, for envelope preparations, the supernatant was not concentrated, and 
instead, subjected to centrifugation at 20,000 rpm for 60 min at 4°C using the above 
rotor to pellet total envelopes. To isolate total envelope proteins, this total envelope 





Protein concentrations in all samples were quantified using Biorad Protein 
Assay Dye Reagent Concentrate according to the manufacturer’s instructions. Protein 
concentration was calculated using Equation 1. Proteins (2.5 μg/lane for total cell 
proteomics or 5 µg/lane for envelope protein analysis) were separated by SDS-PAGE 
(see below) using 11% acrylamide, 0.5% bis-acrylamide (Biorad) gels and a Biorad 
Min-Protein Tetracell chamber model 3000X1. Gels were resolved at 200 V until the 
dye front had moved approximately 1 cm into the separating gel. Proteins in all gels 
were stained with Instant Blue (Expedeon) for 20 min and de-stained in water.  
The 1 cm of gel lane was subjected to in-gel tryptic digestion using a DigestPro 
automated digestion unit (Intavis Ltd).  The resulting peptides from each gel fragment 
were fractionated separately using an Ultimate 3000 nanoHPLC system in line with an 
LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific). In brief, peptides in 1% 
(v/v) formic acid were injected onto an Acclaim PepMap C18 nano-trap column 
(Thermo Scientific). After washing with 0.5% (v/v) acetonitrile plus 0.1% (v/v) formic 
acid, peptides were resolved on a 250 mm × 75 μm Acclaim PepMap C18 reverse 
phase analytical column (Thermo Scientific) over a 150 min organic gradient, using 7 
gradient segments (1-6% solvent B over 1 min, 6-15% B over 58 min, 15-32% B over 
58 min, 32-40% B over 5 min, 40-90% B over 1 min, held at 90% B for 6 min and then 
reduced to 1% B over 1 min) with a flow rate of 300 nL/min.  Solvent A was 0.1% 
formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% formic acid. Peptides 
were ionized by nano-electrospray ionization MS at 2.1 kV using a stainless-steel 
emitter with an internal diameter of 30 μm (Thermo Scientific) and a capillary 
temperature of 250°C. Tandem mass spectra were acquired using an LTQ-Orbitrap 
Velos mass spectrometer controlled by Xcalibur 2.1 software (Thermo Scientific) and 
operated in data-dependent acquisition mode. The Orbitrap was set to analyze the 
survey scans at 60,000 resolution (at m/z 400) in the mass range m/z 300 to 2000 and 
the top twenty multiply charged ions in each duty cycle selected for MS/MS in the LTQ 
linear ion trap. Charge state filtering, where unassigned precursor ions were not 
selected for fragmentation, and dynamic exclusion (repeat count, 1; repeat duration, 30 
s; exclusion list size, 500) were used. Fragmentation conditions in the LTQ were as 
follows: normalized collision energy, 40%; activation q, 0.25; activation time 10 ms; and 
minimum ion selection intensity, 500 counts. 
The raw data files were processed and quantified using Proteome Discoverer 
software v1.4 (Thermo Scientific) and searched against the UniProt S. maltophilia 
strain K279a database (4365 protein entries; UniProt accession UP000008840) using 




at 10 ppm, and MS/MS tolerance was set at 0.8 Da. Search criteria included 
carbamidomethylation of cysteine (+57.0214) as a fixed modification and oxidation of 
methionine (+15.9949) as a variable modification. Searches were performed with full 
tryptic digestion and a maximum of 1 missed cleavage was allowed. The reverse 
database search option was enabled and all peptide data was filtered to satisfy false 
discovery rate (FDR) of 5 %. The Proteome Discoverer software generates a reverse 
“decoy” database from the same protein database used for the analysis and any 
peptides passing the initial filtering parameters that were derived from this decoy 
database are defined as false positive identifications. The minimum cross-correlation 
factor filter was readjusted for each individual charge state separately to optimally meet 
the predetermined target FDR of 5 % based on the number of random false positive 
matches from the reverse decoy database. Thus, each data set has its own passing 
parameters. Protein abundance measurements were calculated from peptide peak 
areas using the Top 3 method (201) and proteins with fewer than three peptides 
identified were excluded. The proteomic analysis was repeated three times for each 
parent and mutant strain, each using a separate batch of cells. Data analysis was as 
follows: all raw protein abundance data were uploaded into Microsoft Excel. Raw data 
from each sample were normalised by division by the average abundance of all 30S 
and 50S ribosomal protein in that sample. A one-tailed, unpaired T-Test was used to 
calculate the significance of any difference in normalised protein abundance data in the 
three sets of data from the parent strains versus the three sets of data from the mutant 
derivative. A p-value of <0.05 was considered significant. The fold change in 
abundance for each protein in the mutant compared to its parent was calculated using 
the averages of normalised protein abundance data for the three biological replicates 
for each strain.  
2.12 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Samples were prepared according to amount of protein required for proteomics 
analysis and then mixed with SDS-PAGE loading buffer (100mM Tris pH 6.8, 4% SDS, 
0.2% bromophenol blue, 20% glycerol, 5% β-mercaptoethanol) and heated at 95°C for 
5 min. The separating gel was obtained from combining 4.2 mL of 30% 
acrylamide/bisacrylamide solution (37.5:1 Bio-Rad), 2.5 mL of separating buffer (1.5M 
Tris-Base pH 8.8, 4% SDS), 2.3 mL of Elgastat water, 100µL of 10% w/v ammonium 
persulphate, and 20 µL of 10% TEMED. The stacking gel solution was made up of 2 
mL of 30% acrylamide/bisacrylamide solution (37.5:1, Bio-Rad), 2.5 mL of the stacking 




ammonium persulphate, and 20 µL of 10% TEMED. High- molecular- weight pre-
stained protein marker was used (SeeBlue Plus2, Life Technologies). Gels were run at 
170 V until they reached the desired distance for proteomics analysis. InstantBlue stain 
(Expedeon) was used for 15 min to visualize the proteins and then removed with 
Elgastat water.  
2.13 Polymerase Chain Reaction and Sequence Analysis 
 
A bacterial colony was resuspended in 100 µL of molecular biology grade water 
and heated at 100˚C for 5 min. Sample was centrifuged at 13000 rpm for 5 min. One 
microlitre of the resulting supernatant was used as a DNA template for downstream 
PCR reactions. Alternatively, a single colony was resuspended directly in the PCR 
reaction and used as a template. 
2.13.1 Polymerase chain reaction (PCR) 
 
When using MyTaq PCR Master Mix (BioLine), PCR reactions were set up in 
0.2 mL thin-walled PCR tubes using 12.5 µL of MyTaq PCR Master Mix, 0.5 µL of 
forward primer (10 µM), 0.5 µL of reverse primer (10 µM), 10.5 µL of molecular biology 
grade water and 1 µL of DNA template. A PCRmax Alpha Cycler 2 Thermal Cycler 
(Cole-Parmer) was used to carry out the reaction. The cycling conditions were the 
following: 1 cycle of 95˚C for 1 min, 30 cycles of : 95˚C for 15 s, 55˚C-68˚C for 15 s, 
and 72˚C for 10 s, 1 cycle of 72˚C for 10 min for final extension. When using Phusion ® 
High-Fidelity DNA Polymerase (New England Biolabs) for high-GC-content DNA 
fragments, PCR reaction was set up using 5µL of 5X Phusion GC Buffer, 0.5µL of 
dNTPs (10mM), 1.25 µL of forward primer (10µM), 1.25 µL of reverse primer (10µM), 
0.75µL of DMSO, 0.25 µL of Phusion DNA Polymerase, 1µL of DNA template, and 15 
µL of molecular biology grade water. The cycling conditions were the following: 1 cycle 
of 98˚C for 30 s, 30 cycles of: 98˚C for 10 s, 60˚C-68˚C for 30 s, and 72˚C for 30 s, 1 
cycle of 72˚C for 10 min for final extension. 
PCR products were visualized in 1% Tris/Acetate/EDTA agarose gel. One gram 
of agarose was dissolved in 100 mL TAE buffer (0.04 M Tris Base, 0.02 M Glacial 
Acetic Acid, 1 mM EDTA pH 8.0) with ethidium bromide (0.1 µg.mL-1). 10 µL PCR 
products obtained with Phusion DNA Polymerase required being mixed with 2 µL of 5X 
DNA loading buffer whilst PCR products obtained with MyTaq PCR Master Mix include 
loading buffer in the PCR reaction. 3 µL of Hyperladder (1 Kb, BioLine) was used as a 
marker. Samples were run at 120 V for 30 min and then agarose gels visualised using 




PCR products were purified using QIAquick PCR Purification Kit (Qiagen) 
according to the manufacturer’s instructions. DNA concentration of purified samples 
was quantified using NanoDrop Lite spectrophotomer (Thermo Scientific). Samples 
were sent to Eurofins (Germany) according to the sample submission guide provided 
by Eurofins. Sequences obtained were analysed with ClustalW OMEGA or 
MultiAlignPro. Alignments were represented using ESPript 3.0. 
2.14 Reverse Transcription Quantitative PCR (RT-qPCR) 
 
2.14.1 RNA Isolation and DNase Treatment 
 
From an overnight culture, 200 µL were used to set up a 20 mL NB subculture. 
Cells were grown to OD600 0.6. 10 mL of the culture was centrifuged at 4, 000 × g for 
10 min and then resuspended in 2 mL of NB. Four mililitres of Bacterial RNA Protect 
Reagent (Qiagen) was added to the sample. The stabilized culture was centrifuged for 
10 min at 4, 000 × g and the supernatant discarded. 
Total RNA was isolated from the cell pellet using the RNeasy Mini Kit (Qiagen) 
following the manufacturer’s instructions. However, a modification was added after 
incubation of the sample with lysozyme (15 mg.mL-1, TE buffer) at 37˚C for 10 min, and 
immediate addition of buffer RLT. Samples were transferred to a lysing tube, 
containing acid-washed 0.1 mm silica spheres, (Lysing matrix B, MP Biochemicals, 
Eschwege, Germany). Next, lysing tubes were processed in a Hybaid Ribolyser 
(Hybaid International, UK) for two cycles of 45 s at speed 6. Samples were then 
centrifuged at 13 000 rpm at 4˚C for 1 min. The resulting supernatant was used to 
continue with RNA isolation using RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. Purified total RNA was quantified using Nanodrop Lite 
(Thermo Scientific) and stored at -70 ˚C until required.  
DNA was removed from RNA samples using Turbo DNase (Life technologies) 
according to the manufacturer’s instructions.  
2.14.2 RT-PCR 
 
RNA concentrations in DNase treated RNA samples were quantified using 
Nanodrop Lite (Thermo Scientific) and then standardized to 100 ng.µL-1. One 
microgram of RNA from each sample was converted to cDNA using qScript cDNA 
SuperMix (Quantabio). cDNA was synthesized with the following conditions: 25˚C for 5 




PCRmax Alpha Cycler 2 Thermal Cycler (Cole-Parmer) without an initial heating of the 




Real-time quantitative PCR (qPCR) reactions were prepared using PowerUpTM 
SYBRTM Green Master Mix (Applied Biosystems). Briefly, 1 µL of forward primer (10 
µM), 1 µL of reverse primer (10 µM), 7µL molecular biology grade water, 1 µL of cDNA 
and 10 µL of PowerUpTM SYBRTM Green Master Mix (2X) were mixed to set up a 20 µL 
reaction. qPCR was carried out in a StepOnePlus TM Real-Time PCR System (Applied 
Biosystems). Each qPCR analysis had three biological replicates (i.e. cDNA from three 
separate preparations of RNA) and 4 technical replicates (assays using a given a 
preparation of cDNA). The cycling conditions were the following: 1 cycle of 95˚C for 
2 min, 40 cycles of: 95˚C for 2 s, 60˚C for 30 s. Relative quantification was calculated 
using the comparative method (202). 
2.15 Whole genome sequencing to Identify Mutations 
 
Whole genome resequencing was performed by MicrobesNG (Birmingham, 
UK) on a HiSeq 2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed 
using Trimmomatic (203) and assembled into contigs using SPAdes 3.10.1 
(http://cab.spbu.ru/software/spades/). Assembled contigs were mapped to reference 
genome for S. maltophilia K279a (173) obtained from GenBank (accession number 
NC_010943) using progressive Mauve alignment software (204). 
2.16 DNA manipulation 
 
2.16.1 Plasmid isolation, digestion and purification 
 
Plasmid preparations were obtained from overnight cultures (10 mL) using 
QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer’s instructions. 
Plasmid yield was measured using a NanoDrop Lite spectrophotometer (Thermo 
Scientific). 
Restriction digestions were carried out according to the manufacturer’s 
instructions. Three micrograms of plasmid DNA were digested with 3 units of the 
appropriate restriction enzyme (New England Biolabs), 6 µL of the restriction buffer 




and molecular biology grade water to complete a final volume reaction of 60 µL.  The 
reaction was incubated at 37˚C for 1- 3 h depending on the specificity of the enzyme 
(high-fidelity or standard) and then visualized and purified from a 1% w/v agarose gel 
(see above). Bands were cut out with a scalpel and DNA purified using a Qiaquick Gel 
Extraction Kit (Qiagen) according to the manufacturer’s instructions. 
2.16.2 DNA ligation 
 
Ligations reactions were carried out by adding a 3:1 molar ratio of insert to the 
vector, 1 unit of T4 DNA ligase (Promega), 1 µL of ligase buffer (10X) and molecular 
biology grade water to complete a final volume reaction of 10 µL. Ligation reaction was 
incubated overnight at 4˚C. When LigaFast TM Rapid DNA Ligation System (Promega) 
ligations were performed, the same 3:1 molar ratio of insert to the vector and 1 unit of 
T4 DNA ligase (Promega) was used but 5 µL of rapid ligation buffer (2X) and molecular 
biology grade water to complete a final volume reaction of 10 µL. Rapid Ligation 
reactions were incubated at room temperature for 30 min.  
2.17 Transformation 
 
2.17.1 Making chemically competent cells and heat-shock 
 
500 µL of an overnight culture was used to set up a 50 mL fresh subculture in 
LB broth at 37°C until the OD600 0.6. The culture was then aliquoted in 25 mL falcon 
tubes and centrifuged at 4,000 × g for 10 min. Cells were then resuspended in 25 mL 
of sterile ice cold CaCl2 (100 mM) and placed on ice for 30 min. Cells were centrifuged 
at 4,000 × g for 10 min and supernatant was removed. The resulting cell pellet was 
resuspended in 1 mL of sterile ice cold CaCl2 (100 mM, 15% v/v Glycerol). Cells were 
stored as 75 µL aliquots at -70˚C.  
Transformation of chemically competent cells was carried out by heat shock. 
75 µL of the chemically competent cells were incubated with the 150 ng of the plasmid 
or 5 µL of the ligation reaction for 30 min, heat-shocked at 42˚C for 1 min and 
incubated on ice for 3 min before adding 900 µL of pre-warmed SOC medium. Heat-
shocked cells were then incubated in a shaking incubator at 37°C for 1 h. Cells were 
centrifuged at 8000 rpm for 2 min and then resuspended in 100 µL of the same SOC 
medium. 100 µL was then plated on 1.6% LB agar (containing 20 µg.mL-1 
chloramphenicol, 15 µg.mL-1 gentamicin or 100 µg.mL-1 ampicillin, depending upon the 




antibiotic selection marker, plates also contained 
isopropyl-β-D-1-thiogalactopyranoside (IPTG 0.1 mM) and X-Gal (40 µg.mL-1 ). 
Colonies were selected for colony PCR from where PCR products were sequenced 
and analysed to confirm the presence of the insert in the vector.  
2.17.2 Making electro-competent cells and Electroporation 
 
One mililitre of an overnight culture was used to set up a 100 mL fresh 
subculture in LB broth grown at 37°C until the OD600 0.6. The culture was then 
aliquoted in 50 mL falcon tubes and centrifuged at 4,000 × g for 10 min. The 
supernatant was discarded and cells were washed in 50 mL of sterile ice cold water to 
be then pelleted at 4,000 × g for 10 min. A second washing step followed, and cells 
were resuspended in sterile ice cold 12.5% v/v glycerol and then pelleted at 4,000 × g 
for 10 min. A second washing step with sterile ice cold 12.5% glycerol and a second 
centrifugation at 4,000 × g for 10 min followed. Finally, 300 µL of sterile ice cold 12.5% 
glycerol was used to resuspend the final cell pellet. Cells were stored as 75 µL aliquots 
at -70°C. 
Electroporation was carried out by incubation of 75µL of the electro-competent 
cells with 150 ng of DNA for 5 min in ice. The mixture was then transferred to an ice 
cold 2 mm-electroporation cuvette (Cell Project). A pulse was applied with a Bio-Rad 
Gene Pulser (Bio-Rad, UK) at 2.5 kV, 25 µF and 200 Ω. 950 µL of pre-warmed LB 
broth was added. The cuvette containing cells, DNA and broth was incubated at 37°C 
for 1 h. Cells were transferred to a 1.5 mL microtube (Eppendorf) and centrifuged at 
8000 rpm for 2 min and then resuspended in 100 µL of the same LB medium and the 
entire sample was plated on 1.6% LB agar (containing antibiotic selection as described 
above). Colonies were selected for colony PCR from where PCR products were 
sequenced and analysed to confirm the presence of the insert in the vector. 
2.17.3 L2 Crystallisation, Data Collection and Structure Modelling  
 
Initial L2 crystals grew using sitting-drop vapour diffusion in 96-well MRC 2-
drop plates (Molecular Dimensions) with the Morpheus sparse matrix screen (205). 
Conditions were refined in CrysChem 24-well sitting-drop plates (Hampton Research, 
18°C), and diffraction-quality crystals were obtained by mixing 1 µL of L2 protein (42 
mg/mL) with 1.5 µL reagent (10% w/v PEG 20000, 20% v/v PEG MME 550, 0.02 M 
DL-Glutamic acid; 0.02 M DL-Alanine; 0.02 M Glycine; 0.02 M DL-Lysine; 0.02 M DL-




complexes were obtained by soaking crystals in bicyclic boronate 2 (5 min, 2.5 mM) or 
avibactam (40 min, 5 mM) dissolved in reservoir reagent. L2 crystals were 
cryoprotected using reservoir solution plus 20% glycerol and flash frozen in liquid 
nitrogen. Crystallographic data were collected at 100K (I04-1, I04 or I03, Diamond 
Light Source, UK) and integrated in XDS(206) or DIALS (207), and scaled in Aimless in 
the CCP4 suite (208). Phases were calculated by molecular replacement in Phaser 
(209) using PDB 1O7E (unpublished) as a starting model. Avibactam and boronate 
structures, covalently bound to Ser70, and geometric restraints were generated using 
Phenix eLBOW (210). Structures were completed by iterative rounds of manual model 
building in Coot (211)and refinement in Phenix (212). Structure validation was assisted 
by Molprobity (213) and Phenix (212). Figures were prepared using Pymol 




















3 Characterisation of new mechanisms of ceftazidime 




S. maltophilia clinical isolates are resistant to almost all β-lactams because of 
the production of two β-lactamases: L1, a subclass B3 metallo-β-lactamase and L2, a 
class A ESBL (214) Production of L1 and L2 is co-ordinately controlled by AmpR, a 
LysR-type transcriptional activator and induced during β-lactam challenge of cells 
(215). Where previously characterised, AmpR regulators have been shown to bind two 
ligands in a competitive manner (160, 216). As summarised in Figure 3.1, the AmpR 
activator ligand, an anhydro-muramyl-penta-peptide is produced during β-lactam 
challenge via the concerted actions of lytic transglycosylases, which release 
N-acetylglucosamine-anhydro-muramyl-peptides from peptidoglycan (217) and AmpG, 
a permease that transports them into the cytoplasm (218, 219). NagZ, an enzyme that 
removes the N-acetylglucosamine moiety is also necessary to release the AmpR 
activator ligand in some species (220), though not in S. maltophilia (221). The AmpR 
repressor ligand is a UDP-muramyl-penta-peptide (222). It is produced via sequential 
addition of amino acids to a UDP-muramyl substrate, via four separate ligase 
enzymes, MurC (223), MurD (224), MurE (225) and MurF (226), with the last adding a 
D-alanine/D-alanine dipeptide made by Ddl (227). Mpl is an enzyme that can ligate a 
ready-made penta-peptide onto the UDP-muramyl substrate, skipping the MurC, D, E, 
Ddl and MurF ligation reactions, each of which requires ATP hydrolysis (228). This Mpl 
catalysed reaction therefore saves considerable amounts of energy for the cell. Its 
penta-peptide substrate comes from breakdown of anhydro-muramyl-penta-peptides 
by the peptide amidase AmpD. In this way, breakdown of the anhydro-muramyl-penta-
peptide AmpR activator ligand by AmpD is also directly linked to production of the 
UDP-muramyl-penta-peptide AmpR repressor ligand by Mpl (215, 217, 229, 230) 
(Figure 3.1). 
Despite inducible production of L1 and L2 β-lactamases many S. maltophilia 
clinical isolates remain ceftazidime susceptible (152). However, mutants that have 
acquired ceftazidime resistance can easily be identified in the laboratory, and 
ceftazidime resistant isolates are commonly encountered in the clinic. In many cases, 
these mutants hyperproduce L1 and L2 (214). Mutations that reduce AmpD function 
are known to boost L1/L2 production, because the AmpR activator ligand is broken 




peptidoglycan turnover, releasing more muropeptides, also activate L1/L2 production, 
e.g. those in PBP1A, encoded by mcrA (232) and in the lytic transglycosylase MltD, 
because this mutation stimulates the net production of lytic transglycosylase activity in 
the cell (233). Mutations in AmpR also activate L1/L2 production (160). Prior to the 
start of this PhD project, the group had characterised ceftazidime resistant, β-
lactamase hyper-producing laboratory selected mutants derived from the extremely 
well studied clinical isolate K279a. One of these mutants, KCAZ14, was wild-type for 
ampR, ampD, and mcrA (214) suggesting the participation of an additional gene in β-
lactamase hyperproduction. The first part of this chapter describes identification of this 
additional regulatory gene, 
The same study (214) also identified ceftazidime resistant mutants that did not 
hyperproduce β-lactamase. It was hypothesised that these mutants might have 
reduced accumulation of ceftazidime in the periplasm due to reduced porin expression 
or increased ceftazidime efflux. Accordingly, the second part of this chapter describes 









Figure 3.1 Role of Mpl in peptidoglycan recycling and AmpR activation 
The schematic shows that N-acetylglucosamine (black square)-anhydro-muramyl 
(green diamond)-penta-peptide (purple triangle) is removed from peptidoglycan by lytic 
transglycosylases such as Slt70 and enters the cytoplasm through the permease 
AmpG. NagZ removes the N-acetylglucosamine group to produce the anhydro-
muramyl-penta-peptide AmpR activator ligand (“+ve”). AmpD then releases the penta-
peptide ready to be linked to a UDP-muramic acid molecule (red diamond) by Mpl to 
produce the UDP-muramyl-penta-peptide AmpR repressor ligand (“-ve”). This can then 
be further incorporated into the biosynthetic pathway and processed by MurG and 
MraY, which add N-acetylglucosamine and penicillin binding proteins, which add these 
high energy N-acetylglucosamine-muramyl (white diamond)-penta-peptide substrates 
to the nascent peptidoglycan strand. UDP-muramyl-penta-peptide formation can also 
occur without peptidoglycan recycling, through the sequential addition of amino acids 
to UDP-Muramic acid. However, this requires five moles of ATP per mole of UDP-








3.2 Results and discussion 
 
3.2.1 Involvement of mpl mutation in β-lactamase hyperproduction in 
S. maltophilia  
 
To identify the mechanism for β-lactamase hyperproduction in the previously 
identified ceftazidime resistant mutant KCAZ14 whole genome sequencing was 
performed. The only mutation identified in KCAZ14 was a deletion of 18 nucleotides in 
the mpl gene, deleting amino acids 141-146 of Mpl (Figure 3.2). The level of 
β-lactamase production was similar for this mpl mutant KCAZ14, KCAZ10, a previously 
identified ampD loss of function mutant (214) and KM11, a previously identified ampR 





Figure 3.2 Mpl amino acid sequence comparison from K279a and β-lactamase 
hyperproducing mutants 
Alignment of predicted translations of PCR sequences that confirmed the Mpl 
mutation (non-highlighted region for KCAZ14 residues 141-146) found during whole 
genome sequencing analysis. Residues 165-176 (black bar) and 91-93 (green bar) 
may be important for Mpl function given its uniqueness when compared to Mur 
ligases. Blue bar (residues 8-14) and blue circle (Asp32) are likely involved in UTP 
binding; blue circle (Tyr163) may participate in substrate recognition. Pink circles 
(Asn186, His282, His286) are important for ATP especifically adenine binding while 
orange circle (Asp332) allows ribose binding. Gly114-Thr117 (light blue circles), 
Arg317, His335 (orange circles) likely involved in tri-phosphate binding. Residues 
likely involved in metal binding are Thr116, His191, and Glu162 (234). The 




3.2.2 mpl complementation in KCAZ14 restores ceftazidime susceptibility  
To confirm involvement of mpl loss in the β-lactamase hyper-producing, 
ceftazidime resistant phenotype of KCAZ14, complementation was attempted in trans. 
K279a mpl was amplified by PCR as previously (214) with primers mpl_F1 and  
mpl_R2 (Table 2.1) . The product was blunt-end ligated into pBBR1MCS-5 (GmR) 
(235, 236) digested with SmaI and the resulting recombinant plasmid used to transform 
KCAZ14 to gentamicin resistance (15 µg.mL-1) via electroporation Figure 3.3. The 
ceftazidime MIC against KCAZ14 (pBBR1MCS-5) was 64 µg.mL-1 and reduced to 4 
µg.mL-1 in KCAZ14 (pBBR1MCS-5::mpl), the same as the MIC against wild-type 
K279a. Production of β-lactamase was also reduced to wild-type levels in 
KCAZ14 (pBBR1MCS-5::mpl) (Table 3.1) and disc susceptibility testing showed an 
increase in the zone of clearing around a ceftazidime disc for 
KCAZ14 (pBBR1MCS-5::mpl) relative to KCAZ14 (pBBR1MCS-5) adding further 
confirmation of successful complementation (Figure 3.4).  
 
Figure 3.3 mpl PCR products obtained during complementation of KCAZ14∆mpl 
A) Amplification of the cloning vector insert site flanking region using M13F and M13R 
primers corresponding to ~250bp (i.e. no insert) from KCAZ14 (∆mpl) carrying 
pBBR1MCS-5 B) Amplification of the insert site flanking region using M13F and M13R 
primers corresponding to ~1700bp (the expected size for mpl insertion plus some vector 
sequence) from KCAZ14 (∆mpl) carrying pBBR1MCS-5::mpl C) Amplification of mpl using 





Figure 3.4 Complementation of the KCAZ14 (Δmpl) mutant restores 
ceftazidime activity 
A) KCAZ14 (Δmpl) carrying pBBR1MCS-5 ceftazidime disc zone of inhibition= 
13 mm B) KCAZ14 (Δmpl)  carrying pBBR1MCS-5::mpl ceftazidime disc zone of 
inhibition=  27 mm 
 
3.2.3 mpl mutations are common in S. maltophilia clinical isolates 
There are four ceftazidime resistant, β-lactamase hyperproducing S. maltophilia 
clinical isolates in the group’s collection: isolates 49-6147, 3800 and 98 (214) and ULA-
511 (186) (Table 3.1Error! Reference source not found.). Isolate 98 has an Insertion 
Sequence element disrupting ampD (214). Using PCR sequencing,  a mutation 
causing an Ala85Gly change in Mpl was also found in isolate 98, but the same 
mutation is carried by ~5% of S. maltophilia genomes in the Genbank database so is 
probably insignificant. The other three β-lactamase hyperproducing clinical isolates 
tested do have mpl mutations, however. In 49-6147, the mutation causes the deletion 
of amino acids 92-109, which disrupts the conserved Ser-Gly-Pro region (234). In 
3800, there is a frameshift at codon 368 and in ULA-511 there is a nonsense mutation 








Table 3.1 β-Lactamase activity (nmol.min-1.µg-1 protein nitrocefin hydrolysis 
activity in cell extracts) observed in S. maltophilia K279a and in ceftazidime 
resistant K279a mutants and clinical isolates carrying different mutations. 
 
Isolate Mean β-lactamase 
activity ±SEM 
Relevant amino acid changes 
(Relative to K279a) 
K279a 0.02±0.004 WT 
KM11 0.99±0.03 Asp135Asn in AmpR 
KCAZ10 1.52±0.04 159-168del in AmpD 
KCAZ14 0.72±0.01 140-146del in Mpl 
49-6147 0.45±0.12 92_109del Mpl 
3800 0.73±0.03 Truncation at 368 in Mpl 
98 1.76±0.07 IS insertion in ampD; Ala85Gly* in 
Mpl 
ULA-511 1.19±0.01 Truncation at 360 in Mpl 
   
KCAZ14 (pBBRMCS-5) 1.14±0.10  
KCAZ14 (pBBRMCS-5::mpl) 0.03±0.003  
 
*Random Genetic Drift 
Mutations were identified by PCR sequencing, except for KCAZ14, which was 
identified by WGS and confirmed by PCR sequencing 
WT: Wild type 
 
The result of Mpl loss in KCAZ14 and these clinical isolates will be a build-up of 
penta-peptides released by AmpD (Figure 3.1). Even though there are other enzymes 
that can break these penta-peptides down (229, 237), it seems reasonable to 
hypothesise that this net accumulation of penta-peptide will affect AmpD activity by 
feedback inhibition, increasing the concentration of its substrate, the AmpR activator 
ligand, causing β-lactamase hyper-production (230). This has not been confirmed 
however. 
This is the first report of mpl disruption causing β-lactamase hyperproduction in 
S. maltophilia, and to find it in 3/4 clinical isolates was striking. It is also interesting to 




populations carried by people with Cystic Fibrosis during long term colonisation in two 
separate studies (238, 239) and also in 3/4 patients with P. aeruginosa mediated 
ventilator associated pneumonia (240). Indeed, mpl mutation has been identified as a 
cause of AmpC β-lactamase hyperproduction in one P. aeruginosa PAO1 laboratory 
selected transposon-insertion mutant (241). Whilst this did not dramatically increase β-
lactam MICs (241), PAO1 is relatively permeable to β-lactams, because it lacks many 
of the efflux pump/porin altering mutations seen in clinical isolates (242). Therefore, it 
would seem reasonable to propose that these clinically acquired P. aeruginosa mpl 
mutations are being selected by β-lactam therapy. We have a small collection of 
ceftazidime resistant P. aeruginosa clinical isolates, of which 2/5 have previously been 
confirmed to hyperproduce AmpC (243). Both have a mutation in mpl, according to 
WGS. The mutations in isolates 86-14571 and 73-56826 cause Met297Val and an 
Arg103His changes in Mpl, respectively. We conclude, therefore, that mpl loss in S. 
maltophilia and P. aeruginosa is a clinically important and previously under-reported 
cause of β-lactamase hyperproduction and acquired β-lactam resistance. 
3.2.4 Selection and initial characterisation of non-β-lactamase 
hyperproducing ceftazidime resistant mutants  
 
As previously described, ceftazidime resistant mutants can be selected from 
K279a that do not hyperproduce β-lactamase (214). To identify the mechanism (s) 
involved, ceftazidime resistant mutants were selected from K279a as described in 
section 2.4. All mutants were tested for elevated basal levels (i.e. measured in the 
absence of β-lactam challenge) of β-lactamase activity and mutants with basal 
β-lactamase activity, similar to K279a (~0.02 nmol of nitrocefin hydrolysed.min-1.µg-1 of 
extracted protein) were taken forward for study. Of these, mutants M1 and M52 are 
exemplars. They are not β-lactamase hyperproducers Table 3.2 and yet susceptibility 
to all β-lactams tested was reduced, as shown by an observed reduction in the 
inhibition zone diameter around various β-lactam discs. However, where non-β-lactams 
were tested the impact on susceptibility (zone diameter) of the mutations wasminimal 






Table 3.2 β-Lactamase activity of non- β-lactamase hyperproducing ceftazidime 
resistant mutants 
 




β-lactamase activity (nmol.min-1.µg-1 protein nitrocefin hydrolysis activity 







Figure 3.5 Antibiotic susceptibilities for non-β-lactamase hyperproducers  
 
Growth inhibition zone diameters (mm) of ceftazidime resistant mutants (M1 and 
M52) in comparison with the parental strain (K279a). Smaller zone diameters means 
reduced susceptibility. Disc susceptibility was performed using MHA and antibiotic 
discs for β-lactam group: cefoxitin (FOX 30 µg), ceftazidime (CAZ 30 µg), cefepime 
(FEP 30 µg), ticarcillin-clavulanic acid (TIM 85 µg), piperacillin-tazobactam (TZP 110 
µg), doripenem (DOR 10 µg), meropenem (MEM 10 µg). Aminoglycosides: 
amikacin (AK 30 µg) gentamicin (CN 10 µg). Quinolones: ofloxacin (OFX 5 µg), 
ciprofloxacin (CIP 5 µg), norfloxacin (NOR 10 µg). Tetracyclines: tigecycline (TGC 
15 µg), Minocycline (MH 30 µg), trimethoprim-sulfamethoxazole (SXT 25 µg). 
Chloramphenicol (C 30 µg). Zone of inhibition are reported as a mean value, n=3. 





3.2.5 Non-β-lactamase hyperproducers, M1 and M52, show reduction in 
envelope permeability  
 
Hoescht dye (H33342) accumulation was assayed to estimate the effect of the 
mutations on envelope permeability. Previously, this assay has been tested in other 
Enterobacteriaceae species such as E. coli and K. pneumoniae (200, 244). However, 
non-fermentative bacteria have a peculiarity in terms of permeability when compared to 
E. coli. Solute diffusion in P. aeruginosa, Burkholderia cepacia, A. baumanii, and 
S. maltophilia is only 1-11% of that seen for E. coli (245). In S. maltophilia, this 
percentage is attributable to a reduced copy number of porins since the porin size is 
similar to those present in E. coli (245, 246). Hence, while the concentration of H33342 
used to test permeability in Enterobacteriaceae species was 2.5 µM in other studies 
(200, 244), here dye concentration was optimised to 25 µM. Cytoplasmic accumulation 
of the dye in the non-β-lactamase hyperproducers, M1 and M52 when compared to the 
parental strain K279a, was reduced (Figure 3.6).  Differences in permeability between 
M1 and M52 were seen, and this was clearer during growth in a low-osmolarity 
medium (NB) than in a high-osmolarity medium (MHB). Therefore, downstream 






Figure 3.6 Envelope permeability in low-osmolarity (NB) and high-osmolarity 
(MHB) media, measured using fluorescent dye accumulation 
Absolute accumulation of H33342 (25 µM) is expressed as fluorescence units over a 
31 cycle incubation period (78 min). Each curve plots mean data for three biological 
replicates with eight technical replicates. Error bars represent standard error of the 
mean (SEM) 
 
3.2.6 Disruption of the putative proline-rich TonB energy transducer 
protein (Smlt0009) causes ceftazidime resistance 
 
Whole genome sequencing was performed to identify the mutations present in 
the ceftazidime resistant mutants M1 and M52. The only gene found to be mutated in 




transducer protein’. The mutated region is repetitive and short-read technologies such 
as standard Illumina libraries can be biased to extreme GC-content (247). Therefore, it 
was decided to re-sequence the gene but this time using a PCR product amplified with 
Phusion ® High-Fidelity DNA polymerase. Sequences obtained confirmed mutation in 
smlt0009 in both mutants M1 and M52 relative to K279a (Figure 3.7). To confirm the 
role of smlt0009 in ceftazidime resistance, knock-out of the gene was carried out by 
another member of the group (Punyawee Dulyayangkul) using a suicide gene 
replacement methodology. K279a ∆smlt0009 was confirmed to be ceftazidime resistant 
(disc inhibition zone diameter of 6 mm) when compared to the parent strain, K279a 
(zone diameter of 27mm). 
 
 
Figure 3.7 Sequence alignment of Smlt0009 putative proline-rich TonB energy 
transducer of ceftazidime resistant mutants 
Alignment of translated PCR sequences that confirmed loss of proline-rich region 
(non-highlighted region) in M1 and M52 mutants. PCR amplification using Phusion ® 
High-Fidelity DNA polymerase showing loss of the proline-rich region in the TonB 
energy transducer. Comparison of proline-rich residues present in TonB E.coli with 
Smlt0009, based on (248), suggests the importance of the proline rich region to achieve 
the length that allows the energy transducer to spans the periplasm. Blue bar 
corresponds to 2.9nm, the green bar to 4nm, pink bar 4.6nm and purple bar 3.3nm; the 
rest of the C-terminus might correspond to 6.5 nm to give a total of ~20nm. Alignment 





To understand the mechanism of resistance conferred by this mutation, whole 
envelope proteomics was performed in M1 and M52 compared with K279a.  
Proteomics confirmed that the β-lactamases, L1 and L2, are not overporoduced, in M1 
and M52 mutants relative to K279a. 162 proteins were identified that are up or down 
regulated in both M1 and M52 relative to K279a; 83 are downregulated in both and 79 
upregulated in both. Within the group of downregulated proteins, the putative proline-
rich TonB energy transducer protein Smlt0009 (Uniprot: B2FT87) was 1.8-fold 
downregulated in M1, and 2.5- fold in M52 when compared to K279a (Figure 3.9). 
Certainly, the mutations seen in Smlt0009 in M1 and M52 are not expected to block 
production of the protein, but the mutated, presumably inactive, protein may be less 
stable than wild-type explaining this apparent downregulation of Smlt0009 production 
in the mutants. Proteomics for K279a ∆smlt0009 confirmed lack of Smlt0009 
(Dulyayangkul, unpublished). Amongst proteins upregulated in M1 and M52 were 
proteins with the Uniprot accession numbers B2FHQ4, encoded by entB, smlt2820 
(Figure 3.10), B2FRE6 (fepC, smlt2356) and B2FRE7 (fepD, smlt2357). Indeed the 
entire smlt2354-7 operon was upregulated (Annex 1). These upregulated Fep proteins 
have been shown to be involved in siderophore production (249). Siderophore 
production was detected on modified CAS agar, as described in section 2.5, and found 
to be increased in M1 and M52, relative to K279a, as predicted from the upregulation 
of these Fep proteins, as seen in the proteomics (Figure 3.11).  
Import of siderophores (iron chelating molecules) relies on energy-dependent 
mechanisms (250). Ferric-siderophore-complex import requires a TonB complex 
(formed by a proline rich TonB energy transducer protein, ExbB and ExbD) which 
interacts with one or more of many possible ligand-gated porins (LGPs). The model 
that describes that interaction is termed ROSET (rotational surveillance and energy 
transfer). TonB energy transducer proteins have an N-terminus that creates a complex 
with ExbBD in the inner membrane, a proline-rich region that spans the periplasm and 
a C-terminus close to the outer membrane. Proton motive force, generated in the inner 
membrane, is transduced by ExbBD (Smlt0010 and Smlt0011 are the closest 
homologues in S. maltophilia) to cause rotational motion of the N terminus of the TonB 
energy transducer (Smlt0009). This movement triggers lateral movement on the TonB 
complex and the TonB C-terminus which surveys the outer membrane to interact with 
whichever LGP has an exposed TonB box. Ligand binding to an LGP exposes the 
TonB box. Thus, the TonB energy transducer C-terminus bind to specific LGPs in the 
presence of their LGP ligands allowing transduction of energy generated in the inner 




and ultimately the passage of the ligand into the cell; for example, a siderophore (251) 
(Figure 3.8).  
 
Figure 3.8 Proposed model for TonB dependent uptake  
 
LGPs (ligand-gated porins) embedded in the outer membrane (OM) experiment 
conformational changes that enable substrate uptake. After substrate binding, the 
TonB box of the LGP is exposed which allows interaction with the TonB complex 
(TonB-ExbBD) and consequently transduction of the energy generated in the inner 
membrane (IM) through proton motive force. Thus ligand binding in the OM and 









Mutants M1 and M52 have mutations in this proline rich TonB energy 
transducer protein, Smlt0009, so TonB complex depend import of LGP ligands is likely 
to be reduced. These mutants also have upregulation of proteins involved in 
siderophore production, leading to observed enhanced siderophore production. One 
hypothesis to explain this is that, loss of the TonB energy transducer Smlt0009 impede 
iron-siderophore uptake, which increases siderophore production due to the resulting 
iron starvation. 
In other bacteria, the proline rich TonB energy transducer has been shown to 
assume different roles in substrate transport. Due to its ability to interact with different 
LGPs, TonB complexes participate in import of different substrates ranging from 
iron/siderophore, vitamin B12 to maltodextrines and sucrose. In fact, in the 
environmental species Xanthomonas campestris, only 15% of LGPs are involved in 
iron/siderophore uptake (252). S. maltophilia Smlt0009 TonB energy transducer shares 
50% identity with the protein from X. campestris. Interestingly, of 162 proteins 
differently regulated in M1 and M52, 19 are TonB-dependent LGP proteins. Suggesting 
that mutants are responding to a breakdown in TonB-dependent energy transduction.  
In terms of ceftazidime resistance, seen here in M1 and M52, we hypothesise 
that in S. maltophilia, ceftazidime and probably other β-lactams are TonB-dependent 
substrates. Thus, TonB energy transducer mutations, such as loss of the proline-rich 
region of Smlt0009 seen in M1 and M52 reduces energy-dependent-ceftazidime 
uptake due to the inability of the β-lactam specific LGP to open. This is the first time 
that β-lactam entry via a TonB-dependent mechanism has been proposed in any 
bacterium. However, it is interesting to note that, unlike all other pathogens studied 
previously, porin loss has never previously been seen to be involved in β-lactam 







Figure 3.9 Downregulation of the TonB energy transducer protein Smlt0009 in M1 
and M52 
Protein abundance data of whole envelope proteomics are normalised to the average 
ribosomal content of each sample (including abundance of 30S and 50S ribosomal 
proteins). Fold change of Smlt0009 (Uniprot: B2FT87) is calculated after testing statistical 
significant difference between the parental strain and the mutants (p <0.05). Values are 




































































































Protein abundance data of whole envelope proteomics are normalised to the average 
ribosomal content of each sample (including abundance of 30S and 50S ribosomal 
proteins). Fold change of EntB (Uniprot: B2FH84) is calculated after testing statistical 
significant difference between the parental strain and the mutants (p <0.05). Values are 
reported as mean +/- Standard Error of the Mean (n=3). Full Proteomics data are shown 
in Annex 1.  
 
 
Figure 3.11 Siderophore overproduction of M1 and M52 
Diameter values show diffusion of the siderophore production after spotting 10 µL of a 
PBS washed bacterial suspension (OD600 0.2) onto a modified CAS agar (as 
described in section 2.4). Values are reported as mean of three biological repeats; the 
images are representative 
 
3.2.7 Ceftazidime uptake reduces in non-β-lactamase producers 
 
As stated before, we hypothesised that ceftazidime is a TonB-dependent 
substrate in S. maltophilia and that M1 and M52 do not import ceftazidime at the same 
rate as K279a, resulting in resistance. To test this, we measured the remaining 
ceftazidime present in a filtered culture supernatant after exposing K279a, M1 and M52 
to ceftazidime (50 µg.mL-1 and 25 µg.mL- 1). To estimate ceftazidime concentration, we 
spotted the supernatant onto a lawn of a ceftazidime susceptible E.coli laboratory 
strain (DH5α) spread as if of CLSI disc susceptibility testing. As expected, the residual 
antimicrobial (ceftazidime) activity in supernatants of M1 and M52 was greater than 
that in supernatants of K279a cultures. This, demonstrates that K279a takes up more 
ceftazidime than M1 and M52 (Figure 3.12). To add further evidence we tested 
envelope permeability to the Hoescht dye in the presence of ceftazidime at increasing 
concentrations. In K279a, permeability reduced in presence of ceftazidime, which 
means both antibiotic and dye are competing for the same uptake system. This 




ceftazidime chosen does not impact on cell growth during mid-exponential phase 
where cells are harvested to test permeability. OD600 reached 0.6 at cycle 49 (Figure 
3.13A). As previously shown, M1 and M52 are generally less permeable to the dye 
than K279a, but importantly, in M1 and M52, ceftazidime no longer competes for the 
dye; i.e. the reduction in permeability seen in the presence of ceftazidime is negligible 
(Figure 3.13A).  Therefore, we conclude that the Smlt0009-loss reduces ceftazidime 
uptake.  
 
Figure 3.12  Inhibition zone(mm) generated by ceftazidime uptake of 
non-β-lactamase producers against DH5α 
K279a, M1 and M52 were incubated in the presence of ceftazidime (50 µg.mL-1 
and 25 µg.mL-1). Each supernatant was recovered, filtered (0.2 µm) and spotted 
(10 µL) onto a lawn of E. coli DH5α. Zones of inhibition generated, reveal reduced 
uptake (27 mm) of non-β-lactamase hyperproducers, M1 and M52, when 
compared to the control, ceftazidime colution, (28 mm). K279a has a superior 
uptake evidenced by a smaller zone of inhibition (25 mm) meaning a lower 
ceftazidime concentration in the supernatant. The image shows zone of inhibition 
generated with ceftazidime (50 µg.mL-1) but the table shows the same tendency 
for a different concentration of ceftazidime tested (25 µg.mL-1). Values for both 







Figure 3.13 Ceftazidime uptake in non-β-lactamase producers responds to 
changes in permeability 
 
A) Growth curve in NB in absence of ceftazidime (K279a, red and M1, dark blue) 
and ceftazidime at (1 µg.mL-1) (K279, pink and M1 light blue) over a 73 cycle (12h) 
incubation period. Growth is conserved during mid-exponential phase 
B) Permeability reduction in presence of CAZ in K279a and maintenance of 
reduced permeability in M1. Each curve plots mean data for three biological 





3.2.8 Rate of ceftazidime susceptibility in world-wide collection of 
S. maltophilia clinical isolates is low 
 
In our world-wide collection of 50 clinical isolates, only 10 isolates are 
susceptible to ceftazidime and within the 40 ceftazidime resistant isolates only four of 
them are β-lactamase hyperproducers. This would open the possibility to find the 
mechanism of resistance here proposed where the change of permeability is attributed 
to the loss of the TonB energy transducer.  
3.3 Conclusions 
 
Two novel mutational causes of ceftazidime resistance have been reported. 
Although the first one described is another method of activating L1 and L2 β-lactamase 
production, the role of a novel regulatory protein involved in their production has been 
described. It has been shown that Mpl loss is a clinically important result of β-lactam 
exposure in S. maltophilia and P. aeruginosa that emerges as a response to long-term 
β-lactam exposure, as it happens in cystic fibrosis patients, and ventilator associated 
pneumonia patients on long-term β-lactam therapy (238, 253). 
Characterisation of non-β-lactamase hyperproducers has identified an entirely 
novel mechanism of ceftazidime resistance that appears to work by reducing the entry 
of ceftazidime (and other β-lactams but not other classes of antimicrobial) into the cell 
without affecting the production of porins or efflux pump proteins.  
Other work has suggested the possibility of combining ceftazidime and a 
siderophore group to improve cellular uptake as it happens with cefiderocol (254). 
However, the improved uptake and hence increase in antimicrobial activity has been 
mainly attributed to the presence of the siderophore. Here we suggest that the iron 
uptake systems might not only recognise the siderophore group but instead the 
structure of ceftazidime. For the first time in bacteria, we have been able to suggest 
that β-lactam uptake can be TonB-dependent since the phenotype is caused by loss of 
the TonB energy transducer protein Smlt0009. TonB is frequently involved in 
iron/siderophore uptake, and indeed there is evidence of this in S. maltophilia because 
Smlt0009 mutants, since siderophore production is enhanced, presumably as an 
attempt to acquire more iron.  
Clinically speaking, this perhaps suggests that Smlt0009-loss mediated 




should attenuate virulence. However, in our S. maltophilia collection, there are 
ceftazidime resistant isolates that do not hyper-produce β-lactamase, and it would be 




3.4 Annex 1 
 
Table 3.3 Normalised proteomics data for M1 and M52 relative to K279a 
Abundance changes significantly according to a t-Test (P<0.05). Proteins that are >1.5 fold up and down regulated are highlighted 
green or red, respectively. Proteins are ordered based on Uniprot Accession number. Consecutive numbers are suggestive of operons 
 
Accession Description T-Test K279a vs M1 Fold K279a vs M1  T-Test K279a vs M52 Fold K279a vs M52 
B2FHA2 
Putative ferredoxin oxidoreductase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0136 
PE=4 SV=1 - [B2FHA2_STRMK] 
0.034 0.42 0.022 0.17 
B2FHA8 
Putative phospholipase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0142 PE=4 SV=1 - 
[B2FHA8_STRMK] 
0.018 0.53 0.022 0.56 
B2FHB5 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0149 PE=4 SV=1 - 
[B2FHB5_STRMK] 
0.019 0.53 0.011 0.53 
B2FHB7 
Glutamine synthetase OS=Stenotrophomonas maltophilia (strain K279a) GN=glnA PE=3 SV=1 - 
[B2FHB7_STRMK] 
<0.05 >100 <0.05 >100 
B2FHD6 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0170 PE=4 SV=1 - 
[B2FHD6_STRMK] 
0.044 0.62 0.047 0.61 
B2FHF0 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0184 PE=4 SV=1 - 
[B2FHF0_STRMK] 
0.034 0.58 0.007 0.46 
B2FHF9 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0193 PE=4 SV=1 - 
[B2FHF9_STRMK] 
<0.05 >100 <0.05 >100 
B2FHH2 
Putative TonB dependent siderophore receptor OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt1426 PE=3 SV=1 - [B2FHH2_STRMK] 
0 13.73 0 22.44 
B2FHH7 
Putative peptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1431 PE=4 SV=1 - 
[B2FHH7_STRMK] 
0.004 0.32 0.003 0.3 
B2FHJ2 
Putative outer membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1446 
PE=3 SV=1 - [B2FHJ2_STRMK] 
0.001 0.3 0.001 0.23 
B2FHJ5 
Putative phosphodiesterase-nucleotide pyrophosphatase OS=Stenotrophomonas maltophilia (strain 
K279a) GN=Smlt1449 PE=4 SV=1 - [B2FHJ5_STRMK] 
0.014 0.47 0.005 0.41 
B2FHL6 
Putative ABC transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1471 PE=3 SV=1 
- [B2FHL6_STRMK] 
0.007 0.63 0.05 0.62 
B2FHL9 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1474 PE=4 SV=1 - 
[B2FHL9_STRMK] 
0.023 0.54 0.014 0.51 
B2FHM1 
Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1476 PE=4 
SV=1 - [B2FHM1_STRMK] 
0.01 0.55 0.018 0.59 
B2FHN2 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1491 PE=4 SV=1 - 
[B2FHN2_STRMK] 





Putative hydrolase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2820 PE=4 SV=1 - 
[B2FHQ4_STRMK] 
<0.05 >100 <0.05 >100 
B2FHT4 
Putative TonB dependent extracellular heme-binding protein OS=Stenotrophomonas maltophilia (strain 
K279a) GN=Smlt2850 PE=3 SV=1 - [B2FHT4_STRMK] 
<0.05 >100 <0.05 >100 
B2FHT9 
Putative iron transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2858 PE=3 SV=1 - 
[B2FHT9_STRMK] 
0.003 3.49 0.001 4.77 
B2FHX5 
Putative CBS domain protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4098 PE=4 
SV=1 - [B2FHX5_STRMK] 
<0.05 >100 <0.05 >100 
B2FI00 
Putative outer membrane Omp family protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt4123 PE=4 SV=1 - [B2FI00_STRMK] 
0.046 0.6 0.012 0.49 
B2FI12 
Putative colicin I receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=cirA PE=3 SV=1 - 
[B2FI12_STRMK] 
0.001 27.93 0 76.72 
B2FI43 
Putative peptidyl-dipeptidase Dcp (Dipeptidyl carboxypeptidase) OS=Stenotrophomonas maltophilia 
(strain K279a) GN=dcp PE=3 SV=1 - [B2FI43_STRMK] 
0.032 0.58 0.037 0.58 
B2FIA8 
Elongation factor Ts OS=Stenotrophomonas maltophilia (strain K279a) GN=tsf PE=3 SV=1 - 
[EFTS_STRMK] 
0.004 1.68 0.033 1.81 
B2FIA9 
30S ribosomal protein S2 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsB PE=3 SV=1 - 
[RS2_STRMK] 
0.042 0.71 0.015 0.65 
B2FIF8 
Peptidyl-prolyl cis-trans isomerase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1559 
PE=4 SV=1 - [B2FIF8_STRMK] 
0.013 1.86 0.001 1.84 
B2FII5 
Putative CDP-diacylglycerol pyrophosphatase OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt2903 PE=4 SV=1 - [B2FII5_STRMK] 
0.012 0.4 0.006 0.39 
B2FIJ2 
Putative L-lactate permease OS=Stenotrophomonas maltophilia (strain K279a) GN=lctP PE=4 SV=1 - 
[B2FIJ2_STRMK] 
0.048 1.7 0.013 2 
B2FIL8 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt2937 PE=3 SV=1 - [B2FIL8_STRMK] 
<0.05 >100 <0.05 >100 
B2FIN7 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4151 
PE=3 SV=1 - [B2FIN7_STRMK] 
<0.05 1.22 <0.05 >100 
B2FIQ3 
Putative lipid A biosynthesis lauroyl acyltransferase OS=Stenotrophomonas maltophilia (strain K279a) 
GN=htrB PE=4 SV=1 - [B2FIQ3_STRMK] 
0.035 0.62 0.05 0.69 
B2FIS6 
Protease 4 OS=Stenotrophomonas maltophilia (strain K279a) GN=sppA PE=3 SV=1 - 
[B2FIS6_STRMK] 
0.011 0.54 0.006 0.51 
B2FIU9 
60 kDa chaperonin OS=Stenotrophomonas maltophilia (strain K279a) GN=groL PE=3 SV=1 - 
[CH60_STRMK] 
0.045 1.7 0.011 1.95 
B2FIV0 
10 kDa chaperonin OS=Stenotrophomonas maltophilia (strain K279a) GN=groS PE=3 SV=1 - 
[CH10_STRMK] 
0.001 2.49 0.006 2.92 
B2FJ60 
Putative transmembrane PepSY domain protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt1566 PE=4 SV=1 - [B2FJ60_STRMK] 
<0.05 >100 <0.05 >100 
B2FJ75 
Putrescine-binding periplasmic protein OS=Stenotrophomonas maltophilia (strain K279a) GN=potF 
PE=3 SV=1 - [B2FJ75_STRMK] 
0.018 0.54 0.019 0.58 
B2FJ77 
Polyamine-transporting ATPase OS=Stenotrophomonas maltophilia (strain K279a) GN=potG PE=3 
SV=1 - [B2FJ77_STRMK] 
0.021 0.44 0.019 0.46 
B2FJB1 
Putative oar family adhesion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1619 
PE=4 SV=1 - [B2FJB1_STRMK] 
0.032 0.6 0.023 0.54 
B2FJJ3 
Putative hydroxamate-type ferrisiderophore receptor OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3022 PE=3 SV=1 - [B2FJJ3_STRMK] 





Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4275 PE=4 SV=1 - 
[B2FJR9_STRMK] 
0.045 1.59 0.027 2.19 
B2FJS3 
Putative multidrug efflux system HlyD family transmembrane protein OS=Stenotrophomonas maltophilia 
(strain K279a) GN=Smlt4279 PE=4 SV=1 - [B2FJS3_STRMK] 
0.022 0.54 0.013 0.47 
B2FJU4 
50S ribosomal protein L13 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplM PE=3 SV=1 - 
[RL13_STRMK] 
0.044 1.25 0.004 1.43 
B2FJV0 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0387 PE=4 SV=1 - 
[B2FJV0_STRMK] 
0.014 0.54 0.002 0.4 
B2FK68 
Putative glutamate synthase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1693 PE=3 
SV=1 - [B2FK68_STRMK] 
0.005 0.38 0.002 0.28 
B2FK88 Enolase OS=Stenotrophomonas maltophilia (strain K279a) GN=eno PE=3 SV=1 - [ENO_STRMK] <0.05 6.86 <0.05 11.58 
B2FKE9 
Putative P-protein [bifunctional includes: chorismate mutase and prephenate dehydratase 
OS=Stenotrophomonas maltophilia (strain K279a) GN=pheA PE=4 SV=1 - [B2FKE9_STRMK] 
0.022 0.08 0.005 0.07 
B2FKJ7 
50S ribosomal protein L9 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplI PE=3 SV=1 - 
[RL9_STRMK] 
0.023 1.51 0.015 1.62 
B2FKJ9 
30S ribosomal protein S6 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsF PE=3 SV=1 - 
[B2FKJ9_STRMK] 
0.003 1.77 0.009 1.67 
B2FKL0 
Putative haloacid dehalogenase hydrolase OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt4308 PE=4 SV=1 - [B2FKL0_STRMK] 
0.05 0.57 0.044 0.58 
B2FKM2 
Putative K(+)/H(+) antiporter subunit A/B (PH adaptation potassium efflux system protein A/B) 
OS=Stenotrophomonas maltophilia (strain K279a) GN=phaAB PE=4 SV=1 - [B2FKM2_STRMK] 
0.021 1.59 0.028 1.55 
B2FKX4 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0503 PE=4 SV=1 - 
[B2FKX4_STRMK] 
<0.05 >100 <0.05 >100 
B2FL08 
Putative transmembrane anchor protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt0538 PE=4 SV=1 - [B2FL08_STRMK] 
0.002 0.25 0.003 0.34 
B2FL10 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0540 PE=4 SV=1 - 
[B2FL10_STRMK] 
0.002 0.26 0.002 0.31 
B2FL33 
Alanine--tRNA ligase OS=Stenotrophomonas maltophilia (strain K279a) GN=alaS PE=3 SV=1 - 
[SYA_STRMK] 
<0.05 0.9 <0.05 0.68 
B2FL51 
Putative ferric siderophore receptor protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt1762 PE=3 SV=1 - [B2FL51_STRMK] 
<0.05 >100 <0.05 >100 
B2FL84 
Putative succinate dehydrogenase cytochrome b-556 subunit OS=Stenotrophomonas maltophilia (strain 
K279a) GN=sdhC PE=4 SV=1 - [B2FL84_STRMK] 
0.019 0.63 0.005 0.48 
B2FL86 
Putative succinate dehydrogenase flavoprotein subunit OS=Stenotrophomonas maltophilia (strain 
K279a) GN=sdhA PE=4 SV=1 - [B2FL86_STRMK] 
0.02 0.44 0.006 0.28 
B2FL87 
Succinate dehydrogenase iron-sulfur subunit OS=Stenotrophomonas maltophilia (strain K279a) 
GN=sdhB PE=3 SV=1 - [B2FL87_STRMK] 
0.021 0.54 0.004 0.36 
B2FLB8 
Peptidyl-prolyl cis-trans isomerase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3182 
PE=4 SV=1 - [B2FLB8_STRMK] 
0.038 0.62 0.007 0.44 
B2FLD3 
Dihydrolipoyl dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=odhL PE=3 SV=1 - 
[B2FLD3_STRMK] 
0.033 1.95 0.017 2.31 
B2FLE4 
Putative outer membrane antigen protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3210 PE=4 SV=1 - [B2FLE4_STRMK] 
0.023 0.59 0.002 0.4 
B2FLE9 
Putative outer membrane antigen lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3215 PE=4 SV=1 - [B2FLE9_STRMK] 





Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3232 PE=4 SV=1 - 
[B2FLG5_STRMK] 
0.025 0.56 0.049 0.64 
B2FLQ1 
D-amino acid dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=dadA PE=3 SV=1 
- [DADA_STRMK] 
0.016 0.4 0.016 0.41 
B2FLR8 
Putative vitamin B12 receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0585 
PE=3 SV=1 - [B2FLR8_STRMK] 
0.023 0.57 0.018 0.57 
B2FLT1 
Asparagine synthetase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0598 PE=4 SV=1 - 
[B2FLT1_STRMK] 
<0.05 >100 <0.05 >100 
B2FLX9 
Putative outer membrane lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1826 
PE=3 SV=1 - [B2FLX9_STRMK] 
0.03 0.57 0.01 0.49 
B2FM92 
Ribonuclease E OS=Stenotrophomonas maltophilia (strain K279a) GN=rnE PE=3 SV=1 - 
[B2FM92_STRMK] 
0.003 2.12 0.01 1.92 
B2FME8 
Putative DNA binding protein/regulator OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3308 PE=3 SV=1 - [B2FME8_STRMK] 
<0.05 >100 <0.05 >100 
B2FMF2 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3312 PE=4 SV=1 - 
[B2FMF2_STRMK] 
0.04 0.57 0.018 0.51 
B2FMI1 
Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4498 PE=4 
SV=1 - [B2FMI1_STRMK] 
0.025 0.57 0.01 0.55 
B2FMN3 
Putative transmembrane anchor short-chain dehydrogenase OS=Stenotrophomonas maltophilia (strain 
K279a) GN=Smlt0632 PE=4 SV=1 - [B2FMN3_STRMK] 
0.03 0.62 0.035 0.68 
B2FMP6 
Putative electron transfer flavoprotein subunit beta OS=Stenotrophomonas maltophilia (strain K279a) 
GN=etfS PE=4 SV=1 - [B2FMP6_STRMK] 
0.034 2.22 0.001 2.39 
B2FMY6 
Chaperone protein DnaJ OS=Stenotrophomonas maltophilia (strain K279a) GN=dnaJ PE=3 SV=1 - 
[DNAJ_STRMK] 
0.022 1.66 0.028 3.19 
B2FN04 
Putative reductase Smlt2015 OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2015 PE=3 
SV=1 - [B2FN04_STRMK] 
<0.05 2.18 <0.05 2.38 
B2FN37 
Putative N-acetylmuramoyl-L-alanine amidase OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3330 PE=4 SV=1 - [B2FN37_STRMK] 
0.038 0.56 0.008 0.41 
B2FN47 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3340 
PE=3 SV=1 - [B2FN47_STRMK] 
0.006 0.37 0.003 0.37 
B2FNC5 
Putative dipeptidyl peptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4581 PE=4 
SV=1 - [B2FNC5_STRMK] 
0.006 0.48 0.014 0.53 
B2FND7 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4593 PE=4 SV=1 - 
[B2FND7_STRMK] 
0.003 0.37 0.003 0.45 
B2FNF4 
Putative glycosyl transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4611 PE=4 
SV=1 - [B2FNF4_STRMK] 
0.028 0.53 0.009 0.46 
B2FNG4 
Putative Major Facilitator Superfamily transmembrane transport protein OS=Stenotrophomonas 
maltophilia (strain K279a) GN=Smlt4621 PE=4 SV=1 - [B2FNG4_STRMK] 
<0.05 >100 <0.05 >100 
B2FNG5 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt4622 PE=4 SV=1 - [B2FNG5_STRMK] 
<0.05 5.89 <0.05 5.35 
B2FNG6 
Acetyl-coenzyme A synthetase OS=Stenotrophomonas maltophilia (strain K279a) GN=acsA PE=3 
SV=1 - [B2FNG6_STRMK] 
<0.05 >100 <0.05 >100 
B2FNP5 
30S ribosomal protein S1 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsA PE=3 SV=1 - 
[B2FNP5_STRMK] 
0.01 1.72 0.005 1.84 
B2FNQ0 
Putative epimerase/dehydratase polysaccharide-related biosynthesis protein OS=Stenotrophomonas 
maltophilia (strain K279a) GN=wbiI PE=4 SV=1 - [B2FNQ0_STRMK] 





NADH-quinone oxidoreductase subunit I OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoI 
PE=3 SV=1 - [B2FNX1_STRMK] 
0.018 0.48 0.003 0.31 
B2FNX6 
NADH-quinone oxidoreductase subunit D OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoD 
PE=3 SV=1 - [NUOD_STRMK] 
0.018 0.57 0.004 0.39 
B2FNX7 
NADH-quinone oxidoreductase subunit C OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoC 
PE=3 SV=1 - [NUOC_STRMK] 
0.011 0.51 0.001 0.33 
B2FNX8 
NADH-quinone oxidoreductase subunit B OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoB 
PE=3 SV=1 - [NUOB_STRMK] 
0.02 0.51 0.003 0.34 
B2FNY0 
Putative general secretory pathway protein-export membrane protein OS=Stenotrophomonas 
maltophilia (strain K279a) GN=secG PE=4 SV=1 - [B2FNY0_STRMK] 
0.001 0.43 0.003 0.52 
B2FNY4 
Putative lipopolysaccharide core biosynthesis glycosyl transferase OS=Stenotrophomonas maltophilia 
(strain K279a) GN=Smlt3411 PE=4 SV=1 - [B2FNY4_STRMK] 
0.04 0.64 0.046 0.67 
B2FP19 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3449 PE=4 SV=1 - [B2FP19_STRMK] 
0.039 1.64 0.01 2.53 
B2FP56 
Ferrochelatase OS=Stenotrophomonas maltophilia (strain K279a) GN=hemH PE=3 SV=1 - 
[B2FP56_STRMK] 
0.048 0.5 0.028 0.44 
B2FP85 
Putative ABC transporter toluene tolerance exported protein OS=Stenotrophomonas maltophilia (strain 
K279a) GN=Smlt4673 PE=4 SV=1 - [B2FP85_STRMK] 
0.005 1.75 0.004 1.76 
B2FPA5 
Membrane protein insertase YidC OS=Stenotrophomonas maltophilia (strain K279a) GN=yidC PE=3 
SV=1 - [YIDC_STRMK] 
0.028 0.56 0.014 0.52 
B2FPD1 
Putative glycosyl transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0784 PE=4 
SV=1 - [B2FPD1_STRMK] 
0.011 0.45 0.015 0.54 
B2FPD9 
Probable Na+ dependent nucleoside transporter OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt0792 PE=4 SV=1 - [B2FPD9_STRMK] 
0.003 0.73 0.032 0.76 
B2FPE2 
Putative exported heme receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=huvA 
PE=3 SV=1 - [B2FPE2_STRMK] 
0 22.44 0 43.14 
B2FPE4 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0797 PE=4 SV=1 - 
[B2FPE4_STRMK] 
<0.05 >100 <0.05 >100 
B2FPF2 
Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0805 PE=4 
SV=1 - [B2FPF2_STRMK] 
0.044 0.6 0.014 0.49 
B2FPF9 
Prolipoprotein diacylglyceryl transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=lgt 
PE=3 SV=1 - [LGT_STRMK] 
0.005 0.44 0.01 0.47 
B2FPN1 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2175 
PE=3 SV=1 - [B2FPN1_STRMK] 
0.009 2.98 0.013 2.65 
B2FPQ9 
Putative TonB domain protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3477 PE=4 
SV=1 - [B2FPQ9_STRMK] 
<0.05 >100 <0.05 >100 
B2FPR0 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3478 
PE=3 SV=1 - [B2FPR0_STRMK] 
0.019 3.83 0.014 4.26 
B2FPS0 
Putative exported LysM bacterial cell wall related protein OS=Stenotrophomonas maltophilia (strain 
K279a) GN=Smlt3488 PE=4 SV=1 - [B2FPS0_STRMK] 
0.02 0.49 0.009 0.43 
B2FPS4 
Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3492 PE=4 
SV=1 - [B2FPS4_STRMK] 
0.008 0.47 0.012 0.53 
B2FPV6 
Putative thiolase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3525 PE=3 SV=1 - 
[B2FPV6_STRMK] 
<0.05 0.38 <0.05 0.62 
B2FPY0 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3550 PE=4 SV=1 - 
[B2FPY0_STRMK] 





Putative alkyl hydroperoxide reductase subunit c OS=Stenotrophomonas maltophilia (strain K279a) 
GN=ahpC PE=4 SV=1 - [B2FPY7_STRMK] 
0.024 3.37 0.004 4.5 
B2FQ28 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt0885 PE=3 SV=1 - [B2FQ28_STRMK] 
0.016 0.54 0.032 0.59 
B2FQ38 
DNA-directed RNA polymerase subunit beta OS=Stenotrophomonas maltophilia (strain K279a) 
GN=rpoB PE=3 SV=1 - [RPOB_STRMK] 
0.037 2.71 0.018 3 
B2FQ39 
DNA-directed RNA polymerase subunit beta' OS=Stenotrophomonas maltophilia (strain K279a) 
GN=rpoC PE=3 SV=1 - [RPOC_STRMK] 
0.033 2.47 0.022 2.28 
B2FQ42 
Elongation factor G OS=Stenotrophomonas maltophilia (strain K279a) GN=fusA PE=3 SV=1 - 
[EFG_STRMK] 
0.046 2.16 0.009 1.85 
B2FQ45 
50S ribosomal protein L3 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplC PE=3 SV=1 - 
[RL3_STRMK] 
0.006 1.37 0.031 1.28 
B2FQ48 
50S ribosomal protein L2 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplB PE=3 SV=1 - 
[RL2_STRMK] 
0.037 1.57 0.04 1.4 
B2FQ50 
50S ribosomal protein L22 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplV PE=3 SV=1 - 
[RL22_STRMK] 
0.019 1.77 0.025 2.14 
B2FQD3 
Putative carbon starvation protein A OS=Stenotrophomonas maltophilia (strain K279a) GN=cstA PE=4 
SV=1 - [B2FQD3_STRMK] 
0 3.8 0.008 3.55 
B2FQJ8 
30S ribosomal protein S8 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsH PE=3 SV=1 - 
[RS8_STRMK] 
0.028 0.71 0.031 0.73 
B2FQK6 
30S ribosomal protein S11 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsK PE=3 SV=1 - 
[RS11_STRMK] 
0.029 1.37 0 1.73 
B2FQK8 
DNA-directed RNA polymerase subunit alpha OS=Stenotrophomonas maltophilia (strain K279a) 
GN=rpoA PE=3 SV=1 - [RPOA_STRMK] 
0.043 2.11 0.016 1.9 
B2FQL8 
Malate dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=mdh PE=3 SV=1 - 
[MDH_STRMK] 
0.043 2.36 0.034 7.46 
B2FQN3 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0960 PE=4 SV=1 - 
[B2FQN3_STRMK] 
0.008 0.43 0.007 0.43 
B2FQN4 
L-threonine 3-dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=tdh PE=3 SV=1 - 
[TDH_STRMK] 
<0.05 >100 <0.05 >100 
B2FR08 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3645 
PE=3 SV=1 - [B2FR08_STRMK] 
0.003 2.73 0.007 3.67 
B2FR62 
Putative autotransporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1001 PE=4 SV=1 - 
[B2FR62_STRMK] 
0.001 0.1 0 0.09 
B2FRC4 
Putative TonB-dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1067 
PE=3 SV=1 - [B2FRC4_STRMK] 
0.003 4.64 0.003 4.28 
B2FRE3 
Putative esterase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2353 PE=4 SV=1 - 
[B2FRE3_STRMK] 
<0.05 >100 <0.05 >100 
B2FRE4 
Putative ATP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2354 
PE=4 SV=1 - [B2FRE4_STRMK] 
<0.05 >100 <0.05 >100 
B2FRE5 
Putative binding-protein-dependent transport lipoprotein OS=Stenotrophomonas maltophilia 
(strain K279a) GN=Smlt2355 PE=4 SV=1 - [B2FRE5_STRMK] 
0 14.81 0 28.03 
B2FRE6 
Putative FecCD-family transmembrane transport protein OS=Stenotrophomonas maltophilia 
(strain K279a) GN=Smlt2356 PE=4 SV=1 - [B2FRE6_STRMK] 
<0.05 >100 <0.05 >100 
B2FRE7 
Hemin import ATP-binding protein HmuV OS=Stenotrophomonas maltophilia (strain K279a) 
GN=hmuV PE=3 SV=1 - [B2FRE7_STRMK] 





Putative iron transport receptor protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt1148 PE=3 SV=1 - [B2FRZ9_STRMK] 
0.01 2.17 0.005 2.57 
B2FS15 
Putative histone-like protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1164 PE=4 
SV=1 - [B2FS15_STRMK] 
0.02 3.04 0.001 5.72 
B2FSE3 
Putative HlyD-family secretion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=smeM 
PE=4 SV=1 - [B2FSE3_STRMK] 
0.027 0.65 0.001 0.39 
B2FSE4 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3789 
PE=3 SV=1 - [B2FSE4_STRMK] 
0.002 5.18 0 4.28 
B2FSE9 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3796 PE=4 SV=1 - [B2FSE9_STRMK] 
0.002 0.34 0.001 0.34 
B2FSF0 
Fructose-bisphosphate aldolase OS=Stenotrophomonas maltophilia (strain K279a) GN=alf1 PE=3 
SV=1 - [B2FSF0_STRMK] 
0.001 2.16 0 2.92 
B2FSF6 
Glyceraldehyde-3-phosphate dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) 
GN=gap PE=3 SV=1 - [B2FSF6_STRMK] 
0.009 2.79 0 2.91 
B2FSQ7 
Putative TonB-dependent receptor for Fe(III)-coprogen, Fe(III)-ferrioxamine B and Fe(III)-rhodotrulic 
acid OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1233 PE=3 SV=1 - [B2FSQ7_STRMK] 
0 20.43 0 45.94 
B2FSS6 
Putative PTS system, fructose-specific IIBC component OS=Stenotrophomonas maltophilia (strain 
K279a) GN=fruA PE=4 SV=1 - [B2FSS6_STRMK] 
0.046 1.65 0.034 1.8 
B2FST2 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2566 
PE=4 SV=1 - [B2FST2_STRMK] 
0.019 2.9 0.003 3.07 
B2FT59 
Putative extracellular heme-binding protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3898 PE=3 SV=1 - [B2FT59_STRMK] 
0.006 3.3 0.001 8.38 
B2FT68 
Putative transcriptional regulator OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3907 
PE=4 SV=1 - [B2FT68_STRMK] 
0.015 0.5 0.016 0.53 
B2FT80 
DNA polymerase III subunit beta OS=Stenotrophomonas maltophilia (strain K279a) GN=dnaN PE=4 
SV=1 - [B2FT80_STRMK] 
<0.05 >100 <0.05 >100 
B2FT86 
Conserved hypothetical TPR repeat family protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt0008 PE=4 SV=1 - [B2FT86_STRMK] 
0.001 2.82 0 3.24 
B2FT87 
Putative proline-rich TonB dependent receptor protein OS=Stenotrophomonas maltophilia 
(strain K279a) GN=Smlt0009 PE=4 SV=1 - [B2FT87_STRMK] 
0.045 0.53 0.015 0.47 
B2FTK5 
Putative ferric siderophore receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2650 
PE=3 SV=1 - [B2FTK5_STRMK] 
<0.05 7.93 <0.05 12.31 
B2FTR3 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt2712 PE=4 SV=1 - [B2FTR3_STRMK] 
<0.05 >100 <0.05 >100 
B2FTR4 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt2713 PE=4 SV=1 - [B2FTR4_STRMK] 
<0.05 >100 <0.05 >100 
B2FTR5 
Putative TonB dependent protein, possible siderophore receptor OS=Stenotrophomonas maltophilia 
(strain K279a) GN=Smlt2714 PE=3 SV=1 - [B2FTR5_STRMK] 
<0.05 >100 <0.05 >100 
B2FTS4 
Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=pcm PE=4 SV=1 - 
[B2FTS4_STRMK] 
0.025 0.64 0.01 0.49 
B2FTS5 
Protein CyaE OS=Stenotrophomonas maltophilia (strain K279a) GN=tolC PE=3 SV=1 - 
[B2FTS5_STRMK] 
0.001 0.34 0 0.3 
B2FTS8 
Putative lipid A biosynthesis lauroyl acyltransferase OS=Stenotrophomonas maltophilia (strain K279a) 
GN=htrB PE=4 SV=1 - [B2FTS8_STRMK] 
0.045 0.57 0.03 0.55 
B2FTY9 
Putative endonuclease/exonuclease/phosphatase family protein OS=Stenotrophomonas maltophilia 
(strain K279a) GN=Smlt3995 PE=4 SV=1 - [B2FTY9_STRMK] 





Putative iron transporter protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0049 PE=3 
SV=1 - [B2FU12_STRMK] 
0.015 6.19 0.013 3.74 
B2FU42 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt0083 PE=3 SV=1 - [B2FU42_STRMK] 
0.009 0.45 0.003 0.35 
B2FU43 
Acid phosphatase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0084 PE=3 SV=1 - 
[B2FU43_STRMK] 
0 0.45 0 0.39 
B2FU57 
Putative lipoprotein E (Outer membrane protein p4) OS=Stenotrophomonas maltophilia (strain K279a) 
GN=hel PE=4 SV=1 - [B2FU57_STRMK] 
0.029 0.53 0.041 0.61 
B2FUD9 
Putative HlyD family secretion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1406 
PE=4 SV=1 - [B2FUD9_STRMK] 
0.033 0.57 0.039 0.63 
B2FUL1 
Putative respiratory nitrate reductase subunit OS=Stenotrophomonas maltophilia (strain K279a) 
GN=narH PE=4 SV=1 - [B2FUL1_STRMK] 
0.04 0.45 0.018 0.38 
B2FUN9 
Putative TonB-dependent receptor for Fe(III)-coprogen, Fe(III)-ferrioxamine B and Fe(III)-rhodotrulic 
acid OS=Stenotrophomonas maltophilia (strain K279a) GN=fhuE PE=3 SV=1 - [B2FUN9_STRMK] 
0.001 10.25 0 16.63 
B2FUR1 
Putative TonB-dependent outer membrane receptor protein OS=Stenotrophomonas maltophilia (strain 
K279a) GN=Smlt4026 PE=3 SV=1 - [B2FUR1_STRMK] 
0.05 0.64 0.007 0.37 
B2FUV1 
Putative multidrug resistance outer membrane protein OS=Stenotrophomonas maltophilia (strain 
K279a) GN=smeF PE=4 SV=1 - [B2FUV1_STRMK] 





4 Characterisation of new mechanisms of resistance 
against aminoglycosides, quinolones and 




As stated on the introduction, S. maltophilia has been gaining increasing 
recognition for its intrinsic multidrug resistance which translates into limited therapeutic 
options. Co-trimoxazole has exhibited the best rate of success against S. maltophilia 
infections (255). However, its administration becomes limited in presence of the 
sulphonamide-resistant dihydropteroate synthase, in patients who present allergies 
due to the generation of sulfamethoxazole-specific antibodies caused by the nitroso 
metabolite of sulfamethoxazole (152) and in situations where intravenous 
administration is not available. Given the complexity of scenarios that clinicians must 
face in S. maltophilia infections, it becomes imperative to explore therapeutic 
alternatives beyond co-trimoxazole and with it a deeper understanding of the 
mechanisms of resistance against the alternatives. Thus, chemotherapy failure can be 
prevented by increasing the probability of choosing the antibiotic with the greatest 
potential of success. Apart from the β-lactams, discussed in the previous chapter, 
aminoglycosides such as amikacin, tobramycin, and gentamicin (152) have been used 
as part of a combined therapy against S. maltophilia. Whilst third and fourth generation 
quinolones, levofloxacin and moxifloxacin, (256) and the tetracycline derivative 
minocycline (255) have been used either alone or in a combination with other agents. 
Aminoglycosides are normally part of a combined therapy since alone, they 
show poor activity against S. maltophilia infections (257). In fact, mechanisms of 
resistance against aminoglycoside are wide-ranging. For instance, entry of gentamicin 
can be temperature-dependent limited due to lipopolysaccharide changes(258). 
Amikacin efflux can be driven by SmeOP-TolCSm (179) and SmeYZ (259, 260). 
Alternatively, modifying enzymes such as the AAC (6’)-I-type enzyme (116) can 
acetylate and inactive amikacin. In the case of levofloxacin, monotherapy has shown to 
be more advantageous than co-trimoxazole concerning side effects for the patient. 
However, levofloxacin and moxifloxacin have the ability to select resistance at high 
frequency. Overexpression of SmeJK has been attributed to levofloxacin resistance 
(260) while upregulation of SmeDEF could explain moxifloxacin-reduced 
susceptibility(261). Minocycline usage is relatively recent (255) and because of the low 




mechanisms for minocycline resistance in S. maltophilia; on is upregulation of SmeIJK 
(260). 
Previously, two amikacin resistant mutants of S. maltophilia K279a have been 
reported K AMI 8 and K AMI 32. Both have been shown to overexpress the smeYZ 
efflux pump genes, according to RT-PCR and deletion of smeZ reverted amikacin 
resistance (260). Similarly, when trying to unravel the mechanism behind moxifloxacin 
resistance, two mutants K MOX 2 and K MOX 8 were shown to overexpress the 
smeDEF efflux pump. PCR sequencing revealed a mutation in smeT, encoding a 
transcriptional repressor of smeDEF in K MOX 8 but not in K MOX 2, where smeT was 
found to be wild-type (260). Thus, the aims of the work reported in this chapter were to 
identify the reason for enhanced smeYZ expression in K AMI 8 and K AMI 32, and the 
reason for enhanced smeDEF expression in K MOX 2. Furthermore, to select and 
characterise mutants with reduced susceptibility to levofloxacin and minocycline.   
 
4.2 Results and discussion 
 
4.2.1 Identification of rplA mutation in amikacin resistant mutants 
overexpressing smeYZ suggests a novel regulatory mechanism for 
smeYZ expression linking ribosome damage with aminoglycoside 
resistance 
 
Aminoglycoside resistant mutants K AMI 8 and K AMI 32 were recovered from 
storage. Antibiotic susceptibility profiling confirmed both mutants retained the 
previously characteristic phenotype ‘resistance profile 3’ – particularly reduced zone 
diameters for aminoglycosides, quinolones and tetracyclines –, as previously reported 
(260) (Table 4.1). Generally, the zone diameters for K AMI 32 were smaller than for K 
AMI 8. Perhaps explaining this difference, whole envelope proteomics analysis showed 
a 2-fold upregulation of SmeYZ efflux pump in K AMI 8, and 8-fold upregulation in K 
AMI 32 relative to the parental strain, K279a (Figure 4.1). SmeY is an RND-type efflux 
protein and SmeZ is a membrane fusion protein. The outer membrane protein that 
completes the tripartite pump is not known (264). Expression of smeYZ is known to be 
controlled by a two-component system (TCS), SmeSyRy, encoded next to smeYZ on 
the chromosome (180). However, whole genome sequencing (WGS) analysis showed 
that smeSyRy are wild-type in both amikacin mutants, and instead, both have only one 




mutation causes a Gly67Asp change in the largest protein from the 50S ribosomal 
subunit, L1, encoded by the rplA gene. A previously described clinical isolate 9189, 
which also has the aminoglycoside resistance profile 3 and overexpresses smeYZ 
(260) as confirmed in Table 4.1, was found by PCR sequencing to carry mutations in 
rplA causing a Phe22Leu change on RplA and a frameshift mutation in codon 212 
caused by the insertion of an adenine base in rplA. (Figure 4.2). In P. aeruginosa, 
MexXY is considered the most important efflux-pump involved in aminoglycoside 
resistance (265). It has been stated (266) that at least two P. aeruginosa clinical 
isolates that hyperexpress mexXY have truncations in rplA, though the data were not 
presented and reported as ‘unpublished’. Mutations in other ribosomal subunit genes 
have more conclusively been shown to cause mexXY overexpression, however (265)  
given the similarities between MexXY and SmeYZ, it seems reasonable to propose the 
rplA disruption is the cause of smeYZ overexpression in S. maltophilia K279a mutants 
and the clinical isolate 9189.  
 
Table 4.1 Disc testing profile of parental strain K279a, resistance-profile-3 K279a 






















K279a 32 27 23 32 22 24 25 27 
K AMI 8 29 20 17 23 11 18 20 23 
K AMI 32 29 18 14 25 6 9 23 22 
9189 31 24 18 31 6 21 6 6 
 
 
Shaded values represent reduced zone diameters (≥5mm relative to the 
parental strain K279a). K AMI 8, K AMI 32, 9189, belong to the resistant profile 3 











Figure 4.1 Upregulation of efflux-pump SmeYZ proteins in resistance profile 3 
mutants derived from K279a 
 
Protein abundance data of whole envelope proteomics are normalised to the average 
ribosomal content of each sample (including abundance of 30S and 50S ribosomal 
proteins). Fold change of SmeY and SmeZ (Uniprot: B2FQ54-55) is calculate after 
testing statistical difference between the parental strain and the mutants (p<0.05). 



















































Figure 4.2 RplA amino acid sequence comparison of resistance profile 3 
mutants 
 
Alignment of predicted RplA sequences (smlt0895) based on PCR sequencing 
showing the change of well conserved residue Gly67 to Asp in K AMI 8 and 
K AMI 32 when compared to PDB1U63. A Phe22Leu in the clinical isolate likely due 
to genetic drift when compared to the sequence of PDB 1U63. Finally a frameshift in 
the C-terminus of the clinical isolate 9189 (non-highlighted regions).  Alignment was 
performed with CLUSTAL Omega and ESPript 3 
 
 
4.2.2 Expression of smeZ is inducible in presence of sub-lethal 
concentrations of gentamicin 
 
Again in P. aeruginosa, expression of mexXY is inducible in response to 
ribosomal acting agents (267, 268), and since ribosomal protein damage by mutation is 
associated with smeYZ overexpression in S. maltophilia, we next tested the inducibility 
of smeZ expression by ribosomal inhibition caused by aminoglycosides. Expression of 
smeZ was assessed by RT-qPCR from a culture of K279a exposed to the 
aminoglycoside gentamicin (32 µg.mL- 1) versus a control culture. Expression of smeZ 
in the control and gentamicin-treated samples were significantly different (p<0.0001) 
with, as predicted, an increase of smeZ expression during gentamicin challenge 




limited to the presence of the efflux-pump substrate but to membrane-damaging 
agents or ribosomal disruption (269). One of the first pieces of evidence for a 
nonantibotic substrate for RND efflux-pump was found in E. coli. It was proposed that 
metabolite accumulation due to mutations involved in the disruption of nucleotide or 
amino acid biosynthetic pathways may lead to active metabolite efflux to avoid a rise in 
the concentration of toxic metabolic products (270). In P. aeruginosa, it has also been 
proposed that the buil-up of aberrant polypeptides from a damaged ribosome in the 
presence of ribosome-targeting antibiotics may act as signal for induction of MexXY 
production (271). This may also be the case in S. maltophilia for SmeYZ production. 
Here, we have confirmed that ribosomal damaging aminoglycosides activate 
production of an aminoglycoside efflux pump in S. maltophilia and suggest the signal is 
direct ribosomal damage, as for MexXY induction in P. aeruginosa (271). Loss of 
SmeYZ negatively impacts virulence. Whils flagella and biofilm formation decrease, 
susceptibility to human neutrophils increases (259).Thus, as well as affecting 
aminoglycoside susceptibility, increases in smeYZ expression might increase 
virulence, in fact when we checked swimming motility in K AMI 8 and K AMI 32 (data 




Figure 4.3 RT-qPCR analysis of effect of gentamicin on smeZ expression  






























Experimental group was grown in presence of gentamicin (32 µg.mL- 1). Fold change 
of smeZ expression between control and experimental group was calculated using 
the 2^∆∆Ct method and statistical difference between groups was calculated using a 
two-tailed, unpaired T-Test in GraphPrism (p<0.0001) 
 
4.2.3 Reciprocal relationship between smeDEF and smeYZ in resistance 
profile 1 mutants is confirmed by whole envelope proteomics 
 
The ‘resistance profile 1’ mutants K MOX 2 and K MOX 8 were also recovered 
from storage and confirmed to have the expected profile of resistance – decreased 
ciprofloxacin and chloramphenicol susceptibility- (189) (Table 4.2). Whole envelope 
proteomics analysis confirmed the previously reported overexpression of smeDEF in 
these two mutants (189). There was  a 1.5-fold upregulation of SmeDEF in K MOX 2, 
and 3-fold upregulation of SmeDEF in K MOX 8 relative to the parental strain, K279a 
(Figure 4.4). Again, the increased amount of SmeDEF in K MOX 8 versus K MOX 2 
may explain the fact that susceptibility is reduced more in K MOX 8 than K MOX 2 
relative to K279a (Table 4.2). K MOX 2 and K MOX 8 were previously shown to have 
increased susceptibility to amikacin when compared to resistance profile 3 mutants 
(189) (Table 4.1) (Table 4.2) . Comparative proteomics confirmed that in K MOX 2 and 
K MOX 8, SmeYZ was downregulated as SmeDEF was hyperproduced, which would 
explain why aminoglycoside susceptibility increases in K MOX 2 and K MOX 8 as part 
of resistance profile 1. Interestingly, it has recently been reported that overexpression 
of smeYZ leads to reduced smeDEF expression (259) suggesting a reciprocal 
regulation of these pumps in both directions. However, our proteomics showed that 
SmeDEF production was not reduced in the SmeYZ over-producing mutants K AMI 32 






Table 4.2 Disc testing profile of parental strain K279a and resistance-profile-1 






















K279a 32 27 23 32 22 24 25 27 
K MOX 2 30 19 13 27 22 25 23 22 
K MOX 8 31 18 14 27 21 23 22 22 
Shaded values represent reduced zone diameters (≥5mm relative to the 
parental strain K279a). K MOX 2, K MOX 8, belong to the resistant profile 1 







Figure 4.4 Reciprocal relationship of smeDEF and smeYZ expresssion 
Protein abundance data of whole envelope proteomics are normalised to the 
ribosomal content of each samples (including abundance of 30S and 50S proteins). 
Fold change was calculated after testing statistical difference between the parental 
strain and the mutants (p <0.05). p values >0.05 are marked with (*).  A) 
Upregulation of efflux-pump SmeDEF in resistance profile 1 (KMOX2 and KMOX8) 
and profile 3 (KAMI8 and KAMI32) mutants. B) Upregulation of efflux-pump SmeYZ 
in K MOX 8 but not in the opposite way in K AMI 32. Values are reported as mean 
+/- Standard Error of the Mean (n=3). Full Proteomics data for K MOX 8 and K AMI 




The reason behind overexpression of smeDEF in K MOX 8 is a point mutation 
that disrupts the local repressor of smeDEF, SmeT (189). However, K MOX 2 
conserved a wild-type smeT which suggested the involvement of a different regulatory 
mechanism for smeDEF expression and the authors proposed that ‘It may be that the 
mutated regulatory locus in K-M6 (also known as K MOX 2) encodes a protein whose 
function is to regulate the concentration of a ligand that signals for SmeT to derepress 
smeDEF expression’. WGS was performed on K MOX 2 and revealed a single 
mutation relative to K279a predicted to cause a Gly368Ala change in a putative 
glycosyltransferase encoded by the wxocA gene (Figure 4.5). Gly368 is a particularly 
well-conserved residue when searching in the S. maltophilia genomes in the Genbank 
database since no alternative residues were found at that position. 
Glycosyltransferases are responsible of the addition of saccharides onto other 
biomolecules. Therefore they can utilize various substrates and participate in myriad 
cellular functions. For example, synthesis of the core oligosaccharide region of the 
lipopolysaccharide (273) cellular detoxification, solubilisation of substrates (274). 
Currently, there is no information about the specific role of the glycosyltransferase 
encoded by smlt0622. However, the wxocA of a Xanthomonas oryzae strain has been 
reported to have 62% identity and 74% similarity to a homologous lipopolysaccharide 
biosynthesis protein-like protein [Uniprot A5KT55]  (275). When we compared the 
WxocA sequence of K MOX 2 to A5KT55, we found 52% identity and 94% similarity. 
But again, without knowing its exact cellular role, it only seems possible to suggest why 
the alteration found in this particular glycosyltransferase is a reason for constitutive 
activation of SmeDEF. It may be that the earlier publication is correct and that the 
glycosyltransferase is involved in cellular detoxification, and that loss of this 
detoxification leads to the build-up of a toxic chemical that activates SmeDEF 













Figure 4.5 Glycosyltransferase amino acid sequence comparison of type 1 
resistant mutants 
Alignment of glycosyltransferase (wxocA) sequences showing Gly368Ala change in 
K MOX 2 which is a well conserved residue (non-highlighted regions) which is a well 
conserved residue. Alignment was performed with CLUSTAL Omega and ESPript 
3.0 
 
4.2.4 Characterisation of a novel mechanism of enhanced 
fluoroquinolone resistance caused by a bipartite ABC transporter, 
regulated by a divergent two-component system 
 
Next, we attempted to characterise mechanisms that cause resistance to the 
fluoroquinolone levofloxacin, which is showing promise for treatment of S. maltophilia 
infections (256, 276). When trying to select a single-step-levofloxacin resistant mutant 
from K279a, no mutant was recovered. Thus, K LEV 5 was obtained as a second-step-




resistant, retains levofloxacin susceptibility. K LEV 5 presented a similar resistance 
profile to K MOX 2, but with further reduced inhibition zones for ciprofloxacin and 
levofloxacin according to disc testing (Table 4.3). Whole envelope proteomics analysis 
revealed upregulation of a bipartite ABC transporter (annotated as MacAB based on its 
similarity to this well characterised pump from E. coli (173, 277)  in K LEV 5 compared 
with K MOX 2. However, since there is no evidence for this being a macrolide efflux 
pump in S. maltophilia we will refer to this putative efflux pump by its Smlt number 
(Smlt2642-3). We also noticed in the proteomics data that a two-component system 
(Smlt2645-6), encoded immediately adjacent Smlt2642-3 is also overproduced in K 
LEV 5 relative to K MOX 2 (Annex 2). According to WGS K LEV 5 has only one 
mutation, predicted to cause an Ala198Thr change in the sensor histidine kinase 
protein (Smlt2646) (Figure 4.6). This histidine kinase is therefore a good candidate for 
local activation of this ABC transporter given its location in the chromosome. Since the 
output of a two-component system is dominant due to amount of the phosphorylated 
regulator, we aimed to confirm the effect of the mutated version of smlt2646 in a wild-
type background, in trans. The operon, including the response regulator and the 
histidine kinase (smlt2644-smlt2646), was cohesive-end ligated into pBBRMCS-4 
(AmpR) (235, 236) and the recombinant plasmid was used to transform. K279aAmpFS, 
which is an ampicillin susceptible derivative of K279a (160) to ampicillin resistance 
(100 µg.mL- 1) via electroporation. To confirm the insertion of a unique insert we 
digested the plasmid pBBRMCS-4:: smlt2644-6 with EcoRI and observed the presence 
the ~2709bp-expect insert (Figure 4.7). Disc testing showed a reduction in levofloxacin 
susceptibility in K279aAmpFS bearing pBBR1MCS-4::smlt2644-6 relative to the plasmid 
only control transformant. An original zone of inhibition around a levofloxacin disc of 37 
mm decreased to 20 mm in the recombinant (Figure 4.8). Accordingly, this is an 







Table 4.3 Disc testing profile of initial parental strain K279a and resistance-
profile-1 K MOX 2 and its derivative K LEV 5against aminoglycoside, quinolone 






















K279a 32 27 23 32 22 24 25 27 
K MOX 2 30 19 13 27 22 25 23 22 
K LEV 5 30 14 11 27 20 22 22 22 
 
 
Shaded values represent reduced zone diameters (≥5mm relative to the 
parental strain K279a). K MOX 2 and K LEV 5, belong to the resistant profile 1 





Figure 4.6 Histidine kinase amino acid sequence comparison of type 1 resistant 
mutants 
Alignment of histidine kinase (smlt2646) sequences showing Ala198Thr change in 
K LEV 5 (non-highlighted regions) which is a well conserved residue and its mutation 
might interrupt signal transduction since this region is likely to correspond to a 
























Figure 4.7 Enzymatic digestion of the vector containing the operon containing 
the two-component system (Smlt2644-6) during complementation in trans 
 
A) Linearized vector with EcoRI from K279a ampRFS carrying pBBR1MCS-4 (4950bp) 
B) Digested vector where backbone corresponds to 4950bp and the insert (smlt2644-
46) to 2709bp from K279a ampRFS carrying pBBR1MCS-4::smlt2644-46. To improve 








Figure 4.8 Expression in trans of two-component system (Smlt2644-6)  in K279a 
AmpRFS reduces susceptibility to levofloxacin 
A) K279a ampRFS carrying pBBR1MCS-4: zone of inhibition 37 mm B) K279a ampRFS 
carrying pBBR1MCS-4::two-component system 20 mm 
 
4.2.5 Rate of levofloxacin susceptibility in world-wide collection of 
S. maltophilia clinical isolates  
 
Levofloxacin resistance in the collection of S. maltophilia clinical isolates only 
corresponds to 32% according to the CLSI guidelines (197). Hence, it would be 
interesting to test how common are our findings of ABC transporter upregulation are in 
clinical isolates.  
 
4.2.6 Mutants with reduce susceptibility to minocycline overproduce an 
ABC transporter, Smlt1640, regulated by a divergent 
two-component system 
 
Minocycline is another antimicrobial with potential against S. maltophilia 
infections and rates of resistance are very low. In fact, in our world-wide collection all 
clinical isolates were susceptible to minocycline, according to the CLSI breakpoints 






Table 4.4 Zone diameters (mm) around minocycline discs for worldwide 
collection of S. maltophilia clinical isolates (C.A.) All isolates are susceptible to 











C.A. 28 27 
C.A.1 33 C.A. 29 31 
C.A. 2 33 C.A. 30 26 
C.A. 3 20 C.A. 31 28 
C.A. 4 28 C.A. 32 30 
C.A. 7 33 C.A. 33 31 
C.A. 8 35 C.A. 34 30 
C.A. 9 31 C.A. 35 30 
C.A. 10 34 C.A. 36 32 
C.A. 11 31 C.A. 37 32 
C.A. 12 28 C.A. 38 30 
C.A. 13 32 C.A. 39 31 
C.A. 14 29 C.A. 40 30 
C.A. 15 27 C.A. 41 30 
C.A. 16 29 C.A. 42 31 
C.A. 17 29 C.A. 43 30 
C.A. 18 33 C.A. 44 26 
C.A. 19 30 C.A. 45 31 
C.A. 20 33 C.A. 46 31 
C.A. 21 31 C.A. 47 34 
C.A. 22 31 C.A. 49 29 
C.A. 23 35 C.A. 50 29 
C.A. 24 30 C.A. 51 32 
C.A. 26 32 C.A. 52 27 





In order to understand how minocycline resistance might arise we attempted to 
select minocycline resistant mutants. We failed to find colonies that grew above the 
reported breakpoint for minocycline resistance, and the highest MIC seen was 2mg.L-1 
against a mutant selected via two steps from K279a, named K MIN 2. According to 
disc testing, K MIN 2 expresses a resistance phenotype similar to the fluoroquinolone 
resistant mutants (resistance profile 1) but with a slightly smaller zone of clearing for 
minocycline (Table 4.5). Whole envelope proteomics analysis results showed a 4-fold 
upregulation of SmeDEF, relative to K279a, which explains the general resistance 
profile of the isolate. However, in addition, we identified a 1.8-fold upregulation of a 
putative ABC efflux protein annotated as MsbA (Smlt1640) (Figure 4.9) (Annex 3), 
which, in other Gram-negative bacteria, contains two different sites for substrate 
binding. One binding site is involved in transport of lipid A, essential for outer 
membrane integrity, and the other can interact with drugs which suggests a 
physiological role for MsbA as well as multidrug transport (278). When compared to 
K279a genome, WGS showed a Gly115Asp change in a  lauroyl acyltransferase,  
encoded by smlt4167 (data not shown), and an Arg15Cys change in a histidine kinase 
part of a two-component system immediately next to a 10-component operon where 
msbA (smlt1640) is present (Figure 4.10). Many of the other members of this operon 
are also upregulated in K MIN 2. In order to test involvement of this mutation in the 
two-component regulator in decreased minocycline susceptibility, we expressed the 
mutated version of the operon containing the two component system 
(smlt1635-smlt1636) in K279a ampRFS as before. Disc testing confirmed reduction in 
minocycline susceptibility in K279a ampRFS carrying pBBR1MCS-4 with the two-
component system genes (35mm) relative to K279a ampRFS carrying vector only 
(39mm) (Figure 4.12). This suggest an entirely novel, albeit weak, participant in 
minocycline reduced susceptibility in S. maltophilia. However, it is not the first report of 
an ABC transporter being involved in lipid trafficking to be linked to susceptibility to 
tetracyclines. In E. coli, loss of the mlaFEDCB operon, an ABC- dependent participant 
in the preservation of outer membrane lipid asymmetry (279), leads to accumulation of 
phospholipids in the outer leaflet of the outer membrane. When Mla is upregulated by 
mutation, this reduces outer membrane permeability to hydrophobic substances such 
as minocycline (280). It may be that the S. maltophilia ABC transport system reported 





Table 4.5 Disc testing profile (inhibition zone diameters in mm) of initial parental 
strain K279a and resistance-profile-1 derivative with reduced susceptibility to 






















K279a 32 27 23 32 22 24 25 27 
K MIN 2 32 18 15 25 25 26 23 20 
 
Shaded values represent reduced zone diameters (≥5mm relative to the parental 
strain K279a). K MIN 2 belongs to the resistant profile 1 (susceptible to 





Figure 4.9 Upregulation of A) Smlt1640 B) SmeDEF in minocycline 
resistant mutant 
Protein abundance data of whole envelope proteomics are normalised to the 
average ribosomal content of each sample (including abundance of 30S and 
50S ribosomal proteins). Fold change of A) Smlt1640 (Uniprot: B2FK21) and 
B) SmeDEF is calculated after testing statistical significant difference between 
the parental strain and the mutants (p <0.05). Values are reported as mean +/- 






Figure 4.10 Histidine kinase amino acid sequence comparison of minocycline 
resistant mutants 
Alignment of histidine kinase (smlt1636) sequences showing Arg15Cys change in 
K MIN 2 (non-highlighted regions). Alignment was performed with CLUSTAL Omega 








Figure 4.11 smlt1635-6 (two-component system)products obtained during 
complementation in trans 
A) Amplification of the flanking region using M13F and M13R primers corresponding 
to ~250bp from  K279a (ampRFS) carrying pBBR1MCS-4 B) Amplification of the 
flanking region using M13F and M13R primers corresponding to ~2700bp from 
K279a (ampRFS) carrying pBBR1MCS-4::smlt1635-6 C) Amplification of smlt1635-6 
using primer Smlt1636_F and Smlt1636_R corresponding to 2305 bp from K279a 







Figure 4.12 Expression in trans of two-component system in K279a ampRFS 
reduces susceptibility to minocycline 
A) K279a ampRFS carrying pBBR1MCS-4 zone of inhibition 39 mm B) K279a 




Regarding aminoglycoside resistance, we found the reason for overexpression 
of smeYZ in S. maltophilia that does not involve mutation of the local regulator 
smeSyRy. Here, we found that ribosomal mutations and ribosomal-damaging 
aminoglycosides activate smeYZ overproduction. It may be that this is, like the MexXY 
situation in P. aeruginosa, caused by the accumulation of abnormal polypeptides in the 
cell. Given the physiological role of smeYZ (259) , it is logical to propose that smeYZ 
overproduction offers an advantage in terms of virulence. Although we managed to find 
an explanation for smeYZ overproduction, the cause for smeDEF overproduction was 
more complicated. Apart from loss of function mutations in the local repressor of 
smeDEF, we can only suggest one alternative that involves alteration in a 
glycosyltransferase, possibly involved in lipid synthesis or the breakdown of a toxic 
molecule, that act as a signal for constitutive expression of smeDEF. Considerable 
extra work would be needed to identify the signal. 
Characterisation of levofloxacin resistant mutants and those with reduced susceptibility 
to minocycline led us to identify the participation of two novel ABC transporters. 
Recently the overproduction of the MFS transporter, MfsA, was identified as a 
quinolone efflux pump in S. maltophilia that is also involved in efflux of 
aminoglycosides, tetracyclines, chloramphenicol, macrolides and cephalosporins (281, 




quinolones and tetracyclines when SmeDEF is not being overexproduced. In fact, it 
has been found that changes at Gly266 in the SmeVWX regulator, repressor SmeRv, 
are responsible for its overexproduction and consequently quinolone resistance (283). 
In S. maltophilia only two ABC transporters have been identified so far. Whilst SmrA 
has been associated to quinolone and tetracycline resistance (166), MacABCsm has 
been linked to aminoglycoside, macrolide and polymixin resistance (181). Here, we 
identified a bipartite ABC transporter (Smlt2645-6) responsible (in a background that 
already overproduces SmeDEF) for levofloxacin resistance whose expression is 
regulated by the local two-component system. Additionally, we identified an ABC 
transporter (MsbA) possibly involved in lipid export whose overexpression might cause 
reduced minocycline susceptibility perhaps by altering the hydrophobicity of the outer 
membrane. Expression of msbA might be regulated by a local two component system. 
However, overexpression of the mutated version of the two-component system had 
only a minor impact on minocycline susceptibility. In S. maltophilia, only one pump has 
been identified for its role in extrusion of hydrophobic substances and that is 
EmrCABsm (284) but it has not been linked to tetracycline resistance. This reduced 
susceptibility to minocycline required two steps and the mutant also overexpresses 
smeDEF. In fact, overexpression of smeDEF has been related to reduced susceptibility 
to tetracycline in the past (168) No common mutations were found to be responsible for 
upregulation of smeDEF in K MIN 2 and the only additional mutation was in a lauroyl 
acyltransferase (smlt4167). It is possible that this enzyme is also involved in 
detoxifying the cell, and therefore its loss is another way of activating SmeDEF 
production. Overall, however, minocycline resistance was not seen in mutants – even 
following multiple steps – or in any of our collection of highly resistant clinical isoaltes. 
Based on the results of this chapter, it would seem that minocycline, therefore, has a 




4.4 Annex 2 
 
Table 4.6 Normalised proteomics data for KLEV5 relative to KMOX2 
Abundance changes significantly according to a t-Test (P<0.05). Proteins that are >1.5 fold up and down regulated are highlighted green or red, 
respectively. Smaller changes are highlighted in orange. 
 
Accession Description T-Test KMOX2 vs KLEV5 Fold KMOX2 vs KLEV5 
B2FHA8 Putative phospholipase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0142 PE=4 SV=1 - [B2FHA8_STRMK] 0.03 0.37 
B2FHC0 
Putative N-acetylmuramoyl-L-alanine amidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0154 PE=4 SV=1 - 
[B2FHC0_STRMK] 0.01 0.46 
B2FHC6 Superoxide dismutase [Cu-Zn] OS=Stenotrophomonas maltophilia (strain K279a) GN=sodC1 PE=3 SV=1 - [B2FHC6_STRMK] 0.01 0.36 
B2FHC7 Superoxide dismutase [Cu-Zn] OS=Stenotrophomonas maltophilia (strain K279a) GN=sodC2 PE=3 SV=1 - [B2FHC7_STRMK] 0.02 0.46 
B2FHD0 Putative 3-ketoacyl-CoA thiolase OS=Stenotrophomonas maltophilia (strain K279a) GN=fadI PE=3 SV=1 - [B2FHD0_STRMK] 0.05 0.35 
B2FHF3 Putative peroxidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0187 PE=4 SV=1 - [B2FHF3_STRMK] <0.05 >100 
B2FHI7 Glutamate--tRNA ligase OS=Stenotrophomonas maltophilia (strain K279a) GN=gltX PE=3 SV=1 - [SYE_STRMK] <0.05 >100 
B2FHM1 
Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1476 PE=4 SV=1 - 
[B2FHM1_STRMK] 0.02 0.45 
B2FHN2 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1491 PE=4 SV=1 - [B2FHN2_STRMK] 0.05 0.49 
B2FHN5 Lipid-A-disaccharide synthase OS=Stenotrophomonas maltophilia (strain K279a) GN=lpxB PE=3 SV=1 - [B2FHN5_STRMK] 0.02 0.44 
B2FHY7 ATP synthase epsilon chain OS=Stenotrophomonas maltophilia (strain K279a) GN=atpC PE=3 SV=1 - [ATPE_STRMK] 0.01 0.25 
B2FHY8 ATP synthase subunit beta OS=Stenotrophomonas maltophilia (strain K279a) GN=atpD PE=3 SV=1 - [ATPB_STRMK] 0.03 0.41 
B2FHY9 ATP synthase gamma chain OS=Stenotrophomonas maltophilia (strain K279a) GN=atpG PE=3 SV=1 - [ATPG_STRMK] 0.01 0.35 
B2FHZ0 ATP synthase subunit alpha OS=Stenotrophomonas maltophilia (strain K279a) GN=atpA PE=3 SV=1 - [ATPA_STRMK] 0.03 0.38 
B2FHZ1 ATP synthase subunit delta OS=Stenotrophomonas maltophilia (strain K279a) GN=atpH PE=3 SV=1 - [ATPD_STRMK] 0.01 0.42 
B2FI05 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4128 PE=4 SV=1 - 
[B2FI05_STRMK] 0.01 0.38 
B2FI14 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4137 PE=4 SV=1 - [B2FI14_STRMK] 0.01 0.45 
B2FI28 Putative AMP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0208 PE=4 SV=1 - [B2FI28_STRMK] 0.03 0.33 
B2FI43 
Putative peptidyl-dipeptidase Dcp (Dipeptidyl carboxypeptidase) OS=Stenotrophomonas maltophilia (strain K279a) GN=dcp PE=3 
SV=1 - [B2FI43_STRMK] 0.04 0.38 
B2FI64 
Ribonucleoside-diphosphate reductase OS=Stenotrophomonas maltophilia (strain K279a) GN=RRM1 PE=3 SV=1 - 
[B2FI64_STRMK] 0.02 3.26 
B2FIA0 
Outer membrane protein assembly factor BamA OS=Stenotrophomonas maltophilia (strain K279a) GN=bamA PE=3 SV=1 - 




B2FIA9 30S ribosomal protein S2 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsB PE=3 SV=1 - [RS2_STRMK] 0.03 0.82 
B2FIB6 Methionine aminopeptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=map PE=3 SV=1 - [B2FIB6_STRMK] <0.05 >100 
B2FII5 
Putative CDP-diacylglycerol pyrophosphatase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2903 PE=4 SV=1 - 
[B2FII5_STRMK] 0.04 0.51 
B2FIJ0 L-lactate dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=lldD PE=3 SV=1 - [LLDD_STRMK] 0.03 0.47 
B2FIJ2 Putative L-lactate permease OS=Stenotrophomonas maltophilia (strain K279a) GN=lctP PE=4 SV=1 - [B2FIJ2_STRMK] 0.01 0.34 
B2FIM7 
Putative thiol:disulfide interchange protein OS=Stenotrophomonas maltophilia (strain K279a) GN=dsbE PE=4 SV=1 - 
[B2FIM7_STRMK] <0.05 0.00 
B2FIQ9 Putative glycosyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4173 PE=4 SV=1 - [B2FIQ9_STRMK] 0.02 0.24 
B2FIR9 
Putative transmembrane RDD family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4183 PE=4 SV=1 - 
[B2FIR9_STRMK] 0.01 0.39 
B2FIS4 
Putative lipid biosynthesis 3-oxoacyl-[acyl-carrier-protein] reductase OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt4188 PE=4 SV=1 - [B2FIS4_STRMK] <0.05 0.00 
B2FIT3 
Putative pyridine nucleotide-disulphide oxidoreductase OS=Stenotrophomonas maltophilia (strain K279a) GN=ndh PE=4 SV=1 - 
[B2FIT3_STRMK] 0.01 0.36 
B2FJ30 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0359 PE=3 SV=1 - 
[B2FJ30_STRMK] 0.05 0.53 
B2FJ75 
Putrescine-binding periplasmic protein OS=Stenotrophomonas maltophilia (strain K279a) GN=potF PE=3 SV=1 - 
[B2FJ75_STRMK] 0.04 0.39 
B2FJ81 
Putative transmembrane magnesium/cobalt transport protein OS=Stenotrophomonas maltophilia (strain K279a) GN=corA PE=4 
SV=1 - [B2FJ81_STRMK] 0.02 0.40 
B2FJ92 
tRNA-2-methylthio-N(6)-dimethylallyladenosine synthase OS=Stenotrophomonas maltophilia (strain K279a) GN=miaB PE=3 SV=1 
- [MIAB_STRMK] <0.05 >100 
B2FJC8 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1636 PE=4 SV=1 - [B2FJC8_STRMK] 0.03 0.46 
B2FJG9 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2998 PE=4 SV=1 - 
[B2FJG9_STRMK] <0.05 0.00 
B2FJH7 
Putative putative conjugative transfer protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3006 PE=4 SV=1 - 
[B2FJH7_STRMK] 0.02 0.27 
B2FJH9 
Putative transmembrane conjugative DNA transfer protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3008 PE=4 
SV=1 - [B2FJH9_STRMK] 0.02 0.37 
B2FJP7 Putative hydrolase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4251 PE=4 SV=1 - [B2FJP7_STRMK] 0.02 0.36 
B2FJR1 
Putative transmembrane GGDEF signalling protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4266 PE=4 SV=1 - 
[B2FJR1_STRMK] 0.05 0.52 
B2FJR8 
Putative isocitrate dehydrogenase [NADP] OS=Stenotrophomonas maltophilia (strain K279a) GN=icd PE=4 SV=1 - 
[B2FJR8_STRMK] 0.02 0.09 
B2FJR9 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4275 PE=4 SV=1 - [B2FJR9_STRMK] 0.05 0.27 
B2FJT2 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4289 PE=4 SV=1 - [B2FJT2_STRMK] 0.04 0.31 
B2FJU3 30S ribosomal protein S9 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsI PE=3 SV=1 - [RS9_STRMK] 0.01 0.44 
B2FJU4 50S ribosomal protein L13 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplM PE=3 SV=1 - [RL13_STRMK] 0.02 1.77 
B2FJW5 Putative phosphomannomutase OS=Stenotrophomonas maltophilia (strain K279a) GN=spgM PE=4 SV=1 - [B2FJW5_STRMK] 0.04 0.21 
B2FJX2 Orotate phosphoribosyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=pyrE PE=3 SV=1 - [PYRE_STRMK] <0.05 >100 





Putative fatty acid transport system, membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0423 PE=4 
SV=1 - [B2FJY4_STRMK] 0.01 0.34 
B2FK09 
Putative mechanosensitive ion channel OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0448 PE=4 SV=1 - 
[B2FK09_STRMK] 0.05 0.46 
B2FK29 
Putative outer membrane efflux protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1651 PE=4 SV=1 - 
[B2FK29_STRMK] 0.00 0.08 
B2FK30 
Putative ABC transport system, membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1652 PE=4 SV=1 - 
[B2FK30_STRMK] <0.05 >100 
B2FK31 
Putative ABC transporter ATP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1653 PE=3 SV=1 - 
[B2FK31_STRMK] <0.05 >100 
B2FK32 
Putative HlyD family secretion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1654 PE=4 SV=1 - 
[B2FK32_STRMK] <0.05 >100 
B2FK71 Peptidyl-prolyl cis-trans isomerase OS=Stenotrophomonas maltophilia (strain K279a) GN=fkbP PE=4 SV=1 - [B2FK71_STRMK] 0.04 0.51 
B2FK77 
Putative transmembrane CorC/HlyC family transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1704 PE=4 
SV=1 - [B2FK77_STRMK] 0.04 0.42 
B2FK84 CTP synthase OS=Stenotrophomonas maltophilia (strain K279a) GN=pyrG PE=3 SV=1 - [PYRG_STRMK] <0.05 >100 
B2FK97 
Putative subfamily M23B unassigned peptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1724 PE=4 SV=1 - 
[B2FK97_STRMK] 0.03 0.39 
B2FKA2 
ATP-dependent zinc metalloprotease FtsH OS=Stenotrophomonas maltophilia (strain K279a) GN=ftsH PE=3 SV=1 - 
[B2FKA2_STRMK] 0.04 0.42 
B2FKF1 
Conserved hypothetical FHA domain protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3099 PE=4 SV=1 - 
[B2FKF1_STRMK] 0.02 0.42 
B2FKJ3 Cell division protein ZipA OS=Stenotrophomonas maltophilia (strain K279a) GN=zipA PE=3 SV=1 - [B2FKJ3_STRMK] 0.04 0.40 
B2FKL0 
Putative haloacid dehalogenase hydrolase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4308 PE=4 SV=1 - 
[B2FKL0_STRMK] 0.03 0.49 
B2FKN5 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4334 PE=4 SV=1 - [B2FKN5_STRMK] 0.04 0.24 
B2FKN6 
Putative peptide transport protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4335 PE=3 SV=1 - 
[B2FKN6_STRMK] 0.02 0.28 
B2FKP6 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4346 PE=4 SV=1 - [B2FKP6_STRMK] 0.01 0.43 
B2FKR0 Biosynthetic arginine decarboxylase OS=Stenotrophomonas maltophilia (strain K279a) GN=speA PE=3 SV=1 - [B2FKR0_STRMK] <0.05 >100 
B2FKV5 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0481 PE=4 SV=1 - [B2FKV5_STRMK] <0.05 0.00 
B2FL00 Putative NHL repeat protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0528 PE=4 SV=1 - [B2FL00_STRMK] 0.01 0.33 
B2FL33 Alanine--tRNA ligase OS=Stenotrophomonas maltophilia (strain K279a) GN=alaS PE=3 SV=1 - [SYA_STRMK] <0.05 >100 
B2FL57 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1769 PE=4 SV=1 - 
[B2FL57_STRMK] 0.04 0.20 
B2FL62 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1774 PE=4 SV=1 - 
[B2FL62_STRMK] 0.01 0.38 
B2FL73 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1785 PE=4 SV=1 - [B2FL73_STRMK] 0.01 0.40 
B2FL82 
Putative ABC transporter ATP-binding subunit OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1794 PE=4 SV=1 - 
[B2FL82_STRMK] 0.04 0.42 
B2FLC2 
Putative ABC transporter, ATP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3186 PE=4 SV=1 - 
[B2FLC2_STRMK] 0.04 0.52 




K279a) GN=Smlt3190 PE=4 SV=1 - [B2FLC6_STRMK] 
B2FLD2 
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex OS=Stenotrophomonas 
maltophilia (strain K279a) GN=sucB PE=3 SV=1 - [B2FLD2_STRMK] 0.04 3.31 
B2FLF2 Putative phospholipase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3218 PE=4 SV=1 - [B2FLF2_STRMK] 0.03 0.43 
B2FLG5 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3232 PE=4 SV=1 - [B2FLG5_STRMK] 0.03 0.37 
B2FLG9 
Putative peptide transport protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3236 PE=3 SV=1 - 
[B2FLG9_STRMK] 0.02 0.52 
B2FLN0 
Putative pyridoxal-phosphate dependent enzyme OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4470 PE=4 SV=1 - 
[B2FLN0_STRMK] <0.05 >100 
B2FLT1 Asparagine synthetase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0598 PE=4 SV=1 - [B2FLT1_STRMK] <0.05 >100 
B2FLU9 
Putative ABC transporter component, polysaccharide related OS=Stenotrophomonas maltophilia (strain K279a) GN=wzt PE=4 
SV=1 - [B2FLU9_STRMK] 0.04 0.38 
B2FLV2 Putative glycosyl transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=wxocA PE=4 SV=1 - [B2FLV2_STRMK] 0.02 0.45 
B2FLV6 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0626 PE=4 SV=1 - [B2FLV6_STRMK] 0.03 0.51 
B2FLW2 Chaperone protein HtpG OS=Stenotrophomonas maltophilia (strain K279a) GN=htpG PE=3 SV=1 - [B2FLW2_STRMK] 0.03 4.85 
B2FLW5 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1812 PE=4 SV=1 - 
[B2FLW5_STRMK] 0.04 0.38 
B2FLW7 
Putative gamma-glutamyltranspeptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=ggt PE=4 SV=1 - 
[B2FLW7_STRMK] <0.05 >100 
B2FM92 Ribonuclease E OS=Stenotrophomonas maltophilia (strain K279a) GN=rnE PE=3 SV=1 - [B2FM92_STRMK] 0.02 2.12 
B2FM97 
Putative substrate-binding component of ABC transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3252 PE=4 
SV=1 - [B2FM97_STRMK] 0.01 0.39 
B2FMB8 
Putative cytochrome C-type biogenesis protein OS=Stenotrophomonas maltophilia (strain K279a) GN=dsbE PE=4 SV=1 - 
[B2FMB8_STRMK] 0.02 0.19 
B2FMI1 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4498 PE=4 SV=1 - [B2FMI1_STRMK] 0.00 0.41 
B2FMI8 UPF0114 protein Smlt4505 OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4505 PE=3 SV=1 - [B2FMI8_STRMK] 0.05 0.68 
B2FMI9 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4506 PE=4 SV=1 - 
[B2FMI9_STRMK] 0.01 0.23 
B2FMJ3 
Putative ABC transmembrane permease component transport system protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt4510 PE=4 SV=1 - [B2FMJ3_STRMK] 0.00 0.29 
B2FMK1 
Putative ABC transporter ATP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4518 PE=3 SV=1 - 
[B2FMK1_STRMK] 0.04 0.46 
B2FML3 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4532 PE=4 SV=1 - [B2FML3_STRMK] 0.05 0.14 
B2FMN4 
Putative FAD-binding oxidoreductase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0633 PE=4 SV=1 - 
[B2FMN4_STRMK] 0.04 0.37 
B2FMN5 
Putative transmembrane UbiA prenyltransferase family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0634 
PE=4 SV=1 - [B2FMN5_STRMK] 0.03 0.39 
B2FMN6 
Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0635 PE=4 SV=1 - 
[B2FMN6_STRMK] 0.03 0.50 
B2FMP5 
Putative electron transfer flavoprotein subunit alpha OS=Stenotrophomonas maltophilia (strain K279a) GN=etfA PE=4 SV=1 - 
[B2FMP5_STRMK] <0.05 >100 
B2FMQ7 
Putative glycosyltransferase protein OS=Stenotrophomonas maltophilia (strain K279a) GN=wxocA PE=4 SV=1 - 




B2FMR0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0660 PE=4 SV=1 - [B2FMR0_STRMK] 0.05 0.41 
B2FMR2 
Putative permease component of ABC transporter protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0662 PE=4 
SV=1 - [B2FMR2_STRMK] 0.03 0.53 
B2FMS6 
Putative transmembrane permease protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0677 PE=4 SV=1 - 
[B2FMS6_STRMK] 0.02 0.31 
B2FN03 
Protein-export membrane protein SecF OS=Stenotrophomonas maltophilia (strain K279a) GN=secF PE=3 SV=1 - 
[B2FN03_STRMK] 0.02 0.55 
B2FN30 Protease HtpX OS=Stenotrophomonas maltophilia (strain K279a) GN=htpX PE=3 SV=1 - [HTPX_STRMK] 0.01 0.55 
B2FN37 
Putative N-acetylmuramoyl-L-alanine amidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3330 PE=4 SV=1 - 
[B2FN37_STRMK] 0.02 0.46 
B2FN90 Translation initiation factor IF-2 OS=Stenotrophomonas maltophilia (strain K279a) GN=infB PE=3 SV=1 - [IF2_STRMK] 0.05 4.23 
B2FN93 
NADH-quinone oxidoreductase subunit N OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoN PE=3 SV=1 - 
[B2FN93_STRMK] 0.02 0.46 
B2FN94 
Putative NADH dehydrogenase I chain M OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoM PE=4 SV=1 - 
[B2FN94_STRMK] 0.05 0.65 
B2FNC9 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4585 PE=4 SV=1 - [B2FNC9_STRMK] <0.05 >100 
B2FND7 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4593 PE=4 SV=1 - [B2FND7_STRMK] 0.00 0.29 
B2FNG3 Aldehyde dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=calB PE=3 SV=1 - [B2FNG3_STRMK] <0.05 0.00 
B2FNL4 
N utilization substance protein B homolog OS=Stenotrophomonas maltophilia (strain K279a) GN=nusB PE=3 SV=1 - 
[NUSB_STRMK] <0.05 >100 
B2FNN2 Putative penicillin-binding protein 3 OS=Stenotrophomonas maltophilia (strain K279a) GN=ftsI PE=4 SV=1 - [B2FNN2_STRMK] 0.05 0.50 
B2FNN7 
UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase 
OS=Stenotrophomonas maltophilia (strain K279a) GN=murG PE=3 SV=1 - [B2FNN7_STRMK] 0.03 0.35 
B2FNP5 30S ribosomal protein S1 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsA PE=3 SV=1 - [B2FNP5_STRMK] 0.04 2.52 
B2FNR0 
Outer membrane protein assembly factor BamB OS=Stenotrophomonas maltophilia (strain K279a) GN=bamB PE=3 SV=1 - 
[B2FNR0_STRMK] 0.04 0.36 
B2FNX3 
Putative NADH-ubiquinone oxidoreductase, 75 kDa subunit OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoG PE=4 
SV=1 - [B2FNX3_STRMK] 0.03 0.44 
B2FNX4 
Putative NADH dehydrogenase I chain F OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoF PE=4 SV=1 - 
[B2FNX4_STRMK] 0.02 0.29 
B2FNX6 
NADH-quinone oxidoreductase subunit D OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoD PE=3 SV=1 - 
[NUOD_STRMK] 0.04 0.52 
B2FNY0 
Putative general secretory pathway protein-export membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=secG 
PE=4 SV=1 - [B2FNY0_STRMK] 0.03 0.43 
B2FNY5 
Putative lipopolysaccharide core oligosaccharide biosynthesis protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3412 PE=4 SV=1 - [B2FNY5_STRMK] 0.02 0.42 
B2FP04 
Phosphatidylserine decarboxylase proenzyme OS=Stenotrophomonas maltophilia (strain K279a) GN=psd PE=3 SV=1 - 
[PSD_STRMK] 0.04 0.48 
B2FP06 
Putative membrane-bound lytic murein transglycosylase d OS=Stenotrophomonas maltophilia (strain K279a) GN=mltD PE=4 SV=1 
- [B2FP06_STRMK] 0.03 0.36 
B2FP17 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3446 PE=3 SV=1 - 
[B2FP17_STRMK] 0.00 0.49 
B2FP19 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3449 PE=4 SV=1 - 




B2FP30 Putative lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3460 PE=4 SV=1 - [B2FP30_STRMK] 0.04 0.28 
B2FP33 Putative alkaline phosphatase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3463 PE=3 SV=1 - [B2FP33_STRMK] 0.04 0.48 
B2FP55 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4642 PE=4 SV=1 - 
[B2FP55_STRMK] <0.05 >100 
B2FP83 
Putative transmembrane component of ABC transporter protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4671 
PE=4 SV=1 - [B2FP83_STRMK] 0.01 0.34 
B2FP97 
Putative amino-acid transporter transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4685 PE=4 
SV=1 - [B2FP97_STRMK] 0.00 0.29 
B2FPD2 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0785 PE=4 SV=1 - [B2FPD2_STRMK] 0.01 0.78 
B2FPE9 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0802 PE=4 SV=1 - [B2FPE9_STRMK] <0.05 0.00 
B2FPF2 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0805 PE=4 SV=1 - [B2FPF2_STRMK] 0.00 0.55 
B2FPH3 
Putative 2-octaprenyl-3-methyl-6-methoxy-1,4-benzoquinol hydroxylase OS=Stenotrophomonas maltophilia (strain K279a) 
GN=ubiF PE=4 SV=1 - [B2FPH3_STRMK] 0.03 0.38 
B2FPK0 
Putative repetitive protein with two-component sensor and regulator motifs OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt2141 PE=4 SV=1 - [B2FPK0_STRMK] 0.02 0.28 
B2FPN1 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2175 PE=3 SV=1 - 
[B2FPN1_STRMK] <0.05 0.00 
B2FPN2 
Putative copper-transporting P-type ATPase OS=Stenotrophomonas maltophilia (strain K279a) GN=actP PE=3 SV=1 - 
[B2FPN2_STRMK] 0.01 0.37 
B2FPQ4 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2199 PE=4 SV=1 - [B2FPQ4_STRMK] <0.05 0.00 
B2FPR0 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3478 PE=3 SV=1 - 
[B2FPR0_STRMK] 0.04 0.47 
B2FPR6 LPS-assembly lipoprotein LptE OS=Stenotrophomonas maltophilia (strain K279a) GN=lptE PE=3 SV=1 - [B2FPR6_STRMK] 0.03 0.45 
B2FPR7 Leucine--tRNA ligase OS=Stenotrophomonas maltophilia (strain K279a) GN=leuS PE=3 SV=1 - [SYL_STRMK] <0.05 >100 
B2FPS1 
Putative transmembrane GGDEF transcriptional regulatory protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3489 PE=4 SV=1 - [B2FPS1_STRMK] 0.05 0.88 
B2FPV5 
Putative autotransporter subtilisin-like protease OS=Stenotrophomonas maltophilia (strain K279a) GN=sphB PE=4 SV=1 - 
[B2FPV5_STRMK] <0.05 0.00 
B2FPY0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3550 PE=4 SV=1 - [B2FPY0_STRMK] 0.01 0.28 
B2FQ16 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0872 PE=4 SV=1 - [B2FQ16_STRMK] <0.05 >100 
B2FQ28 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0885 PE=3 SV=1 - 
[B2FQ28_STRMK] 0.04 0.39 
B2FQ31 Elongation factor Tu OS=Stenotrophomonas maltophilia (strain K279a) GN=tufB PE=3 SV=1 - [B2FQ31_STRMK] 0.02 3.80 
B2FQ36 50S ribosomal protein L10 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplJ PE=3 SV=1 - [RL10_STRMK] 0.04 1.99 
B2FQ39 
DNA-directed RNA polymerase subunit beta' OS=Stenotrophomonas maltophilia (strain K279a) GN=rpoC PE=3 SV=1 - 
[RPOC_STRMK] 0.04 7.85 
B2FQ42 Elongation factor G OS=Stenotrophomonas maltophilia (strain K279a) GN=fusA PE=3 SV=1 - [EFG_STRMK] 0.04 4.24 
B2FQ48 50S ribosomal protein L2 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplB PE=3 SV=1 - [RL2_STRMK] 0.03 0.64 
B2FQ55 
Putative multidrug ACR family efflux system OS=Stenotrophomonas maltophilia (strain K279a) GN=smeZ PE=4 SV=1 - 
[B2FQ55_STRMK] 0.01 8.78 
B2FQ64 
Putative ferrous iron transport protein B OS=Stenotrophomonas maltophilia (strain K279a) GN=feoB PE=4 SV=1 - 




B2FQC4 Elongation factor 4 OS=Stenotrophomonas maltophilia (strain K279a) GN=lepA PE=3 SV=1 - [LEPA_STRMK] 0.05 3.22 
B2FQE1 
Putative transmembrane sulfatase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3571 PE=4 SV=1 - 
[B2FQE1_STRMK] 0.02 0.35 
B2FQE3 
Putative angiotensin-converting enzyme like peptidyl dipeptidase protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3574 PE=4 SV=1 - [B2FQE3_STRMK] 0.05 0.47 
B2FQH1 
Putative endopeptidase inhibitor (Alpha-2-macroglobulin like protein) OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3603 PE=4 SV=1 - [B2FQH1_STRMK] 0.02 0.27 
B2FQK5 30S ribosomal protein S13 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsM PE=3 SV=1 - [RS13_STRMK] 0.05 1.30 
B2FQK6 30S ribosomal protein S11 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsK PE=3 SV=1 - [RS11_STRMK] 0.01 0.79 
B2FQK8 
DNA-directed RNA polymerase subunit alpha OS=Stenotrophomonas maltophilia (strain K279a) GN=rpoA PE=3 SV=1 - 
[RPOA_STRMK] 0.03 4.78 
B2FQL8 Malate dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=mdh PE=3 SV=1 - [MDH_STRMK] <0.05 >100 
B2FQN1 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0958 PE=4 SV=1 - [B2FQN1_STRMK] <0.05 0.00 
B2FQN3 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0960 PE=4 SV=1 - [B2FQN3_STRMK] 0.00 0.34 
B2FQP8 Putative exopolyphosphatase OS=Stenotrophomonas maltophilia (strain K279a) GN=ppx PE=4 SV=1 - [B2FQP8_STRMK] <0.05 >100 
B2FQR4 Lon protease OS=Stenotrophomonas maltophilia (strain K279a) GN=lon PE=2 SV=1 - [B2FQR4_STRMK] <0.05 >100 
B2FQR5 
Putative DNA-binding protein HU-beta OS=Stenotrophomonas maltophilia (strain K279a) GN=hupB PE=3 SV=1 - 
[B2FQR5_STRMK] <0.05 >100 
B2FQY4 Putative cell division protein OS=Stenotrophomonas maltophilia (strain K279a) GN=ftsK PE=4 SV=1 - [B2FQY4_STRMK] 0.04 0.48 
B2FR06 33 kDa chaperonin OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3643 PE=4 SV=1 - [B2FR06_STRMK] <0.05 >100 
B2FR08 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3645 PE=3 SV=1 - 
[B2FR08_STRMK] 0.00 0.26 
B2FR11 
Putative acyl-coenzyme A dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=fadE PE=4 SV=1 - 
[B2FR11_STRMK] 0.05 0.49 
B2FR15 Putative beta-lactamase protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3652 PE=4 SV=1 - [B2FR15_STRMK] 0.02 0.37 
B2FR23 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3660 PE=4 SV=1 - [B2FR23_STRMK] 0.01 0.23 
B2FR62 Putative autotransporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1001 PE=4 SV=1 - [B2FR62_STRMK] 0.02 0.49 
B2FR78 
Putative outer membrane lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1018 PE=4 SV=1 - 
[B2FR78_STRMK] 0.05 0.30 
B2FRM8 
Putative peptidoglycan-associated lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3703 PE=3 SV=1 - 
[B2FRM8_STRMK] 0.02 0.43 
B2FRM9 Protein TolB OS=Stenotrophomonas maltophilia (strain K279a) GN=tolB PE=3 SV=1 - [B2FRM9_STRMK] 0.04 0.41 
B2FRP3 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3720 PE=4 SV=1 - [B2FRP3_STRMK] 0.02 0.24 
B2FRP4 
Putative transmembrane Na+/H+ antiporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3721 PE=4 SV=1 - 
[B2FRP4_STRMK] 0.04 0.45 
B2FRP8 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3725 PE=3 SV=1 - 
[B2FRP8_STRMK] 0.03 0.42 
B2FRP9 
Putative transmembrane transport protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3726 PE=4 SV=1 - 
[B2FRP9_STRMK] 0.03 0.40 
B2FRQ2 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3730 PE=4 SV=1 - [B2FRQ2_STRMK] 0.00 0.24 
B2FRR0 Putative lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3739 PE=4 SV=1 - [B2FRR0_STRMK] 0.01 0.37 




B2FRS9 Putative pilus-assembly protein OS=Stenotrophomonas maltophilia (strain K279a) GN=pilG PE=3 SV=1 - [B2FRS9_STRMK] <0.05 0 
B2FRV6 
Putative MgtE/divalent cation transmembrane transporter protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1103 
PE=4 SV=1 - [B2FRV6_STRMK] 0.02 0.38 
B2FRX9 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1127 PE=4 SV=1 - 
[B2FRX9_STRMK] 0.03 0.40 
B2FRZ0 Putative oxidoreductase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1138 PE=4 SV=1 - [B2FRZ0_STRMK] 0.05 0.42 
B2FRZ4 
Putative transmembrane PepSY family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1142 PE=4 SV=1 - 
[B2FRZ4_STRMK] 0.03 0.55 
B2FS06 
Putative ABC transporter, ATP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1155 PE=4 SV=1 - 
[B2FS06_STRMK] <0.05 >100 
B2FS41 
Putative cobalt-zinc-cadmium resistance protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2459 PE=4 SV=1 - 
[B2FS41_STRMK] <0.05 0.00 
B2FSD7 
Large-conductance mechanosensitive channel OS=Stenotrophomonas maltophilia (strain K279a) GN=mscL PE=3 SV=1 - 
[MSCL_STRMK] 0.05 0.43 
B2FSE0 
Putative transmembrane symporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3785 PE=4 SV=1 - 
[B2FSE0_STRMK] 0.03 0.23 
B2FSE3 
Putative HlyD-family secretion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=smeM PE=4 SV=1 - 
[B2FSE3_STRMK] 0.02 0.55 
B2FSF0 Fructose-bisphosphate aldolase OS=Stenotrophomonas maltophilia (strain K279a) GN=alf1 PE=3 SV=1 - [B2FSF0_STRMK] 0.03 1.95 
B2FSG6 
Putative transmembrane sodium-dicarboxylate family transporter protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt3814 PE=4 SV=1 - [B2FSG6_STRMK] 0.01 0.43 
B2FSH3 Putative type II/III pilus secretin OS=Stenotrophomonas maltophilia (strain K279a) GN=pilQ PE=4 SV=1 - [B2FSH3_STRMK] <0.05 0 
B2FSH5 
Putative PilO protein (Type 4 fimbrial biogenesis protein PilO) OS=Stenotrophomonas maltophilia (strain K279a) GN=pilO PE=4 
SV=1 - [B2FSH5_STRMK] 0.01 0.12 
B2FSJ9 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1175 PE=4 SV=1 - 
[B2FSJ9_STRMK] 0.00 0.35 
B2FSN4 
Putative transmembrane phosphoesterase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1210 PE=4 SV=1 - 
[B2FSN4_STRMK] 0.02 0.30 
B2FSS6 
Putative PTS system, fructose-specific IIBC component OS=Stenotrophomonas maltophilia (strain K279a) GN=fruA PE=4 SV=1 - 
[B2FSS6_STRMK] 0.01 0.48 
B2FSS7 
Putative outer membrane regulator of pathogenicity factors protein OS=Stenotrophomonas maltophilia (strain K279a) GN=rpfN 
PE=4 SV=1 - [B2FSS7_STRMK] 0.00 0.39 
B2FT31 Putative ACR family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3869 PE=4 SV=1 - [B2FT31_STRMK] 0.03 0.38 
B2FT66 
Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3905 PE=3 SV=1 - 
[B2FT66_STRMK] 0.02 0.18 
B2FT68 Putative transcriptional regulator OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3907 PE=4 SV=1 - [B2FT68_STRMK] 0.04 0.42 
B2FT83 DNA gyrase subunit B OS=Stenotrophomonas maltophilia (strain K279a) GN=gyrB PE=3 SV=1 - [B2FT83_STRMK] 0.04 5.01 
B2FTA2 
Putative oligopeptide transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1245 PE=4 SV=1 - 
[B2FTA2_STRMK] 0.05 0.38 
B2FTA8 
Probable septum site-determining protein MinC OS=Stenotrophomonas maltophilia (strain K279a) GN=minC PE=3 SV=1 - 
[B2FTA8_STRMK] <0.05 >100 
B2FTJ7 
Macrolide export ATP-binding/permease protein MacB OS=Stenotrophomonas maltophilia (strain K279a) GN=macB PE=3 
SV=1 - [B2FTJ7_STRMK] <0.05 >100 






Putative two-component regulatory system family, response regulator protein OS=Stenotrophomonas maltophilia (strain 
K279a) GN=Smlt2645 PE=4 SV=1 - [B2FTK0_STRMK] <0.05 >100 
B2FTK1 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2646 PE=4 SV=1 - [B2FTK1_STRMK] 0.01 9.60 
B2FTS7 
Putative 3-deoxy-D-manno-octulosonic-acid transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=kdtA PE=4 SV=1 - 
[B2FTS7_STRMK] 0.05 0.38 
B2FTS8 
Putative lipid A biosynthesis lauroyl acyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=htrB PE=4 SV=1 - 
[B2FTS8_STRMK] 0.03 0.36 
B2FU10 Fructose-1,6-bisphosphatase class 1 OS=Stenotrophomonas maltophilia (strain K279a) GN=fbp PE=3 SV=1 - [F16PA_STRMK] <0.05 >100 
B2FU42 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0083 PE=3 SV=1 - 
[B2FU42_STRMK] 0.04 0.53 
B2FU43 Acid phosphatase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0084 PE=3 SV=1 - [B2FU43_STRMK] 0.02 0.35 
B2FU94 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1354 PE=4 SV=1 - [B2FU94_STRMK] 0.05 0.25 
B2FUA1 Putative quinol oxidase subunit 1 OS=Stenotrophomonas maltophilia (strain K279a) GN=qoxB PE=3 SV=1 - [B2FUA1_STRMK] 0.01 0.38 
B2FUA6 
Putative chaperone protein HtpG (Heat shock protein HtpG) OS=Stenotrophomonas maltophilia (strain K279a) GN=htpG PE=4 
SV=1 - [B2FUA6_STRMK] <0.05 >100 
B2FUB6 50S ribosomal protein L19 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplS PE=3 SV=1 - [RL19_STRMK] 0.02 0.67 
B2FUE6 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1413 PE=4 SV=1 - [B2FUE6_STRMK] <0.05 >100 
B2FUE7 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1414 PE=4 SV=1 - [B2FUE7_STRMK] <0.05 >100 
B2FUF0 
Putative nucleotide sugar transaminase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1417 PE=3 SV=1 - 
[B2FUF0_STRMK] <0.05 >100 
B2FUL3 
Putative Major Facilitator Superfamily transmembrane nitrite extrusion protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=narK PE=4 SV=1 - [B2FUL3_STRMK] 0.05 0.40 
B2FUR1 
Putative TonB-dependent outer membrane receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4026 PE=3 
SV=1 - [B2FUR1_STRMK] 0.02 0.42 
B2FUT1 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4049 PE=4 SV=1 - 
[B2FUT1_STRMK] 0.05 0.43 
B2FUT3 Putative exported rare lipoprotein A OS=Stenotrophomonas maltophilia (strain K279a) GN=rlpA PE=3 SV=1 - [B2FUT3_STRMK] 0.04 0.30 
B2FUT6 
Putative rod shape-determining protein RodA OS=Stenotrophomonas maltophilia (strain K279a) GN=mrdB PE=4 SV=1 - 










4.5 Annex 3 
 
Table 4.7 Normalised proteomics data for KMIN2 relative to K279a 
Abundance changes significantly according to a t-Test (P<0.05). Proteins that are >1.5 fold up and down regulated are highlighted green or red, 
respectively. Smaller changes are highlighted in orange. 
Accession Description T-Test K279a vs KMIN2 Fold K279a vs KMIN2 
B2FHB0 
Putative transmembrane acetyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0144 PE=4 SV=1 - 
[B2FHB0_STRMK] 0.01 1.48 
B2FHC0 
Putative N-acetylmuramoyl-L-alanine amidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0154 PE=4 SV=1 - 
[B2FHC0_STRMK] 0.02 0.78 
B2FHD1 
Putative transmembrane HemY porphyrin biosynthesis protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0165 PE=4 
SV=1 - [B2FHD1_STRMK] 0.03 1.20 
B2FHF0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0184 PE=4 SV=1 - [B2FHF0_STRMK] 0.00 3.12 
B2FHG4 
Putative electron transfer flavoprotein-ubiquinone oxidoreductase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0198 
PE=4 SV=1 - [B2FHG4_STRMK] 0.04 1.35 
B2FHG9 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0204 PE=4 SV=1 - [B2FHG9_STRMK] 0.03 1.30 
B2FHH2 
Putative TonB dependent siderophore receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1426 PE=3 SV=1 - 
[B2FHH2_STRMK] 0.03 1.31 
B2FHI0 Putative acyl-CoA synthetase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1434 PE=4 SV=1 - [B2FHI0_STRMK] 0.01 2.49 
B2FHJ2 Putative outer membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1446 PE=3 SV=1 - [B2FHJ2_STRMK] 0.02 0.77 
B2FHL6 Putative ABC transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1471 PE=3 SV=1 - [B2FHL6_STRMK] 0.01 1.68 
B2FHN5 Lipid-A-disaccharide synthase OS=Stenotrophomonas maltophilia (strain K279a) GN=lpxB PE=3 SV=1 - [B2FHN5_STRMK] 0.02 0.67 
B2FHP7 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2807 PE=4 SV=1 - [B2FHP7_STRMK] 0.04 1.65 
B2FHR8 Putative autotransporter protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2834 PE=4 SV=1 - [B2FHR8_STRMK] 0.01 0.53 
B2FHR9 
Putative TonB-dependent outer membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2835 PE=3 SV=1 - 
[B2FHR9_STRMK] 0.03 1.27 
B2FHT9 Putative iron transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2858 PE=3 SV=1 - [B2FHT9_STRMK] 0.01 1.60 
B2FHY3 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4106 PE=4 SV=1 - [B2FHY3_STRMK] 0.04 1.25 
B2FHY9 ATP synthase gamma chain OS=Stenotrophomonas maltophilia (strain K279a) GN=atpG PE=3 SV=1 - [ATPG_STRMK] 0.05 0.47 




B2FHZ1 ATP synthase subunit delta OS=Stenotrophomonas maltophilia (strain K279a) GN=atpH PE=3 SV=1 - [ATPD_STRMK] 0.02 0.37 
B2FHZ2 ATP synthase subunit b OS=Stenotrophomonas maltophilia (strain K279a) GN=atpF PE=3 SV=1 - [ATPF_STRMK] 0.04 1.23 
B2FHZ4 ATP synthase subunit a OS=Stenotrophomonas maltophilia (strain K279a) GN=atpB PE=3 SV=1 - [B2FHZ4_STRMK] 0.01 1.80 
B2FHZ8 
Acetyltransferase component of pyruvate dehydrogenase complex OS=Stenotrophomonas maltophilia (strain K279a) GN=pdhB PE=3 
SV=1 - [B2FHZ8_STRMK] 0.00 2.22 
B2FI05 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4128 PE=4 SV=1 - 
[B2FI05_STRMK] 0.02 0.75 
B2FI12 Putative colicin I receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=cirA PE=3 SV=1 - [B2FI12_STRMK] 0.04 0.62 
B2FI22 Putative extracellular serine protease OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4145 PE=4 SV=1 - [B2FI22_STRMK] 0.05 0.79 
B2FI29 Putative NAD(P)H dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0209 PE=4 SV=1 - [B2FI29_STRMK] 0.01 0.35 
B2FI32 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0212 PE=4 SV=1 - [B2FI32_STRMK] 0.01 1.53 
B2FI33 Probable protein kinase UbiB OS=Stenotrophomonas maltophilia (strain K279a) GN=ubiB PE=4 SV=1 - [B2FI33_STRMK] 0.02 1.45 
B2FI94 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0278 PE=4 SV=1 - [B2FI94_STRMK] 0.00 1.81 
B2FIA1 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1499 PE=4 SV=1 - [B2FIA1_STRMK] 0.00 3.97 
B2FIA3 Phosphatidate cytidylyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=cdsA PE=3 SV=1 - [B2FIA3_STRMK] 0.01 1.70 
B2FIA9 30S ribosomal protein S2 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsB PE=3 SV=1 - [RS2_STRMK] 0.00 1.62 
B2FIC3 Putative penicillin acylase 2 OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1522 PE=4 SV=1 - [B2FIC3_STRMK] 0.01 1.68 
B2FIC5 DNA topoisomerase 4 subunit A OS=Stenotrophomonas maltophilia (strain K279a) GN=parC PE=3 SV=1 - [B2FIC5_STRMK] 0.02 1.37 
B2FID6 
23S rRNA (guanosine-2'-O-)-methyltransferase RlmB OS=Stenotrophomonas maltophilia (strain K279a) GN=rlmB PE=3 SV=1 - 
[B2FID6_STRMK] 0.04 1.95 
B2FIF4 
Putative polyphosphate-selective porin O OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1555 PE=4 SV=1 - 
[B2FIF4_STRMK] <0.05 >100 
B2FIJ2 Putative L-lactate permease OS=Stenotrophomonas maltophilia (strain K279a) GN=lctP PE=4 SV=1 - [B2FIJ2_STRMK] 0.03 1.24 
B2FIN7 Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4151 PE=3 SV=1 - [B2FIN7_STRMK] >0.05 0.00 
B2FIQ3 
Putative lipid A biosynthesis lauroyl acyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=htrB PE=4 SV=1 - 
[B2FIQ3_STRMK] 0.00 0.25 
B2FIQ9 Putative glycosyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4173 PE=4 SV=1 - [B2FIQ9_STRMK] 0.01 0.30 
B2FIR8 Putative fimbrial protein (Pilin) OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4182 PE=4 SV=1 - [B2FIR8_STRMK] 0.02 1.38 
B2FIR9 
Putative transmembrane RDD family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4183 PE=4 SV=1 - 
[B2FIR9_STRMK] 0.00 0.59 
B2FIS7 
Putative drug resistance transport protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4191 PE=4 SV=1 - 
[B2FIS7_STRMK] 0.04 1.41 




B2FIU9 60 kDa chaperonin OS=Stenotrophomonas maltophilia (strain K279a) GN=groL PE=3 SV=1 - [CH60_STRMK] 0.01 2.44 
B2FJ52 Putative protease OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0381 PE=4 SV=1 - [B2FJ52_STRMK] 0.02 2.02 
B2FJB1 Putative oar family adhesion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1619 PE=4 SV=1 - [B2FJB1_STRMK] 0.03 0.74 
B2FJB8 
Putative PilE protein (Type 4 fimbrial biogenesis protein PilE) OS=Stenotrophomonas maltophilia (strain K279a) GN=pilE PE=4 SV=1 - 
[B2FJB8_STRMK] 0.05 0.61 
B2FJC8 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1636 PE=4 SV=1 - [B2FJC8_STRMK] 0.00 2.07 
B2FJG0 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2989 PE=4 SV=1 - 
[B2FJG0_STRMK] 0.02 0.43 
B2FJH5 
Putative putative bacterial secretion system protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3004 PE=4 SV=1 - 
[B2FJH5_STRMK] 0.01 0.39 
B2FJH6 Putative VirB9 OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3005 PE=4 SV=1 - [B2FJH6_STRMK] 0.02 0.32 
B2FJH9 
Putative transmembrane conjugative DNA transfer protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3008 PE=4 
SV=1 - [B2FJH9_STRMK] 0.01 0.50 
B2FJJ3 
Putative hydroxamate-type ferrisiderophore receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3022 PE=3 SV=1 - 
[B2FJJ3_STRMK] 0.01 1.83 
B2FJQ7 
Putative cell division ATP-binding protein FtsE OS=Stenotrophomonas maltophilia (strain K279a) GN=ftsE PE=3 SV=1 - 
[B2FJQ7_STRMK] 0.02 0.51 
B2FJR8 Putative isocitrate dehydrogenase [NADP] OS=Stenotrophomonas maltophilia (strain K279a) GN=icd PE=4 SV=1 - [B2FJR8_STRMK] 0.01 2.92 
B2FJR9 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4275 PE=4 SV=1 - [B2FJR9_STRMK] >0.05 0.00 
B2FJS2 Putative amidohydrolase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4278 PE=4 SV=1 - [B2FJS2_STRMK] <0.05 >100 
B2FJS4 
Putative multidrug efflux system transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4280 PE=4 SV=1 - 
[B2FJS4_STRMK] 0.04 1.61 
B2FJS8 
Putative Major Facilitator Superfamily transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4284 PE=4 
SV=1 - [B2FJS8_STRMK] 0.01 2.16 
B2FJU4 50S ribosomal protein L13 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplM PE=3 SV=1 - [RL13_STRMK] 0.02 1.41 
B2FJV0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0387 PE=4 SV=1 - [B2FJV0_STRMK] 0.00 1.53 
B2FJV9 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0397 PE=4 SV=1 - [B2FJV9_STRMK] 0.03 1.31 
B2FJX1 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0410 PE=4 SV=1 - [B2FJX1_STRMK] 0.05 0.61 
B2FJX4 
Putative beta-lactamase induction signal transducer AmpG OS=Stenotrophomonas maltophilia (strain K279a) GN=ampG PE=4 SV=1 - 
[B2FJX4_STRMK] <0.05 >100 
B2FJX9 Putative aminopeptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0418 PE=4 SV=1 - [B2FJX9_STRMK] 0.05 1.30 
B2FJY1 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0420 PE=4 SV=1 - [B2FJY1_STRMK] 0.01 1.45 
B2FJY4 
Putative fatty acid transport system, membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0423 PE=4 SV=1 - 
[B2FJY4_STRMK] 0.00 0.45 
B2FK09 
Putative mechanosensitive ion channel OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0448 PE=4 SV=1 - 





Lipid A export ATP-binding/permease protein MsbA OS=Stenotrophomonas maltophilia (strain K279a) GN=msbA PE=3 SV=1 - 
[B2FK21_STRMK] 0.01 1.88 
B2FK77 
Putative transmembrane CorC/HlyC family transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1704 PE=4 SV=1 - 
[B2FK77_STRMK] 0.00 1.50 
B2FK79 
Putative LOW-AFFINITY INORGANIC PHOSPHATE TRANSPORTER INTEGRAL MEMBRANE PROTEIN PITA 
OS=Stenotrophomonas maltophilia (strain K279a) GN=pitA PE=4 SV=1 - [B2FK79_STRMK] 0.00 1.81 
B2FK88 Enolase OS=Stenotrophomonas maltophilia (strain K279a) GN=eno PE=3 SV=1 - [ENO_STRMK] <0.05 >100 
B2FK95 Protein-L-isoaspartate O-methyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=pcm PE=3 SV=1 - [PIMT_STRMK] 0.02 1.59 
B2FKA2 
ATP-dependent zinc metalloprotease FtsH OS=Stenotrophomonas maltophilia (strain K279a) GN=ftsH PE=3 SV=1 - 
[B2FKA2_STRMK] 0.04 1.25 
B2FKJ7 50S ribosomal protein L9 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplI PE=3 SV=1 - [RL9_STRMK] 0.01 0.45 
B2FKK2 Asparagine--tRNA ligase OS=Stenotrophomonas maltophilia (strain K279a) GN=asnS PE=3 SV=1 - [B2FKK2_STRMK] <0.05 >100 
B2FKL0 
Putative haloacid dehalogenase hydrolase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4308 PE=4 SV=1 - 
[B2FKL0_STRMK] 0.02 0.62 
B2FKS9 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4386 PE=4 SV=1 - [B2FKS9_STRMK] <0.05 >100 
B2FKV7 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0483 PE=4 SV=1 - 
[B2FKV7_STRMK] 0.01 0.59 
B2FKW2 
Pyruvate dehydrogenase E1 component OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0490 PE=4 SV=1 - 
[B2FKW2_STRMK] 0.00 1.96 
B2FL08 
Putative transmembrane anchor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0538 PE=4 SV=1 - 
[B2FL08_STRMK] 0.00 0.15 
B2FL09 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0539 PE=4 SV=1 - [B2FL09_STRMK] 0.00 0.34 
B2FL10 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0540 PE=4 SV=1 - [B2FL10_STRMK] 0.01 0.69 
B2FL20 Putative ZINC METALLOpeptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0550 PE=4 SV=1 - [B2FL20_STRMK] 0.04 1.59 
B2FL73 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1785 PE=4 SV=1 - [B2FL73_STRMK] 0.00 1.99 
B2FL82 
Putative ABC transporter ATP-binding subunit OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1794 PE=4 SV=1 - 
[B2FL82_STRMK] >0.05 0.00 
B2FL84 
Putative succinate dehydrogenase cytochrome b-556 subunit OS=Stenotrophomonas maltophilia (strain K279a) GN=sdhC PE=4 SV=1 
- [B2FL84_STRMK] 0.01 1.70 
B2FLA1 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3164 PE=4 SV=1 - 
[B2FLA1_STRMK] 0.04 1.68 
B2FLA7 
Putative multidrug resistance efflux pump OS=Stenotrophomonas maltophilia (strain K279a) GN=smeH PE=4 SV=1 - 
[B2FLA7_STRMK] 0.03 1.28 
B2FLD1 
Putative 2-oxoglutarate dehydrogenase E1 component OS=Stenotrophomonas maltophilia (strain K279a) GN=sucA PE=4 SV=1 - 
[B2FLD1_STRMK] 0.04 1.95 
B2FLD2 
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex OS=Stenotrophomonas 
maltophilia (strain K279a) GN=sucB PE=3 SV=1 - [B2FLD2_STRMK] 0.00 1.80 
B2FLE0 Asparagine synthetase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3206 PE=4 SV=1 - [B2FLE0_STRMK] 0.02 1.67 






Putative outer membrane antigen lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3215 PE=4 SV=1 - 
[B2FLE9_STRMK] 0.03 1.60 
B2FLG2 
Putative peptidyl dipeptidase/oligopeptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3229 PE=3 SV=1 - 
[B2FLG2_STRMK] 0.00 2.07 
B2FLG5 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3232 PE=4 SV=1 - [B2FLG5_STRMK] 0.04 0.83 
B2FLH4 
Putative transmembrane repetitive protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3241 PE=4 SV=1 - 
[B2FLH4_STRMK] 0.00 2.32 
B2FLQ1 D-amino acid dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=dadA PE=3 SV=1 - [DADA_STRMK] 0.05 0.60 
B2FLR8 
Putative vitamin B12 receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0585 PE=3 SV=1 - 
[B2FLR8_STRMK] 0.01 0.76 
B2FLT5 Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0602 PE=3 SV=1 - [B2FLT5_STRMK] 0.02 0.46 
B2FLU9 
Putative ABC transporter component, polysaccharide related OS=Stenotrophomonas maltophilia (strain K279a) GN=wzt PE=4 SV=1 - 
[B2FLU9_STRMK] 0.02 1.42 
B2FLV2 Putative glycosyl transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=wxocA PE=4 SV=1 - [B2FLV2_STRMK] 0.04 1.23 
B2FLV3 
Putative glycosyltransferase, fusion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=wxocBC PE=4 SV=1 - 
[B2FLV3_STRMK] 0.05 1.78 
B2FLV9 Putative FMN amine oxidoreductase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0629 PE=4 SV=1 - [B2FLV9_STRMK] 0.05 1.43 
B2FLW2 Chaperone protein HtpG OS=Stenotrophomonas maltophilia (strain K279a) GN=htpG PE=3 SV=1 - [B2FLW2_STRMK] 0.05 1.66 
B2FLX9 Putative outer membrane lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1826 PE=3 SV=1 - [B2FLX9_STRMK] 0.02 1.47 
B2FM92 Ribonuclease E OS=Stenotrophomonas maltophilia (strain K279a) GN=rnE PE=3 SV=1 - [B2FM92_STRMK] 0.03 1.72 
B2FMF8 
Putative GAF/GGDEF/EAL domain protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3318 PE=4 SV=1 - 
[B2FMF8_STRMK] 0.05 0.65 
B2FMI1 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4498 PE=4 SV=1 - [B2FMI1_STRMK] 0.01 1.49 
B2FMI9 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4506 PE=4 SV=1 - 
[B2FMI9_STRMK] 0.01 0.55 
B2FMJ3 
Putative ABC transmembrane permease component transport system protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt4510 PE=4 SV=1 - [B2FMJ3_STRMK] 0.05 0.71 
B2FMJ4 
Putative ATP-binding transport protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4511 PE=4 SV=1 - 
[B2FMJ4_STRMK] >0.05 0.00 
B2FMQ7 Putative glycosyltransferase protein OS=Stenotrophomonas maltophilia (strain K279a) GN=wxocA PE=4 SV=1 - [B2FMQ7_STRMK] 0.01 1.55 
B2FMR0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0660 PE=4 SV=1 - [B2FMR0_STRMK] 0.00 0.76 
B2FMR2 
Putative permease component of ABC transporter protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0662 PE=4 SV=1 
- [B2FMR2_STRMK] 0.01 0.69 
B2FMR8 
Putative transmembrane CDP-diacylglycerol--serine O-phosphatidyltransferase OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt0669 PE=3 SV=1 - [B2FMR8_STRMK] 0.00 1.88 
B2FMT0 
Putative thiol:disulfide interchange protein DsbC OS=Stenotrophomonas maltophilia (strain K279a) GN=dsbC PE=4 SV=1 - 




B2FN02 Protein translocase subunit SecD OS=Stenotrophomonas maltophilia (strain K279a) GN=secD PE=3 SV=1 - [B2FN02_STRMK] 0.00 1.72 
B2FN03 Protein-export membrane protein SecF OS=Stenotrophomonas maltophilia (strain K279a) GN=secF PE=3 SV=1 - [B2FN03_STRMK] 0.01 1.38 
B2FN23 
Putative transmembrane TraB family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2036 PE=4 SV=1 - 
[B2FN23_STRMK] 0.03 1.43 
B2FN37 
Putative N-acetylmuramoyl-L-alanine amidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3330 PE=4 SV=1 - 
[B2FN37_STRMK] 0.02 0.70 
B2FN47 Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3340 PE=3 SV=1 - [B2FN47_STRMK] 0.00 0.51 
B2FN59 
Conserved hypothetical repetitive protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3358 PE=4 SV=1 - 
[B2FN59_STRMK] 0.00 1.79 
B2FN82 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3381 PE=4 SV=1 - [B2FN82_STRMK] <0.05 >100 
B2FN86 Polyribonucleotide nucleotidyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=pnp PE=3 SV=1 - [PNP_STRMK] 0.04 1.44 
B2FN87 30S ribosomal protein S15 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsO PE=3 SV=1 - [RS15_STRMK] 0.02 1.54 
B2FN93 
NADH-quinone oxidoreductase subunit N OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoN PE=3 SV=1 - 
[B2FN93_STRMK] 0.04 1.47 
B2FN94 
Putative NADH dehydrogenase I chain M OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoM PE=4 SV=1 - 
[B2FN94_STRMK] 0.00 1.86 
B2FN95 
Putative NADH-ubiquinone oxidoreductase I chain L OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoL PE=4 SV=1 - 
[B2FN95_STRMK] 0.00 2.20 
B2FN97 
Putative transmembrane ankyrin repeat protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4553 PE=4 SV=1 - 
[B2FN97_STRMK] 0.00 1.59 
B2FN99 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4555 PE=4 SV=1 - 
[B2FN99_STRMK] >0.05 0.00 
B2FNC5 Putative dipeptidyl peptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4581 PE=4 SV=1 - [B2FNC5_STRMK] 0.03 1.33 
B2FND5 Universal stress protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4591 PE=3 SV=1 - [B2FND5_STRMK] 0.02 0.48 
B2FND7 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4593 PE=4 SV=1 - [B2FND7_STRMK] 0.00 0.28 
B2FNE2 50S ribosomal protein L33 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpmG PE=3 SV=1 - [RL33_STRMK] >0.05 0.00 
B2FNE3 50S ribosomal protein L28 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpmB PE=3 SV=1 - [RL28_STRMK] 0.03 1.67 
B2FNF1 
Putative transmembrane efflux pump protein OS=Stenotrophomonas maltophilia (strain K279a) GN=smmQ PE=4 SV=1 - 
[B2FNF1_STRMK] 0.00 1.73 
B2FNF2 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4609 PE=4 SV=1 - [B2FNF2_STRMK] <0.05 >100 
B2FNF4 Putative glycosyl transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4611 PE=4 SV=1 - [B2FNF4_STRMK] 0.05 1.34 
B2FNI0 
Putative general secretion pathway protein L OS=Stenotrophomonas maltophilia (strain K279a) GN=pefL PE=4 SV=1 - 
[B2FNI0_STRMK] 0.00 0.54 
B2FNJ1 Putative pili chaperone protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0707 PE=3 SV=1 - [B2FNJ1_STRMK] 0.03 2.55 
B2FNJ2 
Putative outer membrane usher protein mrkc OS=Stenotrophomonas maltophilia (strain K279a) GN=mrkC PE=4 SV=1 - 




B2FNJ3 Putative fimbria adhesin protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0709 PE=4 SV=1 - [B2FNJ3_STRMK] 0.00 3.45 
B2FNK0 
Putative ABC transporter component protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0716 PE=3 SV=1 - 
[B2FNK0_STRMK] 0.00 0.66 
B2FNL0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0726 PE=4 SV=1 - [B2FNL0_STRMK] 0.00 0.28 
B2FNM5 Putative LppC family lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0742 PE=4 SV=1 - [B2FNM5_STRMK] 0.00 1.29 
B2FNP0 Cell division protein FtsQ OS=Stenotrophomonas maltophilia (strain K279a) GN=ftsQ PE=3 SV=1 - [B2FNP0_STRMK] 0.04 0.58 
B2FNQ0 
Putative epimerase/dehydratase polysaccharide-related biosynthesis protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=wbiI PE=4 SV=1 - [B2FNQ0_STRMK] 0.00 1.69 
B2FNQ5 Nucleoside diphosphate kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=ndk PE=3 SV=1 - [NDK_STRMK] 0.00 2.72 
B2FNR0 
Outer membrane protein assembly factor BamB OS=Stenotrophomonas maltophilia (strain K279a) GN=bamB PE=3 SV=1 - 
[B2FNR0_STRMK] 0.01 1.31 
B2FNS0 
Inosine-5'-monophosphate dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=guaB PE=3 SV=1 - 
[B2FNS0_STRMK] 0.05 1.62 
B2FNX6 NADH-quinone oxidoreductase subunit D OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoD PE=3 SV=1 - [NUOD_STRMK] 0.01 1.48 
B2FNX7 NADH-quinone oxidoreductase subunit C OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoC PE=3 SV=1 - [NUOC_STRMK] 0.03 1.29 
B2FNY8 
Acetyl-coenzyme A carboxylase carboxyl transferase subunit beta OS=Stenotrophomonas maltophilia (strain K279a) GN=accD PE=3 
SV=2 - [ACCD_STRMK] 0.02 1.65 
B2FP19 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3449 PE=4 SV=1 - 
[B2FP19_STRMK] 0.00 0.29 
B2FP42 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3472 PE=4 SV=1 - 
[B2FP42_STRMK] 0.00 3.94 
B2FP45 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4632 PE=4 SV=1 - 
[B2FP45_STRMK] 0.00 2.48 
B2FP84 
Putative transmembrane mce related protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4672 PE=4 SV=1 - 
[B2FP84_STRMK] 0.05 1.66 
B2FP90 Putative RmuC family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4678 PE=4 SV=1 - [B2FP90_STRMK] 0.02 1.37 
B2FP97 
Putative amino-acid transporter transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4685 PE=4 SV=1 - 
[B2FP97_STRMK] 0.03 1.62 
B2FPA8 Cell division protein FtsZ OS=Stenotrophomonas maltophilia (strain K279a) GN=ftsZ PE=3 SV=1 - [B2FPA8_STRMK] 0.02 0.71 
B2FPD1 Putative glycosyl transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0784 PE=4 SV=1 - [B2FPD1_STRMK] >0.05 0.00 
B2FPE2 Putative exported heme receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=huvA PE=3 SV=1 - [B2FPE2_STRMK] 0.00 1.70 
B2FPN5 
Putative TonB-dependent outer membrane receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2179 PE=3 
SV=1 - [B2FPN5_STRMK] 0.05 0.59 
B2FPN6 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2180 PE=4 SV=1 - 
[B2FPN6_STRMK] <0.05 >100 
B2FPS6 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3494 PE=4 SV=1 - [B2FPS6_STRMK] 0.00 0.51 
B2FPV5 
Putative autotransporter subtilisin-like protease OS=Stenotrophomonas maltophilia (strain K279a) GN=sphB PE=4 SV=1 - 




B2FPY0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3550 PE=4 SV=1 - [B2FPY0_STRMK] 0.00 0.15 
B2FPY1 Putative signal peptidase I OS=Stenotrophomonas maltophilia (strain K279a) GN=lepB PE=3 SV=1 - [B2FPY1_STRMK] 0.00 1.53 
B2FPY7 
Putative alkyl hydroperoxide reductase subunit c OS=Stenotrophomonas maltophilia (strain K279a) GN=ahpC PE=4 SV=1 - 
[B2FPY7_STRMK] 0.01 2.20 
B2FQ10 UPF0761 membrane protein Smlt0865 OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0865 PE=3 SV=1 - [Y865_STRMK] 0.00 0.57 
B2FQ28 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0885 PE=3 SV=1 - 
[B2FQ28_STRMK] 0.01 0.63 
B2FQ35 50S ribosomal protein L1 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplA PE=3 SV=1 - [RL1_STRMK] 0.05 0.58 
B2FQ39 
DNA-directed RNA polymerase subunit beta' OS=Stenotrophomonas maltophilia (strain K279a) GN=rpoC PE=3 SV=1 - 
[RPOC_STRMK] 0.00 3.33 
B2FQ42 Elongation factor G OS=Stenotrophomonas maltophilia (strain K279a) GN=fusA PE=3 SV=1 - [EFG_STRMK] 0.03 2.14 
B2FQ45 50S ribosomal protein L3 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplC PE=3 SV=1 - [RL3_STRMK] 0.01 0.61 
B2FQ46 50S ribosomal protein L4 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplD PE=3 SV=1 - [RL4_STRMK] 0.02 0.79 
B2FQ54 
Putative secretion protein-HlyD family OS=Stenotrophomonas maltophilia (strain K279a) GN=smeY PE=4 SV=1 - 
[B2FQ54_STRMK] >0.05 0.00 
B2FQ55 
Putative multidrug ACR family efflux system OS=Stenotrophomonas maltophilia (strain K279a) GN=smeZ PE=4 SV=1 - 
[B2FQ55_STRMK] >0.05 0.21 
B2FQ57 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2204 PE=4 SV=1 - [B2FQ57_STRMK] 0.04 1.37 
B2FQ64 Putative ferrous iron transport protein B OS=Stenotrophomonas maltophilia (strain K279a) GN=feoB PE=4 SV=1 - [B2FQ64_STRMK] 0.02 1.64 
B2FQC5 
Putative subfamily S1C unassigned peptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3553 PE=4 SV=1 - 
[B2FQC5_STRMK] 0.00 2.91 
B2FQD7 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3567 PE=4 SV=1 - [B2FQD7_STRMK] 0.04 2.39 
B2FQD9 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3569 PE=4 SV=1 - [B2FQD9_STRMK] 0.00 2.15 
B2FQG3 Protein HflC OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3595 PE=3 SV=1 - [B2FQG3_STRMK] 0.02 1.36 
B2FQG4 Putative HflK protein OS=Stenotrophomonas maltophilia (strain K279a) GN=hflK PE=4 SV=1 - [B2FQG4_STRMK] 0.00 1.90 
B2FQJ5 50S ribosomal protein L24 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplX PE=3 SV=1 - [RL24_STRMK] 0.01 0.35 
B2FQK4 Protein translocase subunit SecY OS=Stenotrophomonas maltophilia (strain K279a) GN=secY PE=3 SV=1 - [B2FQK4_STRMK] 0.01 1.61 
B2FQK8 
DNA-directed RNA polymerase subunit alpha OS=Stenotrophomonas maltophilia (strain K279a) GN=rpoA PE=3 SV=1 - 
[RPOA_STRMK] 0.03 1.43 
B2FQL6 Putative GTP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=typA PE=4 SV=1 - [B2FQL6_STRMK] 0.00 0.54 
B2FQL8 Malate dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=mdh PE=3 SV=1 - [MDH_STRMK] 0.02 1.90 
B2FQM8 Putative outer membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0955 PE=3 SV=1 - [B2FQM8_STRMK] 0.00 1.51 




B2FQN5 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0962 PE=4 SV=1 - [B2FQN5_STRMK] 0.02 2.28 
B2FQQ5 
Putative isocitrate/isopropylmalate dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0982 PE=3 SV=1 - 
[B2FQQ5_STRMK] 0.01 2.30 
B2FQR3 
ATP-dependent Clp protease ATP-binding subunit ClpX OS=Stenotrophomonas maltophilia (strain K279a) GN=clpX PE=3 SV=1 - 
[CLPX_STRMK] 0.00 2.30 
B2FR07 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3644 PE=4 SV=1 - [B2FR07_STRMK] 0.00 2.02 
B2FR08 Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3645 PE=3 SV=1 - [B2FR08_STRMK] 0.00 0.20 
B2FR11 
Putative acyl-coenzyme A dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=fadE PE=4 SV=1 - 
[B2FR11_STRMK] 0.02 1.56 
B2FR23 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3660 PE=4 SV=1 - [B2FR23_STRMK] 0.02 0.69 
B2FR43 Putative penicillin-binding protein 1B OS=Stenotrophomonas maltophilia (strain K279a) GN=mrcB PE=4 SV=1 - [B2FR43_STRMK] 0.00 2.01 
B2FR61 Putative phosphatase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0999 PE=4 SV=1 - [B2FR61_STRMK] 0.03 1.37 
B2FR62 Putative autotransporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1001 PE=4 SV=1 - [B2FR62_STRMK] 0.01 0.65 
B2FR78 Putative outer membrane lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1018 PE=4 SV=1 - [B2FR78_STRMK] 0.00 1.78 
B2FRM9 Protein TolB OS=Stenotrophomonas maltophilia (strain K279a) GN=tolB PE=3 SV=1 - [B2FRM9_STRMK] 0.00 1.74 
B2FRP8 Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3725 PE=3 SV=1 - [B2FRP8_STRMK] 0.00 0.59 
B2FRP9 
Putative transmembrane transport protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3726 PE=4 SV=1 - 
[B2FRP9_STRMK] 0.05 0.87 
B2FRQ4 Putative heat shock chaperone ClpB OS=Stenotrophomonas maltophilia (strain K279a) GN=clpB PE=3 SV=1 - [B2FRQ4_STRMK] 0.01 2.30 
B2FRQ5 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3733 PE=4 SV=1 - [B2FRQ5_STRMK] <0.05 >100 
B2FRR0 Putative lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3739 PE=4 SV=1 - [B2FRR0_STRMK] 0.01 0.43 
B2FRR1 Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3740 PE=3 SV=1 - [B2FRR1_STRMK] 0.00 0.48 
B2FRS9 Putative pilus-assembly protein OS=Stenotrophomonas maltophilia (strain K279a) GN=pilG PE=3 SV=1 - [B2FRS9_STRMK] >0.05 0.00 
B2FRW7 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1115 PE=4 SV=1 - 
[B2FRW7_STRMK] 0.01 1.66 
B2FS15 Putative histone-like protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1164 PE=4 SV=1 - [B2FS15_STRMK] 0.01 1.89 
B2FSD1 tRNA (guanine-N(7)-)-methyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=trmB PE=3 SV=1 - [TRMB_STRMK] >0.05 >100 
B2FSE2 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=smeN PE=4 SV=1 - [B2FSE2_STRMK] 0.03 1.97 
B2FSE3 Putative HlyD-family secretion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=smeM PE=4 SV=1 - [B2FSE3_STRMK] 0.01 1.50 
B2FSG4 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3812 PE=4 SV=1 - [B2FSG4_STRMK] 0.00 2.16 
B2FSG7 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3815 PE=4 SV=1 - [B2FSG7_STRMK] 0.01 1.63 




B2FSH1 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3819 PE=4 SV=1 - [B2FSH1_STRMK] 0.00 1.76 
B2FSH7 
Putative PilM protein (Type 4 fimbrial biogenesis protein) OS=Stenotrophomonas maltophilia (strain K279a) GN=pilM PE=4 SV=1 - 
[B2FSH7_STRMK] 0.02 0.26 
B2FSI7 Citrate synthase OS=Stenotrophomonas maltophilia (strain K279a) GN=gltA PE=3 SV=1 - [B2FSI7_STRMK] 0.02 2.54 
B2FSQ7 
Putative TonB-dependent receptor for Fe(III)-coprogen, Fe(III)-ferrioxamine B and Fe(III)-rhodotrulic acid OS=Stenotrophomonas 
maltophilia (strain K279a) GN=Smlt1233 PE=3 SV=1 - [B2FSQ7_STRMK] 0.02 1.67 
B2FSQ8 Probable malate:quinone oxidoreductase OS=Stenotrophomonas maltophilia (strain K279a) GN=mqo PE=3 SV=1 - [MQO_STRMK] 0.03 0.57 
B2FT44 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3882 PE=4 SV=1 - [B2FT44_STRMK] 0.03 1.61 
B2FT45 
Putative transmembrane DedA family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3883 PE=4 SV=1 - 
[B2FT45_STRMK] 0.02 1.40 
B2FT59 
Putative extracellular heme-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3898 PE=3 SV=1 - 
[B2FT59_STRMK] 0.02 1.67 
B2FT66 Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3905 PE=3 SV=1 - [B2FT66_STRMK] 0.01 0.53 
B2FT88 
Putative biopolymer transport exbB protein OS=Stenotrophomonas maltophilia (strain K279a) GN=exbB1 PE=3 SV=1 - 
[B2FT88_STRMK] 0.01 1.28 
B2FTA3 Putative exported peptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1246 PE=4 SV=1 - [B2FTA3_STRMK] 0.00 2.45 
B2FTA6 Cell division topological specificity factor OS=Stenotrophomonas maltophilia (strain K279a) GN=minE PE=3 SV=1 - [MINE_STRMK] 0.00 2.33 
B2FTB8 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1263 PE=4 SV=1 - [B2FTB8_STRMK] 0.04 0.61 
B2FTC4 
Putative transmembrane protein, similar to that required for pathogenicity of Xanthomonas campestris in plants OS=Stenotrophomonas 
maltophilia (strain K279a) GN=Smlt1270 PE=4 SV=1 - [B2FTC4_STRMK] 0.02 1.46 
B2FTD2 50S ribosomal protein L27 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpmA PE=3 SV=1 - [RL27_STRMK] 0.02 0.79 
B2FTI8 Putative lipid II flippase MurJ OS=Stenotrophomonas maltophilia (strain K279a) GN=mviN PE=3 SV=1 - [B2FTI8_STRMK] 0.01 1.55 
B2FTN0 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2678 PE=4 SV=1 - [B2FTN0_STRMK] 0.00 1.79 
B2FTS1 
Putative drug-resistance cell envelope-related protein OS=Stenotrophomonas maltophilia (strain K279a) GN=smeP PE=4 SV=1 - 
[B2FTS1_STRMK] 0.02 2.06 
B2FTS4 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=pcm PE=4 SV=1 - [B2FTS4_STRMK] 0.04 0.60 
B2FTS5 Protein CyaE OS=Stenotrophomonas maltophilia (strain K279a) GN=tolC PE=3 SV=1 - [B2FTS5_STRMK] 0.04 0.80 
B2FTS7 
Putative 3-deoxy-D-manno-octulosonic-acid transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=kdtA PE=4 SV=1 - 
[B2FTS7_STRMK] 0.01 1.69 
B2FTU3 Putative phosphate selective porin OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3950 PE=4 SV=1 - [B2FTU3_STRMK] 0.04 1.25 
B2FTU5 Putative acetoacetyl-CoA reductase OS=Stenotrophomonas maltophilia (strain K279a) GN=phbB PE=3 SV=1 - [B2FTU5_STRMK] 0.00 3.72 
B2FTY7 Thiol:disulfide interchange protein OS=Stenotrophomonas maltophilia (strain K279a) GN=dsbA PE=3 SV=1 - [B2FTY7_STRMK] 0.04 1.72 
B2FTY8 
Putative thiol:disulfide interchange protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3994 PE=4 SV=1 - 
[B2FTY8_STRMK] 0.01 1.60 
B2FU42 
Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0083 PE=3 SV=1 - 




B2FU60 Glycerol-3-phosphate acyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=plsB PE=3 SV=1 - [B2FU60_STRMK] 0.03 1.67 
B2FU91 
Putative outer membrane autotransporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1350 PE=4 SV=1 - 
[B2FU91_STRMK] >0.05 0.00 
B2FUA0 
Putative transmembrane ubiquinol oxidase subunit 2 OS=Stenotrophomonas maltophilia (strain K279a) GN=qoxA PE=4 SV=1 - 
[B2FUA0_STRMK] 0.01 1.73 
B2FUB3 30S ribosomal protein S16 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsP PE=3 SV=1 - [RS16_STRMK] 0.00 1.90 
B2FUE0 
Putative outer membrane efflux protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1407 PE=4 SV=1 - 
[B2FUE0_STRMK] 0.00 0.70 
B2FUL2 
Putative respiratory nitrate reductase alpha chain OS=Stenotrophomonas maltophilia (strain K279a) GN=narG PE=4 SV=1 - 
[B2FUL2_STRMK] 0.01 2.75 
B2FUN9 
Putative TonB-dependent receptor for Fe(III)-coprogen, Fe(III)-ferrioxamine B and Fe(III)-rhodotrulic acid OS=Stenotrophomonas 
maltophilia (strain K279a) GN=fhuE PE=3 SV=1 - [B2FUN9_STRMK] 0.01 1.37 
B2FUP4 Putative transglycosylase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4007 PE=4 SV=1 - [B2FUP4_STRMK] 0.01 1.94 
B2FUP9 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4012 PE=4 SV=1 - [B2FUP9_STRMK] >0.05 0.00 
B2FUR1 
Putative TonB-dependent outer membrane receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4026 PE=3 
SV=1 - [B2FUR1_STRMK] 0.00 0.43 
B2FUS7 
Putative exported tail-specific protease OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4045 PE=3 SV=1 - 
[B2FUS7_STRMK] 0.00 2.13 
B2FUT1 
Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4049 PE=4 SV=1 - 
[B2FUT1_STRMK] 0.04 0.75 
B2FUT2 Putative penicillin-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=dacC PE=3 SV=1 - [B2FUT2_STRMK] 0.01 1.55 
B2FUT3 Putative exported rare lipoprotein A OS=Stenotrophomonas maltophilia (strain K279a) GN=rlpA PE=3 SV=1 - [B2FUT3_STRMK] 0.00 0.70 
B2FUT4 Putative murein hydrolase OS=Stenotrophomonas maltophilia (strain K279a) GN=mltB PE=4 SV=1 - [B2FUT4_STRMK] 0.00 1.42 
B2FUT7 Putative penicillin-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=mrdA PE=4 SV=1 - [B2FUT7_STRMK] 0.01 1.67 
B2FUT9 Putative rod shape-determining protein OS=Stenotrophomonas maltophilia (strain K279a) GN=mreC PE=4 SV=1 - [B2FUT9_STRMK] 0.03 1.37 
B2FUU0 Putative rod shape-determining protein OS=Stenotrophomonas maltophilia (strain K279a) GN=mreB PE=4 SV=1 - [B2FUU0_STRMK] 0.04 0.65 
B2FUU5 Putative PEPTIDASE OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4064 PE=4 SV=1 - [B2FUU5_STRMK] 0.01 1.51 
B2FUV1 
Putative multidrug resistance outer membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=smeF PE=4 
SV=1 - [B2FUV1_STRMK] 0.00 4.00 
B2FUV2 
Putative acriflavin resistance protein B OS=Stenotrophomonas maltophilia (strain K279a) GN=smeE PE=4 SV=1 - 
[B2FUV2_STRMK] 0.00 4.74 
B2FUV3 
Putative acriflavin resistance protein A OS=Stenotrophomonas maltophilia (strain K279a) GN=smeD PE=4 SV=1 - 
[B2FUV3_STRMK] 0.00 2.42 
B2FUV6 
ATP-dependent protease ATPase subunit HslU OS=Stenotrophomonas maltophilia (strain K279a) GN=hslU PE=3 SV=1 - 







5 Characterisation of β-lactamase inhibitors in 




β-lactamases are the most commonly encountered cause of resistance to 
β-lactams, which are the most frequently prescribed class of antibacterial drug world-
wide (285-287). β-lactamases render β-lactams inactive through catalysing efficient 
hydrolysis of the β-lactam ring (288, 289). There are many hundreds of known 
β-lactamases, which are grouped based on sequence and mechanism into the serine 
β-lactamase (SBL) classes A, C and D, and the metallo-β-lactamase (MBL) subclasses 
B1, B2 and B3) (290, 291). Broad-spectrum, clinically useful β-lactamase inhibitors are 
being sought, but the varying chemistries and active site architectures of the different 
β-lactamase classes makes the development of cross-class inhibitors extremely 
challenging (114, 292, 293). 
Clavulanic acid (Figure 5.1, top) is a well-established clinically deployed 
β-lactam-based inhibitor of, principally, class A SBLs. Clavulanic acid is used in 
combination with penicillin derivatives such as amoxicillin (Figure 1.4) and ticarcillin 
(Figure 1.4), whose bactericidal effects improve against some β-lactamase-carrying 
isolates of species such as E. coli and K. pneumoniae (294-297). Clavulanic acid is an 
irreversible inhibitor of class A enzymes, whose activity arises from fragmentation of 
the acyl-enzyme complex formed by reaction with the active-site serine nucleophile, to 
generate a near permanently inactivated species (136, 298, 299). In contrast, 
avibactam (formerly NXL104), a recently introduced relatively broad spectrum non-β-
lactam-based SBL inhibitor contains a diazobicyclo heterocyclic core structure which 
reversibly acylates SBLs. The potency of avibactam against class A, C and some class 
D SBLs is attributed to the stabilization of the carbamoyl complex due to interactions 
with polar residues present in the active sites, with de-acylation preferentially occurring 
due to recyclization rather than hydrolytic turnover (300). This recyclization results in 
release of intact active inhibitor rather than an inactive hydrolysis product (Figure 5.1, 
middle) (272, 301-304). Avibactam has recently been licenced for clinical use in 
partnership with the oxy-amino cephalosporin ceftazidime, though the combination is 
not universally efficacious and has no useful activity against MBL-producing bacteria 




Boronic acid-based compounds have long been studied as potential SBL 
inhibitors (306-308) but, in most cases, are ineffective against MBL targets. For 
example, the monocyclic boronate vaborbactam (RPX7009) ( Figure 5.1, bottom left), 
is effective against Class A, C and D β-lactamases, but not MBLs (309). However, we 
recently  demonstrated that bicyclic boronate scaffolds can act as potent inhibitors of 
multiple SBL classes as well as subclass B1 MBLs (293). Accordingly, one method of 
overcoming the poor activity of ceftazidime/avibactam (Figure 1.6) against MBL 
producing bacteria would be to combine ceftazidime with a bicyclic boronate inhibitor, 
such as 2 (Figure 5.1, bottom right), or 1, which is derived from the same scaffold 
(310). Together, 1 and 2 represent the closest approach to a pan-β-lactamase inhibitor 
that has, to-date, been reported in the literature (310). Another bicyclic boronate β-
lactamase inhibitor (VNRX-5133) has recently completed phase 1 clinical trials (311). 
 
Figure 5.1 Chemical structures of β-lactamase inhibitors 
Top, clavulanic acid. Middle, avibactam and the acyl-enzyme complex formed 
on reaction of avibactam with SBLs. Bottom, cyclic boronate 2 
 
Thiol-based compounds provided the first insights in MBL inhibition (111, 312-




compounds that include metal-chelating moieties (315) that displaces zinc atom from 
the active site to impede β-lactam hydrolysis (316). Rhodanine-based compounds 
possess a thiazolidine core with two-chelating moieties, sulphur and a nitrogen atom. 
In fact, rhodanines and their derivatives have shown to inhibit MBLs (IMP-1, VIM-2, 
NDM-1) with submicromolar Ki values (316, 317). Other zinc-binding inhibitors include 
a phosphonate moiety that have shown the potential to become broad-spectrum MBLs 
inhibitors (318). Mercaptophosphonate compounds have shown to inhibit VIM-4, CphA, 
and L1 with Ki values ranging from 0.4 to > 400 µM (319) (Figure 1.21).  
While S. maltophilia possesses multiple efflux systems (283, 320-322) that 
reduce the net rate of entry for many antimicrobials, as discussed in Chapter 4,  β-
lactam resistance arises primarily from production of two β-lactamases, a subclass B3 
MBL “L1”, which hydrolyses all β-lactams except for the monobactam, aztreonam 
(Figure 1.8), and the class A Extended Spectrum SBL (ESBL) “L2”, which hydrolyses 
all first to third generation cephalosporins, all penicillins, and aztreonam (153, 156, 
157). The combination of L1 and L2, therefore renders S. maltophilia resistant to all 
β-lactam antibiotics although in clinical practice, ceftazidime can be useful, because 
most clinical isolates do not produce enough β-lactamase to give resistance (323, 
324). However, ceftazidime resistant mutants rapidly emerge as discussed in Chapter 
3. Accordingly, S. maltophilia represents one of the most challenging targets for β-
lactam/β-lactamase inhibitor combinations.  
Here, we aimed to provide kinetic and structural insights of the interaction of 
S. maltophilia β-lactamases and β-lactamase inhibitors as well as testing various 
β-lactam/β-lactamase inhibitor combinations against extensively drug resistant clinical 
S. maltophilia isolates and characterisation of acquired resistance to these 
combinations. 
 
5.2 Results & discussion 
 
5.2.1 β-lactamase inhibitors restore aztreonam, but not meropenem activity 
against S. maltophilia  
 
As a prelude to investigating the effects of β-lactamase inhibitors, we first 
evaluated the hydrolysis of a range of candidate β-lactams in vitro by purified L1 
(subclass B3 MBL) and L2 (class A ESBL) under steady state conditions. These data 




substrate for L1, with L2 showing only weak hydrolytic activity, the monobactam 
aztreonam to be a substrate for L2 only, and that both L1 and L2 can hydrolyse the 
oxyamino-cephalosporin ceftazidime with similar efficiencies. 
 
Table 5.1 Kinetic data for β-lactams tested against metallo L1 and serine L2 S. 
maltophilia β-lactamases. 
















L1 Ceftazidime 0.5 259.5 1.67 6.4 
 Aztreonam 0.5 - - - 
 Meropenem 10 105 23.8 227 
 FC5 0.05 29.6 146 4,932 
L2 Ceftazidime 0.5 548.5 1.88 3.4 
 Aztreonam 0.5 119.4 0.08 0.67 
 Meropenem 0.625 28.83 0.028 0.97 
 FC5 0.05 17.9 208.6 11,653  
 
We next tested the ability of three β-lactamase inhibitors: clavulanic acid, 
avibactam and the bicyclic boronate 2 (each at 2 mg/L) to potentiate the activity of the 
target β-lactams against S. maltophilia (Table 5.2) All three inhibitors reversed 
aztreonam, but not meropenem resistance in ceftazidime susceptible clinical isolates 
(K279a, CI-20, CI-29). Furthermore, all three inhibitors reversed ceftazidime and 
aztreonam, but not meropenem, resistance in a ceftazidime-resistant L1/L2 hyper-
producing mutant (K CAZ 10), derived from K279a (Table 5.2) (214). Interestingly, all 
three inhibitors were unable to restore ceftazidime susceptibility in a ceftazidime 
resistant L1/L2 hyper-producing clinical isolate (CI-31), but they all restored aztreonam 







Table 5.2 Minimum Inhibitory Concentrations (mg/L) of β-lactams against S. 
maltophilia in the presence of β-lactamase inhibitors used at 2 mg/L 
 Ceftazidime Aztreonam Meropenem 
 - +CLA +BOR +AVI - +CLA +BOR +AVI - +CLA +BOR +AVI 
K279a 4 4 0.5 1 128 1 1 1 8 32 4 16 
CI-20 16 16 2 4 128 4 2 2 64 32 8 64 
CI-29 8 4 0.5 1 128 1 1 1 32 16 8 32 
K CAZ 10 64 8 4 8 256 0.5 1 1 64 8 16 64 
KCAZ14 64 32 8 2 256 - 2 1 128 32 32 128 
CI-31 256 128 128 128 256 2 4 4 256 256 256 256 
K AMI 32 2 1 1 0.5 128 0.5 1 0.5 4 8 4 16 
K MOX 8 4 1 0.5 0.5 128 0.25 1 0.5 4 8 8 16 
 
Shaded values indicate clinically relevant resistance according to CLSI breakpoints 
(325) 
(-) Inconsistent values 
CLA, clavulanic acid; BOR, bicyclic boronate 2; AVI, avibactam 
 
Efflux pumps play a major role in antimicrobial resistance in S. maltophilia (130, 
173). Thus, to investigate the possible effect of multi-drug efflux pumps on β-lactamase 
inhibitor efficacy, we tested the effect on K AMI 32 and K MOX 8, SmeYZ and 
SmeDEF hyperproducers, respectively as described in Chapter 4.  All three β-
lactamase inhibitors retained full activity against these efflux pump hyper-producing 
mutants (Table 5.2) ruling out efflux (or at least SmeDEF and SmeYZ) as a 
contributing factor to the observed variation in efficacy of the various β-lactam/β-
lactamase inhibitor combinations. 
5.2.2 The bicyclic boronate 2 does not inhibit the S. maltophilia L1 MBL 
 
Based on these in vitro data we conclude that the bicyclic boronate 2 acts 
against S. maltophilia in a similar fashion to avibactam and clavulanic acid: it reverses 
aztreonam and, when due to L1/L2 hyperproduction, ceftazidime resistance (Table 
5.2). As 2 has been shown to inhibit multiple MBLs (293), we anticipated that it might 




5.2), which is predominantly hydrolysed by L1 (Table 5.1) suggests that L1 inhibition 
by 2 does not occur to a significant extent.  
As, to date, the inhibition of subclass B3 MBLs by bicyclic boronates has not 
been reported, we investigated the inhibition of purified L1 and L2 by the three β-
lactamase inhibitors using the fluorogenic β-lactamase substrate FC5 as a new 
reporter for L1 and L2 (192). Calculated kcat/KM values clearly demonstrate that FC5 is 
hydrolysed with a higher efficiency than other β-lactams by both L1 and L2 (Table 5.1). 
IC50 measurements revealed that while all three β-lactamase inhibitors inhibit L2 with 
nanomolar potencies (Table 5.3), no inhibition of L1 was observed, even when using 
inhibitor concentrations up to 2.5 mM. Thus, unlike the case for subclass B1 MBLs 
(293), the bicyclic boronate 2 is not an effective inhibitor of the subclass B3 MBL L1. 
 
Table 5.3 Inhibition of L2 by β-lactamase inhibitors in vitro 
 
Inhibitor IC50 (nM) pIC50 
Clavulanic Acid 22.3 7.41 
Avibactam 14.36 7.84 
Bicyclic Boronate 2 5.25 8.27 
 
 
5.2.3 Structural basis for inhibition of L2 by avibactam and the bicyclic 
boronate 2 
 
Collaboration with Dr. Philip Hinchliffe (University of Bristol) allowed data 
collection, refinement and final structure modelling. The results above demonstrate 
that, consistent with the effectiveness of β-lactam/β-lactamase inhibitor combinations 
against S. maltophilia strains, L2 is effectively inhibited by both avibactam and the 
bicyclic boronate 2. To investigate the molecular basis for this inhibition we crystallised 
L2 and soaked the crystals in avibactam or 2. (Consistent with our inhibition kinetics 
results, we were unable to obtain crystal structures of complexes of L1 with either of 




asymmetric unit (Table 5.4), and closely conserves the overall SBL fold with, for 
example, a C alpha RMSD to KPC-2 (PDB 2OV5) of 0.2 Å.  
Table 5.4 Data collection and refinement statistics 
 
 Native/(D)-glutamate avibactam cyclic boronate 
Data collection     
Space group P21212 P21212 P21212 
Molecules/ASU 2 2 2 
Cell dimensions      
    a, b, c (Å) 69.68, 84.72, 93.71 69.49, 84.31, 93.67 70.38, 85.69, 113.18 
    α, β, γ  ()  90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Wavelength(s) (Å) 0.97625 0.97949 0.92819 
Resolution (Å)* 55.92 – 1.19 (1.21 – 
1.19) 
53.62 – 1.35 (1.37 – 
1.35) 
44.10 – 2.09 (2.14 – 
2.09) 
Rpim 0.050 (0.778) 0.053 (0.806) 0.126 (0.800) 
CC1/2 0.999 (0.625) 0.998 (0.616) 0.992 (0.534) 
I / σ(I) 10.7 (1.9) 9.8 (1.3) 8.0 (1.4) 
Completeness (%) 99.7 (98.3) 96.8 (94.2) 99.3 (99.5) 
Redundancy 8.6 (8.0) 11.5 (9.9) 13.1 (13.3) 
    
Refinement    
Resolution (Å) 55.92 – 1.19 53.62 – 1.35 42.845 – 2.09 





 0.1522 / 0.1640 0.1618 / 0.1781 0.1756 / 0.2143 
No. atoms    
    Protein 8180 3478 4035 
    Solvent 763 644 335 
    Ligand 34 56 25 
B-factors (Å
2
)    
    Protein 15.9 17.3 28.8 
    Solvent 29.3 34.5 41.2 







R.m.s. deviations    
    Bond lengths 
(Å) 
0.007 0.011 0.010 
    Bond angles () 0.963 1.349 1.249 
Ramachandran 
(%) 
   
    Outliers 0.00 0.00 0.00 
    Favoured 97.38 97.36 97.16 
*Values in parentheses are for highest-resolution shell.  
1
Chain A B-factor 18.4; chain B B-factor 30.3 
2
Chain A B-factor 22.9; chain B B-factor 22.0 
3




L2 crystals formed in a reagent containing racemic mixture of the amino acids 
glutamate, alanine, lysine and serine. The active site manifests clear Fo-Fc density into 
which a molecule of D-glutamate could be modelled (Figure 5.2), indicating the 
D-enantiomer preferentially binds to L2. However, binding does not perturb the active 
site conformation compared with an un-complexed L2 crystal structure (PDB 1O7E) 




Glu166, Asn170 and Ser70 (see Table 5.5 for distances), and the conformation of the 
conserved, catalytically important Lys73 (326-328).  
 
 
Figure 5.2 L2 active site views showing electron density maps calculated after 
removal of ligand 
 
Fo-Fc density (green, contoured at 3σ) calculated from the final model after removal of (A) 
D-glutamate, (B) Boronate 2 and (C) avibactam. Residues coordinating the ‘hydrolytic’ 
water (red sphere, ‘Wat’) are shown as sticks and labelled (Ser70, Glu166 and Asn170). 
 
Figure 5.3 Comparison of the active sites of L2:D-glutamate with L2 native 
 
L2:D-glutamate (green) and L2 native (PDB 1O7E, orange) are superposed and shown in 






Table 5.5 Catalytic water interactions (distances in Å) in L2 structures 
 Glu166-OE2 Asn170-OD1 Ser70-OG 
L2:native (PDB 1O7E) 2.50 2.71 2.71 
L2:D-glutamate 2.63 2.63 2.55 
L2:avibactam 2.55 2.76 2.87 
L2:boronate 2 2.49 2.60 2.70 
 
D-glutamate binds non-covalently, through interactions of its carbonyl oxygen 
with the backbone amides in the oxyanion hole (formed by residues Ser70 and 
Ser237), the C-terminal oxygen with Ser130-Oγ, and the glutamate amide with the 
deacylating water (Figure 5.4A). Despite these extensive interactions, there is little 
inhibitory effect, with 100 mM D-glutamate reducing L2 activity by just 20% (Figure 
5.5). D-glutamate binds differently compared with the high affinity binding (Ki = 84 pM) 
of the β-lactamase inhibitory protein (BLIP) to the class A β-lactamase KPC-2 (PDB 
3E2K) (329). Interestingly, BLIP binding to KPC-2 involves localisations of an 
L-aspartate residues at the active site, in a manner related to, but different from, D-
glutamate binding to L2, and one that does not involve interactions with the oxyanion 
hole (Figure 5.6) (330). 
 
 
Figure 5.4 Interaction of β-lactamase inhibitors with the L2 active site 
View of L2 (shown in green cartoon) active sites with bound ligands (blue sticks), (A) 
D-glutamate, (B) bicyclic boronate 2 and (C) avibactam. Interactions between 
residues and the catalytic water are shown as red dashes, and interactions between 
residues and ligand as blue dashes. Labelled residues are those that specifically 

















Figure 5.5 Inhibitory effect of D-glutamate on L2 catalysis 
 
L2 activity against FC5 reduces by 20% in presence of the highest concentration of 







Figure 5.6 Superposition of L2:D-glutamate with KPC-2:BLIP 
The L2:D-glutamate structure is superposed with the crystal structure (PDB 3E2K) of 
BLIP (yellow) bound in the active site of KPC-2 (grey). Asp49 (stick, labelled) is the 
only BLIP residue making interactions in the KPC-2 active site, although binding is 
significantly different to D-glutamate (blue), with the exception of hydrogen bond 
formation to the side chains of S130 and T237 (labelled sticks; S237 in L2). Residues 
which interact with the catalytic water (red sphere) or form the oxyanion hole are 
labelled and shown as sticks. 
 
 
L2:avibactam and L2:bicyclic boronate 2 complex structures were solved to 
1.35 Å and 2.09 Å resolution, respectively, with clear Fo-Fc density indicating that both 
inhibitors react with the active site nucleophile Ser70 to form covalent complexes 
(Figure 5.2B and Figure 5.2C). Binding by both compounds reveals no significant 
changes in the L2 active site in comparison with the apo or D-glutamate structures. 
Indeed, in both structures the deacylating water is positioned similarly to the native and 
D-glutamate-bound structures (Table 5.5).  
The bicyclic boronate 2 binds L2 (Figure 5.4B) with the boron atom clearly in a 
tetrahedral geometry, as observed previously on binding of the cyclic boronate 1 to 
CTX-M-15 (another class A ESBL) (310) and OXA-10 (a class D SBL) (293), mimicking 




binding, the assigned OH group on the boron atom is positioned to make strong 
interactions with the backbone amides of Ser70 (2.95 Å) and Ser237 (3.1 Å) in the 
oxyanion hole. The bicyclic boronate 2 makes additional hydrogen bonds to the side 
chains of the catalytically important residues Ser130 (2.77 Å to the bicyclic ring 
oxygen), Asn132 (3.0 Å to the acetamide oxygen), Ser237 (2.96 Å to the carboxylate) 
Thr235 (2.65 Å to the carboxylate), and the backbone carbonyl oxygen of Ser237 (3.1 
Å to the acetamide nitrogen). In addition, binding is stabilised by significant 
hydrophobic interactions with His105.  
Avibactam (Figure 5.4C) binds to L2 in its ring opened form, forming a 
carbamoyl-enzyme complex (300) in which its six-membered ring is in a chair 
conformation, a conserved feature in other structurally characterised avibactam:β-
lactamase complexes (113, 331-335). Highlighting the importance of the oxyanion 
hole, as with both D-glutamate and the bicyclic boronate 2, the avibactam derived 
carbamoyl oxygen is positioned to make hydrogen bonds with the oxyanion hole 
backbone amides of Ser70 (2.75 Å) and Ser237 (2.85 Å). His105 is also involved in 
providing stabilising hydrophobic interactions (3.49 Å), while the carbamoyl NH 
interacts with the backbone carbonyl of Ser237 (3.08 Å) and the Asn132 sidechain 
(2.97 Å). The carbamoyl NH interactions may be relatively less important as they 
present in only one molecule in the asymmetric unit (chain B). The avibactam sulfate 
moiety interacts with the OH groups of both Thr235 (3.10 Å) and Ser130 (2.88 Å), with 
an additional 3.19 Å interaction with Ser237 in chain B. 
Our structural data reveal that the bicyclic boronate 2 binds to the ESBL L2 in a 
manner similar to that previously observed for the closely related bicyclic boronate 1 
binding to the ESBL CTX-M-15. For the bicyclic boronate 2, binding of the tetrahedral 
boron atom to L2 and conformation of the bicyclic fused core are all consistent with the 
CTX-M-15:bicyclic boronate 1 structure (310); there is only slight variation in the 
amide/benzamide side chain conformations (Figure 5.7A). Furthermore, formation of 
the L2 carbamoyl-enzyme complex by avibactam results in a conformationally similar 
mode of binding compared with structurally-characterised complexes with the class A 
SBLs KPC-2 (PDB 4ZBE) (331), SHV-1 (PDB 4ZAM) (331) and CTX-M-15 (PDB 4S2I) 
(332) (Figure 5.7B), and is consistent with data indicating avibactam to be similarly 
effective against these enzymes (300, 331, 336) However, some subtle differences in 
active-site interactions are observed (Figure 5.8). In particular, while the avibactam 
carbamoyl hydrogen bond with Asn132 is conserved, the weaker carbamoyl interaction 
with the carbonyl oxygen of L2-Ser237 is not, highlighting that such an interaction is 




with Thr235 is likely important as it presents in all SBLs, while interaction with Ser130 
is present in KPC-2 alone. In SHV-1:avibactam, interaction of the sulfate group with the 
non-conserved Arg244 essentially substitutes for the sulfate-Ser237 interaction in other 
SBLs (Thr237 in KPC-2). In both SHV-1:avibactam and KPC-2:avibactam the 
‘hydrolytic’ deacylating water molecule hydrogen bonds to the avibactam carbamoyl, 
while this interaction is not observed with either CTX-M-15:avibactam or L2:avibactam. 
The avibactam-derived sulfate-bonded nitrogen is in the same conformation as in KPC-
2/SHV-1:avibactam and, unlike in the CTX-M-15:avibactam complex, is directed away 
from the six-membered ring and distant from Ser130 (Ser130, 3.57 Å) (332) and 
consequently is not primed for re-cyclization (304) in which this residue is involved 
(Figure 5.7B). The CTX-M-15:avibactam complex therefore remains to date as the 
only crystallographic evidence for avibactam reacting with an SBL in a conformation 
ideal for re-cyclization (332). Thus, the rate at which the avibactam derived complex 
can re-cyclize to reform intact avibactam may vary between SBLs.  
 
 
Figure 5.7 Bicyclic boronate and avibactam binding conformations in Class A β-
lactamases 
Superposition of inhibitors, shown as sticks, bound in the active sites of Class A β-
lactamases. (A) Bicyclic boronates bound to L2 (blue, bicyclic boronate 2) and CTX-M-15 
(grey, bicyclic boronate 1). (B) Avibactam bound to L2 (blue), SHV-1 (grey), KPC-2 
(green) and CTX-M-15 (orange). Note the common binding mode for the bicyclic 
boronate bicyclic core and most of the avibactam structure; there are differences in the 






Figure 5.8 Comparisons of structurally characterised modes of binding of 
avibactam in class A SBLs 
Avibactam (grey sticks) is shown as complexed with L2 (blue, this study), SHV-1 
(orange, PDB 4ZAM), KPC-2 (green, PDB 4ZBE), and CTX-M-15 (cyan, PDB 4S2I). 
 
5.2.4 β-lactamase production is not induced by avibactam and the bicyclic 
boronate 2 
 
One important consideration when deploying β-lactamase inhibitors into clinical 
practice is that some can interact with penicillin binding proteins and trigger β-
lactamase induction pathways carried by many bacteria (110). L1 and L2 production in 
S. maltophilia is controlled by a transcriptional regulator, AmpR, which is responsive to 
β-lactam challenge via sensing β-lactam mediated perturbations in peptidoglycan 
breakdown and recycling (215, 338). Hence we tested the ability of β-lactamase 
inhibitors to induce β-lactamase production in S. maltophilia. Clavulanic acid induces 
L1 production (measured using meropenem hydrolysis in cell extracts) at a similar level 
to the positive control β-lactam cefoxitin in the S. maltophilia wild type strain K279a 
(Figure 5.9). This observation rationalizes why clavulanic acid does not reduce the 




5.9) overcomes inhibition of L2 (Table 5.3) because L1 can hydrolyse ceftazidime 
(Table 5.1). Since L1 does not hydrolyse aztreonam (Table 5.1), however, clavulanic 
acid reduces the aztreonam MIC against K279a, despite its ability to induce L1 
production (Table 5.2, Figure 5.9). Notably, by contrast with clavulanic acid, both 
avibactam and the bicyclic boronate 2 reduce ceftazidime MICs against K279a (Table 
5.2). This observation is explained by the important finding that neither avibactam nor 2 
induces L1 to any measurable extent (Figure 5.9), yet both inhibit L2 (Table 5.3). 
 
 
Figure 5.9 L1 β-lactamase induction by β-lactamase inhibitors in S. maltophilia 
K279a 
 
S. maltophilia isolate K279a was incubated in presence of different potential 
inducers (cefoxitin, clavulanic acid, the bicyclic boronate 2, or avibactam) at 50 
mg/L). L1 activity was measured from the cell extracts in a 96-well plate reader by 
determining meropenem hydrolysis (100 µM) at λ=300 nm. Protein concentration 
was determined by using the BioRad protein assay dye reagent. Specific activity was 
calculated by using the extinction coefficient of 9600 AU/M/cm and a pathlength 






5.2.5 Selection and characterisation of mutants which overcome the reversal of 
ceftazidime resistance by avibactam and the bicyclic boronate 2 
 
Avibactam is currently only clinically available in combination with ceftazidime. 
The fact that L1 induction by clavulanic acid overcomes its ability to reduce ceftazidime 
MICs against S. maltophilia (Figure 5.9, Table 5.2) led us to suggest that L1/L2 hyper-
producing, ceftazidime resistant strains might further mutate to be ceftazidime resistant 
in the presence of avibactam and the bicyclic boronate 2 by producing even more L1. 
To investigate this possibility, we used a K279a ampR mutant, M11, which is 
ceftazidime resistant due to L1/L2 hyper-production but where ceftazidime resistance 
can be reversed following treatment with avibactam or 2 at 10 mg/L (Table 5.6). We 
aimed to identify mutants able to grow on ceftazidime at >32 mg/L (i.e. clinically 
resistant, according to CLSI breakpoints (325) in the presence of either avibactam or 2 
at 10 mg/L. Mutants were readily obtained; those selected using ceftazidime/avibactam 
were also resistant to ceftazidime/2, and vice versa (Table 5.6). To investigate the 
basis for resistance, LC-MS/MS proteomics was used to quantify changes in protein 
production in the two mutants. In both cases, L1 was produced at levels ~3-fold greater 
than in the parent strain (Annex 4, Figure 5.10A). This result was confirmed by 
measuring L1 enzyme activity in cell extracts using meropenem as substrate (Figure 
5.10B). Thus, hyper-production of L1 can overcome the ability of these L2-specific 
inhibitors to rescue ceftazidime activity against a ceftazidime-resistant strain. 
Importantly, however, the mutants were still sensitive to the aztreonam/avibactam or 
aztreonam/2 combinations (Table 5.6) as L1 cannot hydrolyse aztreonam (Table 5.1). 
The L1 hyper-producing phenotype, blocking reversal of ceftazidime, but not 
aztreonam, resistance by β-lactamase inhibitors is clearly relevant, because it is 
displayed by clinical isolate CI-31 (Table 5.2). WGS analysis of the M11 derivatives 
showed variations in smlt0009 but siderophore production was similar to the K279a 









Table 5.6 MICs (mg/L) of β-lactams against S. maltophilia mutants in the 




- +BOR +AVI - +BOR +AVI 
K279a 4 0.5 1 128 1 1 
M11 128 8 2 256 1 1 
MA27 256 32 32 256 4 4 
MB25 256 64 128 256 4 4 
 
 
Shaded values represent resistance according to CLSI breakpoints. 
BOR, bicyclic boronate 2; AVI, avibactam. 
MA27 and MB25 were selected for growth at 32 mg/L ceftazidime in the presence of 
10 mg/L avibactam or bicyclic boronate 2, respectively using M11 as parent strain. 






Figure 5.10 L1 activity of Inhibitor Resistant Mutants 
In (A), L1 protein abundance data (relative to mean ribosomal protein abundance for 
each sample). Full proteomics data are shown in (272). In (B), L1 enzyme activity in 
cell extracts is reported as meropenem hydrolysis rate. Data are reported as mean 
+/- SEM, n=3 for the parent strain, M11, and the two mutants (MB25 and MA27), 
which are resistant to ceftazidime/avibactam and ceftazidime/2.  
 
Even though our structural and kinetic work confirm that L2 is potently inhibited 
by avibactam and the bicyclic boronate 2, we predicted failure of 
avibactam/ceftazidime against S. maltophilia. Our prediction was based on the 




isolates (Figure 5.10), and avibactam does not inhibit MBLs (305) . Whilst 2 inhibits 
subclass B1 MBLs (293), our work reveals that it does not inhibit the subclass B3 MBL, 
L1 (Table 5.3) and so 2/ceftazidime also overcome by L1 hyper-production (Table 5.6, 
Figure 5.10). It may be possible to modify 2 and so generate a broader-spectrum MBL 
inhibitor. However, a key finding of this work is that such a modification might not be 
essential. Avibactam and 2 both facilitate killing of S. maltophilia when paired with the 
monobactam, aztreonam, reducing MICs to ≤ 4 mg/L even in the pan-resistant clinical 
S. maltophilia isolate, CI-31 (Table 5.2). These data imply that aztreonam/avibactam 
and aztreonam/2 may have a promising clinical future for treatment of infections 
caused by this most intractable of species. The fact that efflux pump over-production 
does not affect aztreonam/2 or aztreonam/avibactam activity (Table 5.2) gives even 
greater cause for optimism. It was interesting to read, therefore, a recent clinical case 
report demonstrating the use of combination therapy with ceftazidime/avibactam plus 
aztreonam to save the life of a patient with an S. maltophilia infection that had failed all 
prior therapy (339). Our structural, kinetic and whole bacterial killing data would lead to 
the conclusion that ceftazidime was probably superfluous in this success, but our work 
indicates that ceftazidime/avibactam plus aztreonam might be routinely considered in 
the clinic for use against seemingly untreatable S. maltophilia infections whilst 
aztreonam/avibactam works its way through the clinical trials system. Positive results 
have been seen with ceftazidime/avibactam plus aztreonam against 
Enterobacteriaceae isolates carrying multiple β-lactamases, but the combination was 
not universally efficacious (340). 
In many respects, because of its inability to inhibit L1, the bicyclic boronate 2 
acts against S. maltophilia very similarly to avibactam. One potentially significant 
difference is that avibactam is hydrolysed by L1, but 2 retains its structural integrity. 
This hydrolysis is slow (272), and even if L1 is hyper-produced, it is not significant 
enough to confer aztreonam/avibactam resistance (Table 5.6). However, there is a 
chance that L1 mutants might be selected with greater avibactam hydrolytic activity, 
reducing the degree of L2 inhibition and raising the MIC of aztreonam/avibactam into 
the resistant range. This observation may also be of relevance to other avibactam-like 
compounds in development, e.g. Relebactam (341). In contrast, given that modification 
of 2 in the presence of wild-type L1 is undetectably slow (272), evolution to increased 
breakdown may require significantly more steps, potentially increasing the long-term 





5.2.6 Potentiation of Meropenem activity in presence of metallo-β-lactamase 
inhibitors 
 
Apart from the aztreonam/2 combination, we explored other alternatives to 
counteract the β-lactamase activity of L1 in S. maltophilia. Here, we tested the simplest 
of a series of 6-phosphonomethylpyridine-2-carboxylate (PMPC) derivatives which 
contains a pyridine core and a phosphonomethyl group at position C6, inhibitor 3a. 
Initially, uptake of 3a, was tested against K AMI 32, the SmeYZ overproducer, and a 
K279a:smeJKWZP-, lacking efflux pumps SmeJ/K/W/Z/P (173). Meropenem MIC 
values showed that increased efflux does not affect activity of 3a. Originally 
meropenem MIC values for both strains are equal given the intrinsic error on the test 
which is two-fold (342). Despite our finding that high concentrations of 3a are needed 
to reverse meropenem resistance (Table 5.7) in S. maltophilia, data here obtained 
present 3a as an interesting scaffold structure on which to generate more potent 
broad-spectrum MBL inhibitors. 































in the presence of PMPC (3a) at 


















16 16 16 8 4 
K AMI 32 Overexpressio
n 
SmeYZ 











A different approach against L1 activity was the use of rhodanine based 
derivatives (provided by University of Oxford). Here, we tested the previously reported 
rhodanine (ML302) and its enethiol fragment (ML302F) (317), as well as the rhodanine 
analogue (210) and the ML302F analogue (310). Meropenem antimicrobial activity was 
tested in presence of the four inhibitors (10mg.L-1) and against the mutants generated 
in previous chapters. Interestingly, all four inhibitors restore meropenem susceptibility 
in the wild-type strain, some clinical isolates, (CI-29, CI-31, CI-20, CI-24), β-lactamase 
hyper-producing strains (KCAZ10, KCAZ14, KM11), efflux-pump overproducers 
(KAMI32 and KMOX8). In the extensively-drug resistant CI-31, only the rhodanine 
analogue 210 is able to restore meropenem susceptibility while in the 
avibactam/ceftazidime and boronate 2/ceftazidime resistant mutants L1 hyper-
producing mutants (MA27 and MB25, described above) not even 210 restores 
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5.3 Conclusion  
 
In conclusion, our combined results reveal the potential of non-classical non 
β-lactam containing β-lactamase inhibitors, including the clinically approved compound 
avibactam, and the cyclic boronates (some of which are presently in clinical trials) for 
treatment of S. maltophilia, particularly when partnered with the monobactam 
aztreonam, and perhaps other aztreonam-like β-lactams currently in development 
(343). Given the structural differences between avibactam, cyclic boronates, and the β-
lactam based inhibitors, it would seem that there is considerable scope for the 
identification of new types of β-lactamase inhibitors of potential clinical utility against 
Gram-negative bacterial pathogens. In fact, within that scope we have managed to 
identify the potential benefits of two compounds, 6-phosphonomethylpyridine-2-
carboxylates and rhodanine based inhibitors, as L1 β-lactamase inhibitors (316, 318). 
However, results here obtained highlight the ability of S. maltophilia to acquire 
resistance mechanisms to overcome inhibitor activity which makes of it an interesting 






















6 Characterisation of sideromimic modified lactivicin 




Lactivicin is highly unusual in that it is the only non β-lactam natural product 
known to target penicillin binding proteins (PBPs). Unlike the β-lactams, which remain 
the most important antimicrobial class, Lactivicin contains cycloserine and γ-lactam 
motifs, but like the β-lactams, Lactivicin reacts covalently with PBPs to form a stable 
acyl-enzyme complex (344) (Figure 6.1A Figure 6.1B). However, Lactivicin has poor 
penetration into Gram-negative bacteria and is susceptible to at least some β-
lactamase enzymes (345-347). A deeper understanding of the interactions between 
Lactivicin and its derivatives and their various enzyme targets has led to the rational 
design of synthetic derivatives with higher potency against bacteria and reduced 
susceptibility to β-lactamases (190, 344, 348). Recently, it has been shown that 
sideromimic modification of the synthetic Lactivicin compound 13 (hereafter referred to 
as LTV13)(347) results in more favourable IC50 values against P. aeruginosa PBPs 
and improved penetration into P. aeruginosa strain PA01 via interaction with the 
siderophore receptors and uptake systems of this strain. One of these Lactivicin 
derivatives, the phthalimide-conjugated compound 17 (hereafter referred to as LTV17; 
Figure 6.1C), seems particularly promising (190).  
This chapter describes the activity of Lactivicin derivatives against S. 
maltophilia. We aimed to test lactivicin derivatives against extensively drug resistant 







Figure 6.1 Structures and mechanism of action of β- and γ-lactams 
A) Structures of β-lactam antibiotics and γ-lactam Lactivicin; B) Outline of 
mechanism of action of β- and γ-lactams; C) Structures of LTV13 and LTV17 used 
in the current study. 
 
6.2 Results  
 
6.2.1 MICs of Lactivicin derivatives against S. maltophilia clinical isolates 
 
MICs for LTV13 and LTV17 were determined against a selection of clinical 
isolates representing key Gram-negative species where multi-drug resistance is 
frequently a problem. These data confirmed the potential of LTV17 and its MIC against 
the multi-drug resistant S. maltophilia isolate K279a (183) is remarkably low, and more 










Table 6.1 MICs of Lactivicin derivatives against clinical Gram negative isolates 







Klebsiella pneumoniae NCTC5055                       2 0.5 
Citrobacter freundii D571                                                    512 16 
Enterobacter cloacae  30950                                           >512 16 
Enterobacter aerogenes 15-8358A                                      64 4 
Serratia marcescens NCTC1041                           4 4 
Pseudomonas aeruginosa NCTC10662                                   256 1 
Stenotrophomonas maltophilia K279a                   64 ≤0.0625 
Acinetobacter baumannii 39-4034C                      >256 8 
 
In Chapter 3, we had established the ceftazidime susceptibility of the world-
wide collection of S. maltophilia clinical isolates whilst in Chapter 4 levofloxacin and 
minocycline susceptibilities were evaluated. Here we expanded the antibiotic 
susceptibility profile by adding trimethoprim-sulfamethoxazole (SXT), chloramphenicol 
and ticarcilllin-clavulanic acid to the survey. 54% of the 50 isolates were susceptible to 
SXT, 18% was susceptible to ticarcillin-clavulanic acid and 38% to chloramphenicol.  
Initially, the isolates were divided into two groups: 23/50 that are STX resistant 
and 27/50 that are STX sensitive. The two groups were then sub-divided based on how 
many alternative antimicrobials they remain sensitive to. Finally, the MICs of LTV13 
and LTV17 were determined against the 50 isolates using standard CLSI broth micro-
dilution methodology (Table 6.2). Clearly, LTV17 is very potent against all of these S. 
maltophilia clinical isolates, including extensively drug resistant strains. The highest 
MIC seen was 0.25 µg.mL-1, and the MIC90 for the 50 isolates was 0.063 µg.mL-1. 
Table 6.2 MICs of Lactivicin derivatives against S. maltophilia clinical isolates 
having different profiles of resistance to last resort antibiotics. 
Resistance 
phenotype 
Number of isolates 
where  
LTV13 MIC (µg.ml-1) is: 
Number of isolates where  
LTV17 MIC (µg.ml-1) is:  
 16 32 64 128 256 ≤0.031 0.063 0.125 0.25 
SXTR. Sensitive to  
0 to 2 alternatives 
0 0 3 5 1 5 3 0 1 
SXTR. Sensitive to  
3 to 5 alternatives 
1 0 7 6 0 13 1 0 0 
SXTS. Sensitive to  
1 to 3 alternatives 
0 0 4 9 1 8 3 3 0 
SXTS. Sensitive to  
4 or 5 alternatives 






6.2.2 MICs of Lactivicin derivatives against S. maltophilia clinical isolates 
 
One of the reasons for the initial failure of Lactivicin and its early derivatives as 
an antibiotic was susceptibility to β-lactamase enzymes, coupled with an ability to 
induce β-lactamase production in bacteria where inducible enzymes exist (345-347). 
As discussed in chapter 3 S. maltophilia has two inducible β-lactamases, L1 and L2, 
which are co-ordinately controlled by an AmpR type transcriptional regulator (160). 
Genetic disruption of one of the main targets of Lactivicin, PBP1A has been shown to 
constitutively activate β-lactamase production in S. maltophilia (214, 232). As 
expected, therefore, we found that treatment of two well characterised S. maltophilia 
clinical isolates, K279a and N531 (183), with LTV13 or LTV17 induced β-lactamase 
production to a similar extent as the β-lactam antibiotics cefoxitin and imipenem when 
added to growing cells at concentrations proportionate to the compounds’ relative 





Figure 6.2 Effect of β-lactams and Lactivicin derivatives on the production of 
β-lactamase by S. maltophilia clinical isolates 
Bacteria were incubated in the presence of inducer (100 µg.mL-1 cefoxitin, 10 µg.mL-
1 imipenem, 50 µg.mL-1 LTV13 and 0.35 µg.mL-1 LTV17),  cell extracts were 
prepared and β-lactamase activity in cell extracts was measured as described (22) 
using 100 μM meropenem as a substrate. Protein concentration was determined 
using the BioRad protein assay dye reagent concentrate, and an extinction 
coefficient of 9600 AU/M/cm for meropenem was used to calculate the specific 
meropenem hydrolysing activity in each cell extract. Data presented are means +/- 
standard error of the mean, n=3. 
 
6.2.3 Breakdown of Lactivicin derivatives by S. maltophilia β-lactamases 
 
This work was performed by our collaborators in Oxford. Since LTV13 and 




the increased potency of LTV17 versus LTV13 is that LTV17 is not such a good 
substrate as LTV13 for the S. maltophilia β-lactamases. To test this hypothesis, NMR 
spectroscopy was used to evaluate the time-dependent hydrolysis of LTV13 and 
LTV17 by purified recombinant L1 and L2 β-lactamases. L2 was able to totally 
hydrolyse 400 µM ampicillin in less than 5 min (- data not shown), whilst ~95% of the 
LTVs remained intact. Longer incubation times confirmed that the Lactivicin derivatives 
are not substrates for L2. They were both found to be substrates for L1, however, and 
underwent enzyme catalysed hydrolysis (349). LTV17 was broken down faster than 
LTV13, however, so reduced susceptibility to L1 does not explain the increased 
potency of LTV17. 
6.2.4 Protection of S. maltophilia from Lactivicin derivatives by 
β-lactamases 
 
Whilst they are clearly substrates, the rate of LTV17 and LTV13 breakdown by 
L1 was very slow compared with breakdown of meropenem (L1 was able to totally 
hydrolyse 400 µM meropenem in less than 5 min using similar assay conditions when 
~95 and 90% of LTV13 and 17 were still intact – data not shown), so we hypothesised 
that LTV13 and LTV17 actually kill S. maltophilia even though they induce β-lactamase 
production simply because cellular β-lactamase hydrolysis is too slow to protect the 
cells. To test this hypothesis, we incubated LTV17 with or without purified L1 and 
spotted the two mixtures onto a lawn of S. maltophilia K279a. In parallel we used 
meropenem as a control (Figure 6.3). Incubation with L1 does not significantly reduce 
the ability of LTV17 to kill S. maltophilia K279a (and also LTV13 – data not shown) 
where meropenem is rendered totally ineffective by L1. Pre-incubation of LTV17 with 
L1 for 1 h prior to spotting onto K279a did reduce the zone of clearing, suggestive of 
modest destruction of LTV17 as shown in the NMR experiments. Importantly, the 
inhibition zone diameter for LTV17 (and LTV13 – data not shown) is the same against 
K279a as it is for the ampR frameshift mutant derivative K279a::ampRFS which cannot 
induce β-lactamase production (160), even though the latter is far more sensitive to 
meropenem (Figure 6.3). This confirms that even though L1 can break down LTV17 at 
a modest rate (349) its induction by LTV17 is not sufficient to protect the cell. This also 
explains why clinical isolates in our world-wide collection that are known to express β-
lactamase constitutively at high levels (11, 22) are no less susceptible to the Lactivicin 
derivatives than are isolates with normally inducible β-lactamases (Table 6.2). Indeed, 
to confirm this, we tested four L1/L2 hyper-producing mutants previously derived from 




derivatives against K279a and these mutants are the same (32 and ≤0.031 µg.mL-1 
respectively for LTV13 and LTV17). 
 
Figure 6.3 Inhibition zone produced by LTV17 and meropenem with and without 
L1 β-lactamase 
A lawn of S. maltophilia K279a or the ampR frameshift mutant (ampRFS) was spread 
as if for CLSI disc susceptibility testing. In all cases, 2 μL of reaction mixture (50 mM 
Tris pH 7.5 with meropenem (MER, 12 mM) or LTV17 (0.4 mM) mixed (+L1) or not (-
L1) with purified L1 β-lactamase (1 μM final) was immediately spotted onto the lawn 
(t=0 h) or was spotted following 1 h of pre-incubation at 37°C (t=1 h).  The plate was 
then incubated for 18 h at 37°C and this figure is representative of three biological 
replicates. 
 
The reason for the dramatically increased potency of LTV17 versus LTV13 
against S. maltophilia is not due to its relatively weak ability to induce L1/L2 β-
lactamase production or its relatively slower hydrolysis by either of these β-lactamases. 
Both LVT17 and LTV13 are only slowly hydrolysed by L1 β-lactamase, and not at a 
detectable level by L2, so β-lactamase production by S. maltophilia is not actually 
protective against either Lactivicin derivative. Accordingly, whilst we have not excluded 
the possibility that there is some increased affinity for its PBP target (s), the 1000-fold 
increased potency of LTV17 over LTV13 is most likely to be due to an increased rate of 
entry into S. maltophilia. The major difference between LTV13 and LTV17 is the 
presence of a catechol-type siderophore on the lactone ring of LTV17 (6). Notably, all 
S. maltophilia clinical isolates previously tested, including the K279a isolate used here, 
exclusively produce catechol-type siderophores (195). Thus it is reasonable to infer 
that they preferentially take up this type of siderophore, and the antibiotics conjugated 




favours uptake by S. maltophilia, explaining its remarkable potency against this 
otherwise extensively drug resistant bacterium. 
 
6.2.5 Characterisation of a mutant with reduced susceptibility to 
lactivicin 
 
A single-step mutant with reduced susceptibility to LTV17 was selected from 
K279a. The mutant was named K LTV. Initial antimicrobial susceptibility 
characterisation showed elevated MICs of LTV17 but also ceftazidime. There was no 
increase in β-lactamase activity (Table 6.4) in K LTV leading us to hypothesise that the 
ceftazidime resistant mutants M1 and M52 identified in chapter 3, would also have 
reduced susceptibility to LTV17. This proved to be correct Table 6.3. When assessing 
cellular permeability using the Hoescht dye (H33342) accumulation assay, K LTV was 
actually less permeable even than M1 or M52 (Figure 6.4). Similarly to M1 and M52, K 
LTV whole envelope proteomics showed very similar changes to those observed in M1 
and M52 (chapter 3). Specifically, there is downregulation of the TonB energy 
transducer (Smlt0009) and upregulation of the EntB siderophore biosynthesis enzyme 
(Figure 6.5). siderophore overproduction was confirmed on CAS agar (Figure 6.6). 
WGS confirmed deletion of the proline-rich region in the TonB energy transducer gene 
(smlt0009) (Figure 6.7). Accordingly, we conclude that LTV17 uptake is also 
dependent on a TonB dependent energy transduction system. This is perhaps less 
surprising than for β-lactams, since siderophore uptake systems are known to be TonB 
dependent, and it is assumed that the siderophore component of LTV17 is the reason 
for its rapid uptake. Indeed mutants with reduced susceptibility to other siderophore 
conjugated antimicrobials have previously been shown to have mutations in 












Table 6.3 Comparison of MICs (mg/L) values of ceftazidime and lactivin 17 




K279a 4 0.03 
M1 256 0.5 
M52 256 0.5 
K LTV 128 0.25 
 
Shaded values represent reduced susceptibility in reference to the parental strain and 
in the case of ceftazidime according to CLSI breakpoints 
 
Table 6.4 β-Lactamase activity of lactivicin mutant  
 
Isolate Mean β-lactamase activity ±SEM 
K279a 0.02±0.004 
K LTV 0.05±0.005 
β-lactamase activity (nmol.min-1.µg-1 protein nitrocefin 






Figure 6.4 Envelope permeability measured by absolute accumulation of 
H33342 in low-osmolality (NB) and high-osmolality (MHB) media 
Absolute accumulation of H33342 (25 µM) is expressed as fluorescence units over 
31 cycle incubation period (78 min). Each curve plots data for three biological 
replicates with eight technical replicates. Error bars represent standard estimation of 









Figure 6.5 A) Downregulation of the TonB energy transducer protein Smlt0009 
and B) upregulation of EntB siderophore biosynthesis enzyme in K LTV  
 
Protein abundance data of whole envelope proteomics are normalised to the 
average ribosomal content of each sample (including abundance of 30S and 50S 
ribosomal proteins). A) Fold change of Smlt0009 (Uniprot: B2FT87) and B) EntB 
(Uniprot: B2FH84) is calculated after testing statistical significant difference between 
the parental strain and the mutants (p <0.05). Values are reported as mean +/- 






Figure 6.6 Siderophore overproduction of K LTV 
Diameter values show diffusion of the siderophore production after spotting 10 µL of 
a PBS washed bacterial suspension (OD600 0.2) onto a modified CAS agar (as 
described in section 2.4). Values are reported as mean of three biological repeats; 
the figure is representative 
 
 
Figure 6.7 Sequence alignment of energy transducer TonB of ceftazidime and 
lactivicin resistant mutants 
Alignment of translated PCR sequences that confirmed loss of proline-rich region 
(non-highlighted region) in M1 and M52 mutants. PCR amplification used a found 
during whole genome sequencing analysis. Alignment was performed with 







6.3 Conclusions  
 
The side chain modification of the core fused bicyclic non β-lactam ring system 
of the Lactivicins has the potential to improve activity in the same way as it has done 
for the β-lactams, e.g.BAL30072, which is in early phase clinical development. This 
can work by increasing potency versus PBPs and/or reducing β-lactamase 
susceptibility, and in addition by improving uptake (354). Moreover, the results here 
presented suggest that siderophore mediated uptake is not a general effect, equally 
seen in all species. It may be that the apparent species-specificity of the effect seen in 
dependent on the conjugation of a particular siderophore preferentially used by a 
particular species. In an era of improved diagnostics for infection (355), the routine use 
of narrow-spectrum antimicrobials becomes a realistic proposition, and the benefit 
would be reduced collateral damage to the host microbiome, and cross-selection for 
the acquisition of resistant isolates of other species of bacteria. Within the time 
allowed, we have found enough evidence to suggest the participation of the TonB 
energy transducer is not only important for ceftazidime uptake but also uptake of 
lactivicins even when they have been modified with a sideromimic group which fits well 
with what has been seen before for mutants resistant to siderophore-conjugated 
antimicrobials. Whilst the MIC of LTV17 is 0.5mg.L-1 against these mutants, we do not 
know whether this would be classed as clinically resistant, because LTV17 is an 
experimental drug and has not yet been administered in humans. Accordingly, it is still 
















6.4 Annex 4 
 
Table 6.5 Normalised proteomics data for K LTV against K279a 




T-Test K279a vs K 
LTV 
Fold K279a vs K LTV 
B2FHA2 Putative ferredoxin oxidoreductase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0136 PE=4 SV=1 - [B2FHA2_STRMK] 0.039 0.13 
B2FHA8 Putative phospholipase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0142 PE=4 SV=1 - [B2FHA8_STRMK] 0.007 0.43 
B2FHB5 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0149 PE=4 SV=1 - [B2FHB5_STRMK] 0.004 0.38 
B2FHB7 Glutamine synthetase OS=Stenotrophomonas maltophilia (strain K279a) GN=glnA PE=3 SV=1 - [B2FHB7_STRMK] <0.05 >100 
B2FHC6 Superoxide dismutase [Cu-Zn] OS=Stenotrophomonas maltophilia (strain K279a) GN=sodC1 PE=3 SV=1 - [B2FHC6_STRMK] 0.003 0.38 
B2FHC7 Superoxide dismutase [Cu-Zn] OS=Stenotrophomonas maltophilia (strain K279a) GN=sodC2 PE=3 SV=1 - [B2FHC7_STRMK] 0.032 0.49 
B2FHD0 Putative 3-ketoacyl-CoA thiolase OS=Stenotrophomonas maltophilia (strain K279a) GN=fadI PE=3 SV=1 - [B2FHD0_STRMK] 0.016 0.48 
B2FHD6 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0170 PE=4 SV=1 - [B2FHD6_STRMK] 0.007 0.41 
B2FHE8 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0182 PE=4 SV=1 - [B2FHE8_STRMK] <0.05 2.85 
B2FHF0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0184 PE=4 SV=1 - [B2FHF0_STRMK] 0.006 0.39 
B2FHF9 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0193 PE=4 SV=1 - [B2FHF9_STRMK] <0.05 >100 
B2FHG4 
Putative electron transfer flavoprotein-ubiquinone oxidoreductase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0198 PE=4 SV=1 - 
[B2FHG4_STRMK] 0.004 0.28 
B2FHH2 Putative TonB dependent siderophore receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1426 PE=3 SV=1 - [B2FHH2_STRMK] 0.000 18.96 
B2FHH7 Putative peptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1431 PE=4 SV=1 - [B2FHH7_STRMK] 0.012 0.36 
B2FHI7 Glutamate--tRNA ligase OS=Stenotrophomonas maltophilia (strain K279a) GN=gltX PE=3 SV=1 - [SYE_STRMK] <0.05 0.41 
B2FHI8 Putative regulatory protein OS=Stenotrophomonas maltophilia (strain K279a) GN=fur PE=4 SV=1 - [B2FHI8_STRMK] <0.05 >100 
B2FHJ2 Putative outer membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1446 PE=3 SV=1 - [B2FHJ2_STRMK] 0.001 0.17 
B2FHJ5 
Putative phosphodiesterase-nucleotide pyrophosphatase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1449 PE=4 SV=1 - 
[B2FHJ5_STRMK] 0.003 0.31 
B2FHK0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1454 PE=4 SV=1 - [B2FHK0_STRMK] <0.05 0.19 
B2FHL6 Putative ABC transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1471 PE=3 SV=1 - [B2FHL6_STRMK] 0.019 0.38 
B2FHL9 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1474 PE=4 SV=1 - [B2FHL9_STRMK] 0.009 0.41 
B2FHN2 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1491 PE=4 SV=1 - [B2FHN2_STRMK] 0.017 0.43 
B2FHN5 Lipid-A-disaccharide synthase OS=Stenotrophomonas maltophilia (strain K279a) GN=lpxB PE=3 SV=1 - [B2FHN5_STRMK] 0.013 0.48 




K279a) GN=entA PE=4 SV=1 - [B2FHQ1_STRMK] 
B2FHQ4 Putative hydrolase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2820 PE=4 SV=1 - [B2FHQ4_STRMK] <0.05 >100 
B2FHQ5 
Putative siderophore specific 2,3-dihydroxybenzoate-AMP ligase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2821 PE=4 SV=1 - 
[B2FHQ5_STRMK] <0.05 >100 
B2FHR5 
Putative transmembrane LINOLEOYL-CoA DESATURASE (DELTA(6)-DESATURASE) OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt2831 PE=4 SV=1 - [B2FHR5_STRMK] <0.05 0.42 
B2FHR8 Putative autotransporter protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2834 PE=4 SV=1 - [B2FHR8_STRMK] 0.032 0.26 
B2FHR9 
Putative TonB-dependent outer membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2835 PE=3 SV=1 - 
[B2FHR9_STRMK] 0.000 3.57 
B2FHT4 
Putative TonB dependent extracellular heme-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2850 PE=3 SV=1 - 
[B2FHT4_STRMK] <0.05 >100 
B2FHT9 Putative iron transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2858 PE=3 SV=1 - [B2FHT9_STRMK] 0.000 4.19 
B2FHW5 Methionine import ATP-binding protein MetN OS=Stenotrophomonas maltophilia (strain K279a) GN=metN PE=3 SV=1 - [B2FHW5_STRMK] 0.012 0.34 
B2FHX5 Putative CBS domain protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4098 PE=4 SV=1 - [B2FHX5_STRMK] <0.05 >100 
B2FHY7 ATP synthase epsilon chain OS=Stenotrophomonas maltophilia (strain K279a) GN=atpC PE=3 SV=1 - [ATPE_STRMK] 0.002 0.43 
B2FHZ2 ATP synthase subunit b OS=Stenotrophomonas maltophilia (strain K279a) GN=atpF PE=3 SV=1 - [ATPF_STRMK] 0.013 0.40 
B2FHZ7 Putative dihydrolipoamide dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=lpdA PE=4 SV=1 - [B2FHZ7_STRMK] 0.001 2.48 
B2FHZ8 
Acetyltransferase component of pyruvate dehydrogenase complex OS=Stenotrophomonas maltophilia (strain K279a) GN=pdhB PE=3 SV=1 - 
[B2FHZ8_STRMK] 0.012 2.71 
B2FI00 Putative outer membrane Omp family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4123 PE=4 SV=1 - [B2FI00_STRMK] 0.002 0.25 
B2FI05 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4128 PE=4 SV=1 - [B2FI05_STRMK] 0.006 0.45 
B2FI10 Glucans biosynthesis glucosyltransferase H OS=Stenotrophomonas maltophilia (strain K279a) GN=opgH PE=3 SV=1 - [B2FI10_STRMK] <0.05 >100 
B2FI12 Putative colicin I receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=cirA PE=3 SV=1 - [B2FI12_STRMK] 0.000 75.12 
B2FI15 Putative methyl-accepting chemotaxis protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4138 PE=4 SV=1 - [B2FI15_STRMK] <0.05 >100 
B2FI22 Putative extracellular serine protease OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4145 PE=4 SV=1 - [B2FI22_STRMK] <0.05 >100 
B2FI29 Putative NAD(P)H dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0209 PE=4 SV=1 - [B2FI29_STRMK] 0.011 0.19 
B2FI43 
Putative peptidyl-dipeptidase Dcp (Dipeptidyl carboxypeptidase) OS=Stenotrophomonas maltophilia (strain K279a) GN=dcp PE=3 SV=1 - 
[B2FI43_STRMK] 0.010 0.41 
B2FI64 Ribonucleoside-diphosphate reductase OS=Stenotrophomonas maltophilia (strain K279a) GN=RRM1 PE=3 SV=1 - [B2FI64_STRMK] 0.008 3.67 
B2FI80 DntE OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0264 PE=3 SV=1 - [B2FI80_STRMK] <0.05 0.39 
B2FIA0 Outer membrane protein assembly factor BamA OS=Stenotrophomonas maltophilia (strain K279a) GN=bamA PE=3 SV=1 - [B2FIA0_STRMK] 0.010 0.48 
B2FIA8 Elongation factor Ts OS=Stenotrophomonas maltophilia (strain K279a) GN=tsf PE=3 SV=1 - [EFTS_STRMK] 0.015 2.07 
B2FIC9 Putative multidrug resistance protein A OS=Stenotrophomonas maltophilia (strain K279a) GN=emrA PE=4 SV=1 - [B2FIC9_STRMK] 0.025 0.37 
B2FIE0 
Putative two-component system, response regulator transcriptional regulatory protein OS=Stenotrophomonas maltophilia (strain K279a) 
GN=Smlt1540 PE=4 SV=1 - [B2FIE0_STRMK] <0.05 0.47 
B2FII5 Putative CDP-diacylglycerol pyrophosphatase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2903 PE=4 SV=1 - [B2FII5_STRMK] 0.009 0.37 
B2FIL8 Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2937 PE=3 SV=1 - [B2FIL8_STRMK] <0.05 >100 
B2FIM0 Putative TonB-like protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2939 PE=4 SV=1 - [B2FIM0_STRMK] <0.05 >100 
B2FIQ4 GTP cyclohydrolase II OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4168 PE=3 SV=1 - [B2FIQ4_STRMK] <0.05 0.42 




B2FIR9 Putative transmembrane RDD family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4183 PE=4 SV=1 - [B2FIR9_STRMK] 0.016 0.47 
B2FIS0 DNA topoisomerase 1 OS=Stenotrophomonas maltophilia (strain K279a) GN=topA PE=3 SV=1 - [B2FIS0_STRMK] <0.05 >100 
B2FIS4 
Putative lipid biosynthesis 3-oxoacyl-[acyl-carrier-protein] reductase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4188 PE=4 SV=1 - 
[B2FIS4_STRMK] <0.05 0.46 
B2FIS6 Protease 4 OS=Stenotrophomonas maltophilia (strain K279a) GN=sppA PE=3 SV=1 - [B2FIS6_STRMK] 0.002 0.38 
B2FIS7 Putative drug resistance transport protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4191 PE=4 SV=1 - [B2FIS7_STRMK] 0.005 0.43 
B2FIU9 60 kDa chaperonin OS=Stenotrophomonas maltophilia (strain K279a) GN=groL PE=3 SV=1 - [CH60_STRMK] 0.001 2.22 
B2FIV0 10 kDa chaperonin OS=Stenotrophomonas maltophilia (strain K279a) GN=groS PE=3 SV=1 - [CH10_STRMK] 0.000 3.64 
B2FJ30 Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0359 PE=3 SV=1 - [B2FJ30_STRMK] 0.022 0.33 
B2FJ60 Putative transmembrane PepSY domain protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1566 PE=4 SV=1 - [B2FJ60_STRMK] <0.05 >100 
B2FJ77 Polyamine-transporting ATPase OS=Stenotrophomonas maltophilia (strain K279a) GN=potG PE=3 SV=1 - [B2FJ77_STRMK] 0.013 0.36 
B2FJ78 Putative putrescine transport system permease protein OS=Stenotrophomonas maltophilia (strain K279a) GN=potH PE=3 SV=1 - [B2FJ78_STRMK] 0.007 0.32 
B2FJ81 
Putative transmembrane magnesium/cobalt transport protein OS=Stenotrophomonas maltophilia (strain K279a) GN=corA PE=4 SV=1 - 
[B2FJ81_STRMK] 0.039 0.49 
B2FJB1 Putative oar family adhesion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1619 PE=4 SV=1 - [B2FJB1_STRMK] 0.002 0.32 
B2FJB8 
Putative PilE protein (Type 4 fimbrial biogenesis protein PilE) OS=Stenotrophomonas maltophilia (strain K279a) GN=pilE PE=4 SV=1 - 
[B2FJB8_STRMK] 0.033 0.43 
B2FJC0 UvrABC system protein B OS=Stenotrophomonas maltophilia (strain K279a) GN=uvrB PE=3 SV=1 - [B2FJC0_STRMK] <0.05 0.43 
B2FJC8 Histidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1636 PE=4 SV=1 - [B2FJC8_STRMK] 0.030 0.47 
B2FJG0 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2989 PE=4 SV=1 - [B2FJG0_STRMK] 0.027 0.42 
B2FJJ3 
Putative hydroxamate-type ferrisiderophore receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3022 PE=3 SV=1 - 
[B2FJJ3_STRMK] 0.000 22.50 
B2FJP1 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4245 PE=4 SV=1 - [B2FJP1_STRMK] 0.017 0.44 
B2FJQ7 Putative cell division ATP-binding protein FtsE OS=Stenotrophomonas maltophilia (strain K279a) GN=ftsE PE=3 SV=1 - [B2FJQ7_STRMK] 0.013 0.39 
B2FJR1 
Putative transmembrane GGDEF signalling protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4266 PE=4 SV=1 - 
[B2FJR1_STRMK] 0.021 0.48 
B2FJR8 Putative isocitrate dehydrogenase [NADP] OS=Stenotrophomonas maltophilia (strain K279a) GN=icd PE=4 SV=1 - [B2FJR8_STRMK] 0.002 4.57 
B2FJS3 
Putative multidrug efflux system HlyD family transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4279 PE=4 SV=1 - 
[B2FJS3_STRMK] 0.007 0.36 
B2FJS5 Putative AcrB/AcrD/AcrF family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4281 PE=4 SV=1 - [B2FJS5_STRMK] <0.05 >100 
B2FJV0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0387 PE=4 SV=1 - [B2FJV0_STRMK] 0.002 0.39 
B2FJV8 Putative oxidoreductase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0396 PE=3 SV=1 - [B2FJV8_STRMK] <0.05 0.49 
B2FJV9 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0397 PE=4 SV=1 - [B2FJV9_STRMK] 0.020 0.48 
B2FJW5 Putative phosphomannomutase OS=Stenotrophomonas maltophilia (strain K279a) GN=spgM PE=4 SV=1 - [B2FJW5_STRMK] 0.022 0.42 
B2FK31 Putative ABC transporter ATP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1653 PE=3 SV=1 - [B2FK31_STRMK] <0.05 >100 
B2FK68 Putative glutamate synthase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1693 PE=3 SV=1 - [B2FK68_STRMK] 0.003 0.22 
B2FK78 Putative pit accessory protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1705 PE=4 SV=1 - [B2FK78_STRMK] 0.020 0.46 
B2FK79 
Putative LOW-AFFINITY INORGANIC PHOSPHATE TRANSPORTER INTEGRAL MEMBRANE PROTEIN PITA OS=Stenotrophomonas maltophilia 
(strain K279a) GN=pitA PE=4 SV=1 - [B2FK79_STRMK] 0.022 0.41 




B2FK88 Enolase OS=Stenotrophomonas maltophilia (strain K279a) GN=eno PE=3 SV=1 - [ENO_STRMK] <0.05 12.72 
B2FK97 Putative subfamily M23B unassigned peptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1724 PE=4 SV=1 - [B2FK97_STRMK] 0.003 0.36 
B2FKE9 
Putative P-protein [bifunctional includes: chorismate mutase and prephenate dehydratase OS=Stenotrophomonas maltophilia (strain K279a) 
GN=pheA PE=4 SV=1 - [B2FKE9_STRMK] 0.012 0.08 
B2FKF1 Conserved hypothetical FHA domain protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3099 PE=4 SV=1 - [B2FKF1_STRMK] 0.021 0.49 
B2FKG5 Putative TonB-dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3115 PE=4 SV=1 - [B2FKG5_STRMK] 0.010 0.47 
B2FKH5 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3125 PE=4 SV=1 - [B2FKH5_STRMK] <0.05 0.35 
B2FKJ7 50S ribosomal protein L9 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplI PE=3 SV=1 - [RL9_STRMK] 0.003 2.68 
B2FKJ9 30S ribosomal protein S6 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsF PE=3 SV=1 - [B2FKJ9_STRMK] 0.003 2.62 
B2FKK8 
Putative cyclic AMP receptor protein,catabolite gene activator OS=Stenotrophomonas maltophilia (strain K279a) GN=cap PE=4 SV=1 - 
[B2FKK8_STRMK] 0.001 2.43 
B2FKM2 
Putative K(+)/H(+) antiporter subunit A/B (PH adaptation potassium efflux system protein A/B) OS=Stenotrophomonas maltophilia (strain K279a) 
GN=phaAB PE=4 SV=1 - [B2FKM2_STRMK] <0.05 0.35 
B2FKR5 Putative nitrogen regulatory protein P-II OS=Stenotrophomonas maltophilia (strain K279a) GN=glnB PE=3 SV=1 - [B2FKR5_STRMK] <0.05 >100 
B2FKV5 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0481 PE=4 SV=1 - [B2FKV5_STRMK] <0.05 0.47 
B2FKV6 
Putative NADH dehydrogenase/NAD(P)H nitroreductase Smlt0482 OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0482 PE=3 SV=1 - 
[Y482_STRMK] <0.05 2.24 
B2FKW2 Pyruvate dehydrogenase E1 component OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0490 PE=4 SV=1 - [B2FKW2_STRMK] 0.010 3.25 
B2FKX4 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0503 PE=4 SV=1 - [B2FKX4_STRMK] <0.05 >100 
B2FL00 Putative NHL repeat protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0528 PE=4 SV=1 - [B2FL00_STRMK] 0.027 0.42 
B2FL08 Putative transmembrane anchor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0538 PE=4 SV=1 - [B2FL08_STRMK] 0.002 0.22 
B2FL10 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0540 PE=4 SV=1 - [B2FL10_STRMK] 0.002 0.26 
B2FL11 Putative aminopeptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0541 PE=4 SV=1 - [B2FL11_STRMK] <0.05 0.23 
B2FL46 Putative cytochrome c family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1757 PE=4 SV=1 - [B2FL46_STRMK] <0.05 >100 
B2FL47 Putative alcohol dehydrogenase cytochrome c subunit OS=Stenotrophomonas maltophilia (strain K279a) GN=adhB PE=4 SV=1 - [B2FL47_STRMK] <0.05 >100 
B2FL51 Putative ferric siderophore receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1762 PE=3 SV=1 - [B2FL51_STRMK] <0.05 >100 
B2FL84 
Putative succinate dehydrogenase cytochrome b-556 subunit OS=Stenotrophomonas maltophilia (strain K279a) GN=sdhC PE=4 SV=1 - 
[B2FL84_STRMK] 0.002 0.26 
B2FL86 Putative succinate dehydrogenase flavoprotein subunit OS=Stenotrophomonas maltophilia (strain K279a) GN=sdhA PE=4 SV=1 - [B2FL86_STRMK] 0.006 0.20 
B2FL87 Succinate dehydrogenase iron-sulfur subunit OS=Stenotrophomonas maltophilia (strain K279a) GN=sdhB PE=3 SV=1 - [B2FL87_STRMK] 0.002 0.23 
B2FLA6 Putative RND family acriflavine resistance protein A OS=Stenotrophomonas maltophilia (strain K279a) GN=smeG PE=4 SV=1 - [B2FLA6_STRMK] 0.011 0.48 
B2FLA7 Putative multidrug resistance efflux pump OS=Stenotrophomonas maltophilia (strain K279a) GN=smeH PE=4 SV=1 - [B2FLA7_STRMK] 0.020 0.41 
B2FLB8 Peptidyl-prolyl cis-trans isomerase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3182 PE=4 SV=1 - [B2FLB8_STRMK] 0.005 0.35 
B2FLC5 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3189 PE=4 SV=1 - [B2FLC5_STRMK] <0.05 2.04 
B2FLD1 Putative 2-oxoglutarate dehydrogenase E1 component OS=Stenotrophomonas maltophilia (strain K279a) GN=sucA PE=4 SV=1 - [B2FLD1_STRMK] 0.027 2.60 
B2FLE4 Putative outer membrane antigen protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3210 PE=4 SV=1 - [B2FLE4_STRMK] 0.036 0.49 
B2FLE9 Putative outer membrane antigen lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3215 PE=4 SV=1 - [B2FLE9_STRMK] 0.015 0.45 
B2FLF2 Putative phospholipase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3218 PE=4 SV=1 - [B2FLF2_STRMK] 0.005 0.41 




B2FLG9 Putative peptide transport protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3236 PE=3 SV=1 - [B2FLG9_STRMK] 0.029 0.48 
B2FLH1 Superoxide dismutase OS=Stenotrophomonas maltophilia (strain K279a) GN=sodA PE=3 SV=1 - [B2FLH1_STRMK] 0.000 2.77 
B2FLH4 Putative transmembrane repetitive protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3241 PE=4 SV=1 - [B2FLH4_STRMK] 0.027 4.81 
B2FLP0 
Putative transmembrane Na+/H+ antiport transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0555 PE=4 SV=1 - 
[B2FLP0_STRMK] 0.038 0.49 
B2FLQ1 D-amino acid dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=dadA PE=3 SV=1 - [DADA_STRMK] 0.016 0.32 
B2FLR8 Putative vitamin B12 receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0585 PE=3 SV=1 - [B2FLR8_STRMK] 0.006 0.48 
B2FLT1 Asparagine synthetase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0598 PE=4 SV=1 - [B2FLT1_STRMK] <0.05 >100 
B2FLU8 Transport permease protein OS=Stenotrophomonas maltophilia (strain K279a) GN=wzm PE=3 SV=1 - [B2FLU8_STRMK] 0.021 0.49 
B2FLV4 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0624 PE=4 SV=1 - [B2FLV4_STRMK] 0.041 0.49 
B2FLV6 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0626 PE=4 SV=1 - [B2FLV6_STRMK] 0.010 0.34 
B2FLW2 Chaperone protein HtpG OS=Stenotrophomonas maltophilia (strain K279a) GN=htpG PE=3 SV=1 - [B2FLW2_STRMK] 0.007 4.25 
B2FLW5 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1812 PE=4 SV=1 - [B2FLW5_STRMK] 0.015 0.46 
B2FLX9 Putative outer membrane lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1826 PE=3 SV=1 - [B2FLX9_STRMK] 0.011 0.43 
B2FLZ4 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1841 PE=4 SV=1 - [B2FLZ4_STRMK] <0.05 0.42 
B2FM92 Ribonuclease E OS=Stenotrophomonas maltophilia (strain K279a) GN=rnE PE=3 SV=1 - [B2FM92_STRMK] 0.023 2.36 
B2FMB8 Putative cytochrome C-type biogenesis protein OS=Stenotrophomonas maltophilia (strain K279a) GN=dsbE PE=4 SV=1 - [B2FMB8_STRMK] 0.027 0.26 
B2FMC4 
Putative ABC transporter ATP-binding protein, cytochrome related OS=Stenotrophomonas maltophilia (strain K279a) GN=cydD PE=3 SV=1 - 
[B2FMC4_STRMK] <0.05 0.25 
B2FMF2 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3312 PE=4 SV=1 - [B2FMF2_STRMK] 0.015 0.46 
B2FMI1 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4498 PE=4 SV=1 - [B2FMI1_STRMK] 0.009 0.45 
B2FMI9 Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4506 PE=4 SV=1 - [B2FMI9_STRMK] 0.010 0.40 
B2FMK1 Putative ABC transporter ATP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4518 PE=3 SV=1 - [B2FMK1_STRMK] 0.014 0.46 
B2FML3 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4532 PE=4 SV=1 - [B2FML3_STRMK] <0.05 >100 
B2FMN5 
Putative transmembrane UbiA prenyltransferase family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0634 PE=4 SV=1 - 
[B2FMN5_STRMK] 0.012 0.37 
B2FMP6 Putative electron transfer flavoprotein subunit beta OS=Stenotrophomonas maltophilia (strain K279a) GN=etfS PE=4 SV=1 - [B2FMP6_STRMK] 0.001 3.18 
B2FMP8 Glucose-1-phosphate thymidylyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=rmlA PE=3 SV=1 - [B2FMP8_STRMK] <0.05 >100 
B2FMQ1 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0651 PE=4 SV=1 - [B2FMQ1_STRMK] 0.021 0.39 
B2FMR2 
Putative permease component of ABC transporter protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0662 PE=4 SV=1 - 
[B2FMR2_STRMK] 0.000 0.28 
B2FMR3 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0663 PE=4 SV=1 - [B2FMR3_STRMK] 0.002 2.24 
B2FMR8 
Putative transmembrane CDP-diacylglycerol--serine O-phosphatidyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0669 
PE=3 SV=1 - [B2FMR8_STRMK] 0.023 0.44 
B2FMS5 Putative transmembrane permease protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0676 PE=4 SV=1 - [B2FMS5_STRMK] 0.008 0.39 
B2FMS6 Putative transmembrane permease protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0677 PE=4 SV=1 - [B2FMS6_STRMK] 0.026 0.45 
B2FMX9 Putative ferric uptake regulation protein OS=Stenotrophomonas maltophilia (strain K279a) GN=fur PE=4 SV=1 - [B2FMX9_STRMK] <0.05 2.61 
B2FN02 Protein translocase subunit SecD OS=Stenotrophomonas maltophilia (strain K279a) GN=secD PE=3 SV=1 - [B2FN02_STRMK] 0.016 0.41 




B2FN25 Putative carbon-nitrogen hydrolase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2038 PE=4 SV=1 - [B2FN25_STRMK] <0.05 >100 
B2FN37 Putative N-acetylmuramoyl-L-alanine amidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3330 PE=4 SV=1 - [B2FN37_STRMK] 0.006 0.29 
B2FN47 Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3340 PE=3 SV=1 - [B2FN47_STRMK] 0.003 0.27 
B2FN55 
Putative acyl-CoA dehydrogenase oxidoreductase protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3352 PE=3 SV=1 - 
[B2FN55_STRMK] <0.05 >100 
B2FN59 Conserved hypothetical repetitive protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3358 PE=4 SV=1 - [B2FN59_STRMK] 0.006 0.34 
B2FN90 Translation initiation factor IF-2 OS=Stenotrophomonas maltophilia (strain K279a) GN=infB PE=3 SV=1 - [IF2_STRMK] 0.042 2.48 
B2FN93 NADH-quinone oxidoreductase subunit N OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoN PE=3 SV=1 - [B2FN93_STRMK] 0.022 0.27 
B2FN94 Putative NADH dehydrogenase I chain M OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoM PE=4 SV=1 - [B2FN94_STRMK] 0.016 0.21 
B2FN95 Putative NADH-ubiquinone oxidoreductase I chain L OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoL PE=4 SV=1 - [B2FN95_STRMK] 0.020 0.25 
B2FNA4 Putative exported lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4560 PE=4 SV=1 - [B2FNA4_STRMK] 0.029 0.21 
B2FNA6 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4562 PE=4 SV=1 - [B2FNA6_STRMK] 0.021 0.48 
B2FNC5 Putative dipeptidyl peptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4581 PE=4 SV=1 - [B2FNC5_STRMK] 0.004 0.42 
B2FND7 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4593 PE=4 SV=1 - [B2FND7_STRMK] 0.002 0.30 
B2FNF1 Putative transmembrane efflux pump protein OS=Stenotrophomonas maltophilia (strain K279a) GN=smmQ PE=4 SV=1 - [B2FNF1_STRMK] <0.05 0.38 
B2FNF4 Putative glycosyl transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4611 PE=4 SV=1 - [B2FNF4_STRMK] 0.003 0.26 
B2FNG6 Acetyl-coenzyme A synthetase OS=Stenotrophomonas maltophilia (strain K279a) GN=acsA PE=3 SV=1 - [B2FNG6_STRMK] <0.05 >100 
B2FNK2 Serine hydroxymethyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=glyA PE=3 SV=1 - [GLYA_STRMK] <0.05 >100 
B2FNL0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0726 PE=4 SV=1 - [B2FNL0_STRMK] 0.045 0.44 
B2FNN2 Putative penicillin-binding protein 3 OS=Stenotrophomonas maltophilia (strain K279a) GN=ftsI PE=4 SV=1 - [B2FNN2_STRMK] 0.005 0.37 
B2FNN3 
UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate ligase OS=Stenotrophomonas maltophilia (strain K279a) GN=murE PE=3 SV=1 - 
[B2FNN3_STRMK] <0.05 0.27 
B2FNN7 
UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase OS=Stenotrophomonas 
maltophilia (strain K279a) GN=murG PE=3 SV=1 - [B2FNN7_STRMK] 0.012 0.45 
B2FNP5 30S ribosomal protein S1 OS=Stenotrophomonas maltophilia (strain K279a) GN=rpsA PE=3 SV=1 - [B2FNP5_STRMK] 0.001 3.19 
B2FNQ8 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2057 PE=4 SV=1 - [B2FNQ8_STRMK] 0.045 0.46 
B2FNQ9 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2058 PE=4 SV=1 - [B2FNQ9_STRMK] 0.020 0.36 
B2FNS0 Inosine-5'-monophosphate dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=guaB PE=3 SV=1 - [B2FNS0_STRMK] 0.005 5.15 
B2FNX0 Putative NADH-ubiquinone oxidoreductase, chain J OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoJ PE=3 SV=1 - [B2FNX0_STRMK] <0.05 0.15 
B2FNX1 NADH-quinone oxidoreductase subunit I OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoI PE=3 SV=1 - [B2FNX1_STRMK] 0.004 0.23 
B2FNX2 NADH-quinone oxidoreductase subunit H OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoH PE=3 SV=1 - [B2FNX2_STRMK] 0.005 0.11 
B2FNX3 
Putative NADH-ubiquinone oxidoreductase, 75 kDa subunit OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoG PE=4 SV=1 - 
[B2FNX3_STRMK] 0.009 0.19 
B2FNX4 Putative NADH dehydrogenase I chain F OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoF PE=4 SV=1 - [B2FNX4_STRMK] 0.019 0.19 
B2FNX5 
Putative respiratory-chain NADH dehydrogenase I, 24 kDa subunit OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoE PE=4 SV=1 - 
[B2FNX5_STRMK] <0.05 >100 
B2FNX6 NADH-quinone oxidoreductase subunit D OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoD PE=3 SV=1 - [NUOD_STRMK] 0.003 0.32 
B2FNX7 NADH-quinone oxidoreductase subunit C OS=Stenotrophomonas maltophilia (strain K279a) GN=nuoC PE=3 SV=1 - [NUOC_STRMK] 0.001 0.21 





Putative general secretory pathway protein-export membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=secG PE=4 SV=1 - 
[B2FNY0_STRMK] 0.002 0.42 
B2FNY5 
Putative lipopolysaccharide core oligosaccharide biosynthesis protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3412 PE=4 SV=1 - 
[B2FNY5_STRMK] 0.010 0.31 
B2FNZ9 Aspartate-semialdehyde dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=asd PE=3 SV=1 - [B2FNZ9_STRMK] <0.05 0.44 
B2FP18 Putative endopeptidase O OS=Stenotrophomonas maltophilia (strain K279a) GN=pepO PE=4 SV=1 - [B2FP18_STRMK] 0.019 0.48 
B2FP46 Putative surface antigen exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4633 PE=4 SV=1 - [B2FP46_STRMK] 0.021 0.49 
B2FP53 Sec-independent protein translocase protein TatB OS=Stenotrophomonas maltophilia (strain K279a) GN=tatB PE=3 SV=1 - [B2FP53_STRMK] 0.008 0.40 
B2FP71 GTP cyclohydrolase 1 OS=Stenotrophomonas maltophilia (strain K279a) GN=folE PE=3 SV=1 - [B2FP71_STRMK] <0.05 >100 
B2FP87 Putative intercellular spreading VacJ lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4675 PE=4 SV=1 - [B2FP87_STRMK] 0.011 0.47 
B2FP99 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4687 PE=4 SV=1 - [B2FP99_STRMK] <0.05 >100 
B2FPA4 
Putative polysaccharide deacetylase family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4692 PE=4 SV=1 - 
[B2FPA4_STRMK] 0.012 0.41 
B2FPA5 Membrane protein insertase YidC OS=Stenotrophomonas maltophilia (strain K279a) GN=yidC PE=3 SV=1 - [YIDC_STRMK] 0.010 0.46 
B2FPC4 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0777 PE=4 SV=1 - [B2FPC4_STRMK] <0.05 0.19 
B2FPD1 Putative glycosyl transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0784 PE=4 SV=1 - [B2FPD1_STRMK] 0.019 0.47 
B2FPD9 Probable Na+ dependent nucleoside transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0792 PE=4 SV=1 - [B2FPD9_STRMK] 0.001 0.44 
B2FPE2 Putative exported heme receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=huvA PE=3 SV=1 - [B2FPE2_STRMK] 0.000 42.38 
B2FPE3 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0796 PE=4 SV=1 - [B2FPE3_STRMK] <0.05 >100 
B2FPE4 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0797 PE=4 SV=1 - [B2FPE4_STRMK] <0.05 >100 
B2FPF2 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0805 PE=4 SV=1 - [B2FPF2_STRMK] 0.006 0.39 
B2FPF9 Prolipoprotein diacylglyceryl transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=lgt PE=3 SV=1 - [LGT_STRMK] 0.010 0.43 
B2FPH9 Glutamine--tRNA ligase OS=Stenotrophomonas maltophilia (strain K279a) GN=glnS PE=3 SV=1 - [B2FPH9_STRMK] <0.05 0.08 
B2FPK0 
Putative repetitive protein with two-component sensor and regulator motifs OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2141 PE=4 
SV=1 - [B2FPK0_STRMK] 0.012 0.24 
B2FPM6 Putative calcineurin phosphoesterase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2170 PE=4 SV=1 - [B2FPM6_STRMK] <0.05 0.48 
B2FPN5 
Putative TonB-dependent outer membrane receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2179 PE=3 SV=1 - 
[B2FPN5_STRMK] 0.006 0.23 
B2FPP8 
Putative amino-acid transporter transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2193 PE=4 SV=1 - 
[B2FPP8_STRMK] 0.002 0.40 
B2FPQ0 Putative D-3-phosphoglycerate dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=serA PE=3 SV=1 - [B2FPQ0_STRMK] <0.05 >100 
B2FPR6 LPS-assembly lipoprotein LptE OS=Stenotrophomonas maltophilia (strain K279a) GN=lptE PE=3 SV=1 - [B2FPR6_STRMK] 0.008 0.46 
B2FPS0 
Putative exported LysM bacterial cell wall related protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3488 PE=4 SV=1 - 
[B2FPS0_STRMK] 0.004 0.28 
B2FPS1 
Putative transmembrane GGDEF transcriptional regulatory protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3489 PE=4 SV=1 - 
[B2FPS1_STRMK] <0.05 >100 
B2FPV6 Putative thiolase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3525 PE=3 SV=1 - [B2FPV6_STRMK] <0.05 0.37 
B2FPY0 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3550 PE=4 SV=1 - [B2FPY0_STRMK] 0.007 0.38 
B2FPY7 Putative alkyl hydroperoxide reductase subunit c OS=Stenotrophomonas maltophilia (strain K279a) GN=ahpC PE=4 SV=1 - [B2FPY7_STRMK] 0.000 7.71 




B2FQ15 Glutamyl-tRNA reductase OS=Stenotrophomonas maltophilia (strain K279a) GN=hemA PE=3 SV=1 - [HEM1_STRMK] <0.05 0.18 
B2FQ17 Outer-membrane lipoprotein LolB OS=Stenotrophomonas maltophilia (strain K279a) GN=lolB PE=3 SV=1 - [B2FQ17_STRMK] 0.038 0.48 
B2FQ28 Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0885 PE=3 SV=1 - [B2FQ28_STRMK] 0.005 0.41 
B2FQ31 Elongation factor Tu OS=Stenotrophomonas maltophilia (strain K279a) GN=tufB PE=3 SV=1 - [B2FQ31_STRMK] 0.001 3.65 
B2FQ33 Transcription termination/antitermination protein NusG OS=Stenotrophomonas maltophilia (strain K279a) GN=nusG PE=3 SV=1 - [B2FQ33_STRMK] 0.036 2.41 
B2FQ36 50S ribosomal protein L10 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplJ PE=3 SV=1 - [RL10_STRMK] 0.001 2.54 
B2FQ38 DNA-directed RNA polymerase subunit beta OS=Stenotrophomonas maltophilia (strain K279a) GN=rpoB PE=3 SV=1 - [RPOB_STRMK] 0.013 5.30 
B2FQ39 DNA-directed RNA polymerase subunit beta' OS=Stenotrophomonas maltophilia (strain K279a) GN=rpoC PE=3 SV=1 - [RPOC_STRMK] 0.006 7.89 
B2FQ42 Elongation factor G OS=Stenotrophomonas maltophilia (strain K279a) GN=fusA PE=3 SV=1 - [EFG_STRMK] 0.003 4.86 
B2FQ57 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2204 PE=4 SV=1 - [B2FQ57_STRMK] 0.049 0.47 
B2FQ62 Putative enoyl-CoA hydratase/isomerase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2209 PE=4 SV=1 - [B2FQ62_STRMK] <0.05 0.44 
B2FQ73 Transcription elongation factor GreA OS=Stenotrophomonas maltophilia (strain K279a) GN=greA PE=3 SV=1 - [B2FQ73_STRMK] <0.05 >100 
B2FQ89 Oxygen-dependent choline dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=betA PE=3 SV=1 - [BETA_STRMK] 0.007 0.35 
B2FQD9 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3569 PE=4 SV=1 - [B2FQD9_STRMK] <0.05 >100 
B2FQE1 Putative transmembrane sulfatase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3571 PE=4 SV=1 - [B2FQE1_STRMK] 0.004 0.22 
B2FQE3 
Putative angiotensin-converting enzyme like peptidyl dipeptidase protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3574 PE=4 
SV=1 - [B2FQE3_STRMK] 0.018 0.37 
B2FQH7 Citrate synthase OS=Stenotrophomonas maltophilia (strain K279a) GN=prpC PE=3 SV=1 - [B2FQH7_STRMK] <0.05 0.38 
B2FQJ2 
Putative two-component histidine kinase/response regulator fusion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3625 PE=4 
SV=1 - [B2FQJ2_STRMK] 0.040 0.41 
B2FQK3 50S ribosomal protein L15 OS=Stenotrophomonas maltophilia (strain K279a) GN=rplO PE=3 SV=1 - [B2FQK3_STRMK] 0.006 2.18 
B2FQK4 Protein translocase subunit SecY OS=Stenotrophomonas maltophilia (strain K279a) GN=secY PE=3 SV=1 - [B2FQK4_STRMK] 0.015 0.40 
B2FQK8 DNA-directed RNA polymerase subunit alpha OS=Stenotrophomonas maltophilia (strain K279a) GN=rpoA PE=3 SV=1 - [RPOA_STRMK] 0.002 3.72 
B2FQL7 Peptidyl-prolyl cis-trans isomerase OS=Stenotrophomonas maltophilia (strain K279a) GN=ppi PE=3 SV=1 - [B2FQL7_STRMK] 0.003 2.10 
B2FQL8 Malate dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=mdh PE=3 SV=1 - [MDH_STRMK] 0.000 3.96 
B2FQM3 Putative glutathione S-transferase OS=Stenotrophomonas maltophilia (strain K279a) GN=gst PE=4 SV=1 - [B2FQM3_STRMK] <0.05 >100 
B2FQN2 Putative 2-amino-3-ketobutyrate coenzyme A ligase OS=Stenotrophomonas maltophilia (strain K279a) GN=kbl PE=4 SV=1 - [B2FQN2_STRMK] <0.05 2.22 
B2FQN3 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0960 PE=4 SV=1 - [B2FQN3_STRMK] 0.003 0.33 
B2FQN4 L-threonine 3-dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=tdh PE=3 SV=1 - [TDH_STRMK] <0.05 >100 
B2FQQ5 
Putative isocitrate/isopropylmalate dehydrogenase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0982 PE=3 SV=1 - 
[B2FQQ5_STRMK] 0.001 4.75 
B2FQR3 ATP-dependent Clp protease ATP-binding subunit ClpX OS=Stenotrophomonas maltophilia (strain K279a) GN=clpX PE=3 SV=1 - [CLPX_STRMK] 0.025 2.39 
B2FQS5 Putative flagellar basal body-associated protein FliL OS=Stenotrophomonas maltophilia (strain K279a) GN=fliL PE=4 SV=1 - [B2FQS5_STRMK] <0.05 0.25 
B2FQU5 Putative flagellin OS=Stenotrophomonas maltophilia (strain K279a) GN=fliC PE=4 SV=1 - [B2FQU5_STRMK] 0.038 2.62 
B2FQU6 Putative flagellin OS=Stenotrophomonas maltophilia (strain K279a) GN=flaA PE=4 SV=1 - [B2FQU6_STRMK] 0.034 2.68 
B2FQY3 Thioredoxin reductase OS=Stenotrophomonas maltophilia (strain K279a) GN=trxB PE=3 SV=1 - [B2FQY3_STRMK] <0.05 >100 
B2FR07 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3644 PE=4 SV=1 - [B2FR07_STRMK] <0.05 >100 




B2FR42 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3680 PE=4 SV=1 - [B2FR42_STRMK] 0.024 0.42 
B2FR45 Putative O-antigen related protein OS=Stenotrophomonas maltophilia (strain K279a) GN=wbpV PE=4 SV=1 - [B2FR45_STRMK] 0.017 0.46 
B2FR62 Putative autotransporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1001 PE=4 SV=1 - [B2FR62_STRMK] <0.05 0.04 
B2FR74 Putative DNA polymerase III subunit Tau OS=Stenotrophomonas maltophilia (strain K279a) GN=dnaX PE=4 SV=1 - [B2FR74_STRMK] <0.05 0.48 
B2FR82 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1022 PE=4 SV=1 - [B2FR82_STRMK] 0.001 0.20 
B2FR90 Acyl carrier protein OS=Stenotrophomonas maltophilia (strain K279a) GN=acpP PE=3 SV=1 - [B2FR90_STRMK] <0.05 >100 
B2FR91 3-oxoacyl-[acyl-carrier-protein] synthase 2 OS=Stenotrophomonas maltophilia (strain K279a) GN=fabF PE=3 SV=1 - [B2FR91_STRMK] <0.05 >100 
B2FRC4 Putative TonB-dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1067 PE=3 SV=1 - [B2FRC4_STRMK] 0.024 3.11 
B2FRE3 Putative esterase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2353 PE=4 SV=1 - [B2FRE3_STRMK] <0.05 >100 
B2FRE4 Putative ATP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2354 PE=4 SV=1 - [B2FRE4_STRMK] <0.05 >100 
B2FRE5 
Putative binding-protein-dependent transport lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2355 PE=4 SV=1 - 
[B2FRE5_STRMK] 0.000 19.84 
B2FRE6 
Putative FecCD-family transmembrane transport protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2356 PE=4 SV=1 - 
[B2FRE6_STRMK] <0.05 >100 
B2FRE7 Hemin import ATP-binding protein HmuV OS=Stenotrophomonas maltophilia (strain K279a) GN=hmuV PE=3 SV=1 - [B2FRE7_STRMK] <0.05 >100 
B2FRM8 Putative peptidoglycan-associated lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3703 PE=3 SV=1 - [B2FRM8_STRMK] 0.005 0.42 
B2FRN1 Putative TolR-related protein OS=Stenotrophomonas maltophilia (strain K279a) GN=tolR PE=3 SV=1 - [B2FRN1_STRMK] 0.013 0.42 
B2FRN2 Putative TolQ transport transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=tolQ PE=3 SV=1 - [B2FRN2_STRMK] 0.018 0.35 
B2FRR0 Putative lipoprotein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3739 PE=4 SV=1 - [B2FRR0_STRMK] 0.001 0.39 
B2FRU0 Pyrroline-5-carboxylate reductase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1087 PE=3 SV=1 - [B2FRU0_STRMK] <0.05 >100 
B2FRV6 
Putative MgtE/divalent cation transmembrane transporter protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1103 PE=4 SV=1 - 
[B2FRV6_STRMK] 0.028 0.47 
B2FRW5 Putative ABC transporter, ATP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1113 PE=4 SV=1 - [B2FRW5_STRMK] 0.014 0.50 
B2FRX9 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1127 PE=4 SV=1 - [B2FRX9_STRMK] 0.013 0.49 
B2FRZ2 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1140 PE=4 SV=1 - [B2FRZ2_STRMK] <0.05 14.83 
B2FRZ3 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1141 PE=4 SV=1 - [B2FRZ3_STRMK] <0.05 >100 
B2FRZ9 Putative iron transport receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1148 PE=3 SV=1 - [B2FRZ9_STRMK] 0.000 2.21 
B2FS06 Putative ABC transporter, ATP-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1155 PE=4 SV=1 - [B2FS06_STRMK] <0.05 2.41 
B2FS15 Putative histone-like protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1164 PE=4 SV=1 - [B2FS15_STRMK] 0.000 4.96 
B2FS22 Putative copper-transporting p-type ATPase OS=Stenotrophomonas maltophilia (strain K279a) GN=copF PE=3 SV=1 - [B2FS22_STRMK] <0.05 0.17 
B2FSD2 Putative transmembrane transporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3777 PE=4 SV=1 - [B2FSD2_STRMK] 0.014 0.41 
B2FSE0 Putative transmembrane symporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3785 PE=4 SV=1 - [B2FSE0_STRMK] 0.017 0.36 
B2FSE3 Putative HlyD-family secretion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=smeM PE=4 SV=1 - [B2FSE3_STRMK] 0.001 0.37 
B2FSE4 Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3789 PE=3 SV=1 - [B2FSE4_STRMK] 0.006 2.18 
B2FSE9 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3796 PE=4 SV=1 - [B2FSE9_STRMK] 0.001 0.28 
B2FSF0 Fructose-bisphosphate aldolase OS=Stenotrophomonas maltophilia (strain K279a) GN=alf1 PE=3 SV=1 - [B2FSF0_STRMK] 0.000 2.71 
B2FSF3 Phosphoglycerate kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=pgk PE=3 SV=1 - [PGK_STRMK] <0.05 3.06 




B2FSF7 Putative outer membrane Omp family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3805 PE=4 SV=1 - [B2FSF7_STRMK] 0.045 0.10 
B2FSF8 Putative endonuclease P1 OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3806 PE=4 SV=1 - [B2FSF8_STRMK] 0.004 0.45 
B2FSG4 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3812 PE=4 SV=1 - [B2FSG4_STRMK] 0.016 0.38 
B2FSG6 
Putative transmembrane sodium-dicarboxylate family transporter protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3814 PE=4 
SV=1 - [B2FSG6_STRMK] 0.025 0.42 
B2FSH0 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3818 PE=4 SV=1 - [B2FSH0_STRMK] <0.05 0.46 
B2FSH4 Putative pilP protein (Type 4 fimbrial biogenesis protein) OS=Stenotrophomonas maltophilia (strain K279a) GN=pilP PE=4 SV=1 - [B2FSH4_STRMK] <0.05 0.32 
B2FSH6 
Putative PilN protein (Type 4 fimbrial biogenesis protein) OS=Stenotrophomonas maltophilia (strain K279a) GN=pilN PE=4 SV=1 - 
[B2FSH6_STRMK] <0.05 0.35 
B2FSH7 
Putative PilM protein (Type 4 fimbrial biogenesis protein) OS=Stenotrophomonas maltophilia (strain K279a) GN=pilM PE=4 SV=1 - 
[B2FSH7_STRMK] 0.038 0.21 
B2FSJ9 Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1175 PE=4 SV=1 - [B2FSJ9_STRMK] <0.05 >100 
B2FSN4 Putative transmembrane phosphoesterase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1210 PE=4 SV=1 - [B2FSN4_STRMK] 0.017 0.31 
B2FSQ7 
Putative TonB-dependent receptor for Fe(III)-coprogen, Fe(III)-ferrioxamine B and Fe(III)-rhodotrulic acid OS=Stenotrophomonas maltophilia (strain 
K279a) GN=Smlt1233 PE=3 SV=1 - [B2FSQ7_STRMK] 0.000 41.01 
B2FT31 Putative ACR family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3869 PE=4 SV=1 - [B2FT31_STRMK] 0.014 0.44 
B2FT45 Putative transmembrane DedA family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3883 PE=4 SV=1 - [B2FT45_STRMK] 0.030 0.50 
B2FT59 Putative extracellular heme-binding protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3898 PE=3 SV=1 - [B2FT59_STRMK] 0.000 8.18 
B2FT63 Inorganic pyrophosphatase OS=Stenotrophomonas maltophilia (strain K279a) GN=ppa PE=3 SV=1 - [B2FT63_STRMK] <0.05 2.30 
B2FT66 Putative TonB dependent receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3905 PE=3 SV=1 - [B2FT66_STRMK] 0.014 0.44 
B2FT80 DNA polymerase III subunit beta OS=Stenotrophomonas maltophilia (strain K279a) GN=dnaN PE=4 SV=1 - [B2FT80_STRMK] <0.05 >100 
B2FT86 Conserved hypothetical TPR repeat family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0008 PE=4 SV=1 - [B2FT86_STRMK] 0.000 4.78 
B2FT87 
Putative proline-rich TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0009 PE=4 SV=1 - 
[B2FT87_STRMK] 0.006 0.34 
B2FTA3 Putative exported peptidase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1246 PE=4 SV=1 - [B2FTA3_STRMK] 0.033 2.06 
B2FTA8 Probable septum site-determining protein MinC OS=Stenotrophomonas maltophilia (strain K279a) GN=minC PE=3 SV=1 - [B2FTA8_STRMK] <0.05 2.27 
B2FTD0 UvrABC system protein A OS=Stenotrophomonas maltophilia (strain K279a) GN=uvrA PE=3 SV=1 - [B2FTD0_STRMK] <0.05 0.45 
B2FTJ0 Isoleucine--tRNA ligase OS=Stenotrophomonas maltophilia (strain K279a) GN=ileS PE=3 SV=1 - [SYI_STRMK] <0.05 2.17 
B2FTK5 Putative ferric siderophore receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2650 PE=3 SV=1 - [B2FTK5_STRMK] <0.05 5.09 
B2FTN0 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2678 PE=4 SV=1 - [B2FTN0_STRMK] <0.05 0.32 
B2FTR3 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2712 PE=4 SV=1 - [B2FTR3_STRMK] <0.05 >100 
B2FTR4 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2713 PE=4 SV=1 - [B2FTR4_STRMK] <0.05 >100 
B2FTR5 
Putative TonB dependent protein, possible siderophore receptor OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2714 PE=3 SV=1 - 
[B2FTR5_STRMK] <0.05 >100 
B2FTS4 Uncharacterized protein OS=Stenotrophomonas maltophilia (strain K279a) GN=pcm PE=4 SV=1 - [B2FTS4_STRMK] 0.007 0.38 
B2FTS5 Protein CyaE OS=Stenotrophomonas maltophilia (strain K279a) GN=tolC PE=3 SV=1 - [B2FTS5_STRMK] 0.001 0.25 
B2FTS8 Putative lipid A biosynthesis lauroyl acyltransferase OS=Stenotrophomonas maltophilia (strain K279a) GN=htrB PE=4 SV=1 - [B2FTS8_STRMK] 0.017 0.44 
B2FTT7 Putative porin P (Outer membrane protein d1) OS=Stenotrophomonas maltophilia (strain K279a) GN=oprP PE=4 SV=1 - [B2FTT7_STRMK] 0.007 0.45 




B2FTV7 Conserved hypothetical exported protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3964 PE=4 SV=1 - [B2FTV7_STRMK] 0.024 0.38 
B2FTY9 
Putative endonuclease/exonuclease/phosphatase family protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt3995 PE=4 SV=1 - 
[B2FTY9_STRMK] <0.05 0.36 
B2FU12 Putative iron transporter protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0049 PE=3 SV=1 - [B2FU12_STRMK] 0.049 5.51 
B2FU40 Putative patatin-like phospholipase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0080 PE=4 SV=1 - [B2FU40_STRMK] 0.005 0.42 
B2FU42 Putative TonB dependent receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0083 PE=3 SV=1 - [B2FU42_STRMK] 0.001 0.24 
B2FU43 Acid phosphatase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt0084 PE=3 SV=1 - [B2FU43_STRMK] 0.000 0.20 
B2FU51 Thymidine kinase OS=Stenotrophomonas maltophilia (strain K279a) GN=tdk PE=3 SV=1 - [B2FU51_STRMK] <0.05 >100 
B2FU87 Putative transmembrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1346 PE=4 SV=1 - [B2FU87_STRMK] 0.012 0.32 
B2FU91 Putative outer membrane autotransporter OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1350 PE=4 SV=1 - [B2FU91_STRMK] <0.05 >100 
B2FUA1 Putative quinol oxidase subunit 1 OS=Stenotrophomonas maltophilia (strain K279a) GN=qoxB PE=3 SV=1 - [B2FUA1_STRMK] 0.011 0.32 
B2FUA6 
Putative chaperone protein HtpG (Heat shock protein HtpG) OS=Stenotrophomonas maltophilia (strain K279a) GN=htpG PE=4 SV=1 - 
[B2FUA6_STRMK] <0.05 0.36 
B2FUD9 Putative HlyD family secretion protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1406 PE=4 SV=1 - [B2FUD9_STRMK] 0.011 0.43 
B2FUF0 Putative nucleotide sugar transaminase OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt1417 PE=3 SV=1 - [B2FUF0_STRMK] <0.05 >100 
B2FUL1 Putative respiratory nitrate reductase subunit OS=Stenotrophomonas maltophilia (strain K279a) GN=narH PE=4 SV=1 - [B2FUL1_STRMK] 0.018 0.28 
B2FUN9 
Putative TonB-dependent receptor for Fe(III)-coprogen, Fe(III)-ferrioxamine B and Fe(III)-rhodotrulic acid OS=Stenotrophomonas maltophilia (strain 
K279a) GN=fhuE PE=3 SV=1 - [B2FUN9_STRMK] 0.000 13.58 
B2FUR1 
Putative TonB-dependent outer membrane receptor protein OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt4026 PE=3 SV=1 - 
[B2FUR1_STRMK] 0.001 0.13 
B2FUT3 Putative exported rare lipoprotein A OS=Stenotrophomonas maltophilia (strain K279a) GN=rlpA PE=3 SV=1 - [B2FUT3_STRMK] 0.001 0.27 
B2FUT4 Putative murein hydrolase OS=Stenotrophomonas maltophilia (strain K279a) GN=mltB PE=4 SV=1 - [B2FUT4_STRMK] 0.011 0.46 
B2FUT9 Putative rod shape-determining protein OS=Stenotrophomonas maltophilia (strain K279a) GN=mreC PE=4 SV=1 - [B2FUT9_STRMK] 0.009 0.44 
B2FUV1 Putative multidrug resistance outer membrane protein OS=Stenotrophomonas maltophilia (strain K279a) GN=smeF PE=4 SV=1 - [B2FUV1_STRMK] 0.002 0.39 
B2FUV2 Putative acriflavin resistance protein B OS=Stenotrophomonas maltophilia (strain K279a) GN=smeE PE=4 SV=1 - [B2FUV2_STRMK] 0.013 0.31 







7 General discussion 
 
A major aim of this work was to test the efficacy of last-line and experimental 
antimicrobials by taking advantage of the better understanding of the mechanisms of 
resistance in S. maltophilia obtained through parallel work characterising novel 
resistance mechanisms. By performing this, we have managed to highlight the 
importance of surveying this particular bacterium for it is an extremely interesting 
model to study antimicrobial resistance given the presence of multiple intrinsic 
mechanisms  but foremost for its increasing prevalence during the last few decades in 
severely debilitated and cystic fibrosis patients.  
The initial aim of the project was to characterise mechanism of resistance 
against some antimicrobial alternatives to co-trimoxazole for treating S. maltophilia 
infections that include: ceftazidime, amikacin, moxifloxacin, levofloxacin, and 
minocyline. In Chapter 3, the aim was to characterise ceftazidime resistant mutants. 
Whole genome sequencing allowed to find a novel cause of β-lactamase 
hyperproduction. The mpl gene that encodes a murein protein ligase also known as 
UDP-N-acetylmuramate:L-alanyl-gamma-D-glutamyl-meso-diaminopimelate ligase was 
found to have a loss of function mutation that affects the joining of the polypeptide 
(356) released during cell wall recycling to UDP-N-acetylmuramate. When we 
assessed the role of mpl in β-lactamase activity and consequently in ceftazidime 
resistance, trans-complementation with the wild-type version of mpl returned β-
lactamase activity to basal levels and restored susceptibility to ceftazidime. Therefore, 
we hypothesised that mpl loss will trigger accumulation of the penta-peptides which 
ultimately inhibit activity of the amidase, AmpD, despite the degradation of those 
penta-peptides by peptidases such as LdcA, MpaA, Ycjl and PepD (222). Losing 
AmpD activity will affect the release of penta-peptide from the muropeptide and 
generate an increased presence of the anhydro-muramyl-penta-peptide which act as 
an activator ligand for the transcriptional regulator of L2 and L1. Interestingly, mpl 
mutations were not only common in laboratory selected β-lactamase hyperproducing 
mutants (30% of the cases) but more important in clinical isolates (75%). In 
P. aeruginosa isolates recovered from cystic fibrosis patients and patients with 
ventilator associated pneumonia, mpl loss has been observed (238) but the 
significance of this finding has been underestimated. In our small collection of P. 
aeruginosa clinical isolates 40% carried an mpl mutation. Therefore, we concluded that 




P. aeruginosa, and that loss might arise during a long-term β-lactam therapy in infected 
patients.  
Following the aim of Chapter 3, we then moved on to the characterisation of 
non-β-lactamase hyperproducers. This time it was the combination of whole genome 
sequencing and comparative proteomics the strategy that helped us to propose a 
totally novel mechanism of ceftazidime resistance. Initial antimicrobial characterisation 
showed pan β-lactam resistance despite exhibiting basal level of β-lactamase activity. 
When using dye accumulation assays to test envelope permeability, we found 
reduction. It is important to mention that the cellular membrane of S. maltophilia is 
inherently less permeable when compared to other bacteria due to its reduced number 
of porins (245), so that might explain why there are no reports of loss of function porin 
mutations that explain reduced antibiotic uptake and why reduction in permeability 
observed in non-β-lactamase producers might be explained by a different reason other 
than porin reduction. Analysis of whole genome sequencing showed mutations within 
the proline-rich TonB energy transducer Smlt0009. Knock out of the gene caused 
ceftazidime resistance. Therefore, we hypothesize that losing the proline rich TonB 
energy transducer impedes energy transduction, generated through proton motive 
force, to enable the conformational shift of the ligand gated porin for the uptake of a 
broad range of substrates, including iron/siderophores and highly likely β-lactams or at 
least ceftazidime. In fact, when testing envelope permeability to a fluorescent dye in 
presence of ceftazidime, permeability decreased when the proline rich TonB energy 
transducer was intact – suggesting competition for import - but permeability remained 
the same when the proline rich TonB energy transducer was altered – suggesting lack 
of ceftazidime import, and so lack of competition with the dye. Proteomics confirmed 
downregulation of the proline rich TonB energy transducer but upregulation of proteins 
involved in siderophore synthesis. When testing phenotypically, we did observe more 
siderophore production in the non-β-lactamase hyperproducers which is likely to be in 
response to low iron uptake, a fundamental element for all forms of life (357). However, 
in terms of virulence, loss of the proline rich TonB energy transducer might not be 
significant advantageous. In order to test this it would be interesting to analyse the 
sequence of the proline rich TonB energy transducer of the many ceftazidime resistant 
non-β-lactamase hyperproducing clinical isolates identified in our worldwide collection.  
In Chapter 4 we aimed to gain a better understanding about the mechanisms 
of resistance involved in aminoglycoside, quinolone and tetracycline resistance. Whole 
envelope proteomics confirmed upregulation of smeYZ in the amikacin resistant profile 




(resistance profile 3). However, when analysing genome sequencing we found 
mutations in the rplA gene which encodes the ribosomal unit, L1. In P. aeruginosa, 
mutations in other ribosomal subunit genes have been found to induce expression of 
mexXY, the most common RND-efflux pump involved in aminoglycoside resistance in 
P. aeruginosa (358). In order to test if ribosomal damage was responsible of enhanced 
expression of smeYZ, we measured expression of smeYZ after induction with a 
ribosomal-acting antibiotic, the aminoglycoside gentamicin, and confirmed 
hyperexpression of smeYZ. Clinical implications of this finding is an increased 
virulence, given the physiological role of SmeYZ in motility, protease secretion, and 
biofilm formation. In fact, laboratory selected mutants exhibited increased swimming 
motility and an rplA mutation was found in a clinical isolate with resistance profile 3. 
Continuing with the physiological role of smeYZ, it has been suggested that its 
downregulation might be compensated by overexpression of smeDEF (180). In fact, 
this was a particular characteristic of resistant profile 1 mutants (resistant to quinolones 
and tetracyclines but susceptible to aminoglycosides) that according to proteomics 
SmeYZ was downregulated as SmeDEF was being upregulated. One of the reasons 
for SmeDEF hyperproduction was an activator mutation Thr84Pro in the local 
repressor SmeT, previously reported. Alternatively, a mutation found the 
glycosyltransferase (Gly368Ala) encoded by smlt0622, possibly involved in lipid 
synthesis, might trigger a different signal for SmeDEF constitutive production. These 
mutations might imply a different signal in the interplay between SmeSyRy, local 
regulator of SmeYZ, and SmeT, local regulator of SmeDEF to try to preserve or 
improve the infection potential.  
Continuing with quinolone resistance mechanisms, we then characterised a 
levofloxacin resistant mutant which also belonged to the previously mentioned 
resistance profile 1, generated as a derivative of a SmeDEF hyperproducer with a 
mutated glycosyltransferase. In the whole genome, we confirmed the mutation in the 
glycosyltransferase but also found a mutation in the Smlt2645-6 two-component 
system which is the first candidate to regulate the expression of an ABC transporter 
annotated as MacAB that according to proteomics results was upregulated. 
Complementation in trans with the mutated version of the operon containing the two-
component system proved to be sufficient to confer resistance to levofloxacin 
regardless the presence of a mutated glycosyltransferase. However, the mutation in 
the glycosyltransferase might ease the acquisition of the mutation in the two-





Despite our attempts to generate minocycline resistant mutants we could only 
obtain a second-step mutant with reduced susceptibility that fitted in the resistance 
profile 1. Two mutations were identified in the whole genome, one in a lauroyl 
acyltransferase and one in the Smlt1635-6 two-component system. The two 
component system is located next to a 10-component operon where the putative 
Smlt1640 ABC transporter is located and that according to proteomics is upregulated. 
An ABC transporter homologue in  E. coli has two binding sites, whilst one participates 
in lipid trafficking, the other is involved in drug transport (278). Other ABC transporters 
involved in lipid transport have been found to be associated with minocycline 
resistance. Upregulation of the mlaFEDCB operon which encodes the ABC transporter 
would be involved in decreased permeability to hydrophobic substrates such as 
minocycline (280) by a reduction of phospholipids in the outer leaftet of the outer 
membrane. According to proteomics there was also SmeDEF upregulation which has 
been found to be involved in tetracycline resistance (168). We could not find a common 
explanation for smeDEF upregulation. However, if we combine the mutation found in 
lauroyl acyltransferase and the glycosyltransferase, above mentioned, it seems 
possible to suggest that alterations in lipid synthesis might be a signal to induce 
smeDEF upregulation.  
Chapter 5 was built on the previous chapters where effectiveness of β-
lactamase inhibitors was assessed once we had a better understanding of the 
mechanism of resistance present in S. maltophilia. Establishing hydrolysis efficiency of 
both β-lactamases produced in S. maltophilia, L1 and L2, against some β-lactams led 
us to prove that ceftazidime showed to be only poorly hydrolysed by both enzymes, 
whilst meropenem was more efficiently hydrolysed by L1 and aztreonam by L2. In the 
cell, the poor hydrolytic activity either by low enzymatic affinity or slow enzymatic 
hydrolysis, is mainly compensated by β-lactamase hyperproduction (359) as shown in 
Chapter 3. Hence the need of efficient β-lactamase inhibitors. When testing the ability 
of clavulanic acid, avibactam and a recently designed bicyclic boronate to rescue β-
lactam activity from β-lactamase production; we observed that none of the inhibitors 
restored meropenem activity but all reversed aztreonam and ceftazidime resistance. In 
addition, its effectiveness is not reduced when cell permeability is altered by 
overproduction of the efflux-pumps SmeYZ and SmeDEF as described in Chapter 4. 
All observations combined concluded that inhibitors are effective but their activity is 
mainly exerted on the SBL, L2, but not on the MBL subclass 3, L1, predominantly 
based on the unrestored meropenem activity even the bicyclic boronate that had 




kinetically active against L2 with nanomolar potencies ranging from 5.25 to 22.3 nM, 
where bicyclic boronate exhibited the lowest; but not L1 even at milimolar 
concentrations of the inhibitor. Clavulanic acid was excluded for further analysis since 
it showed to induce L1 hyperproduction when compared to avibactam and bicyclic 
boronate 2. Analysing the structural basis for inhibition of L2 by the bicyclic boronate 2 
corroborated the covalent binding of both inhibitors in the active site. Bicyclic boronate 
2, showed a similar conformation when compared to the CTX-M-15:bicyclic boronate 1 
(310) complex including the tetrahedral boron atom and the fused bicyclic core with a 
slight variation in the amide/benzamide side chain. Avibactam, also showed a similar 
conformation when compared to other class A SBLs (CTX-M-15 (332), KPC-2 (331), 
SHV-1(331)) where avibactam is in an opened chair conformation to establish the 
carbamoyl-L2 complex with some differences establishing the importance of the 
Asn132 and Thr235 for interaction with avibactam in L2. Despite microbiological, 
kinetic, and structural confirmation of inhibition of L2 by avibactam and bicyclic 
boronate we predicted failure for the last-line combination ceftazidime/avibactam and 
ceftazidime/ bicyclic boronate since selected mutants will overcome their effectivity by 
L1 hyperproduction. However, we proposed aztreonam/avibactam and 
aztreonam/bicyclic boronate as alternatives to treat infections caused by β-lactamase 
hyperproduction. In the search of providing more choices to a possibly emerging L1 
production, other experimental MBL-inhibitors were tested. A phosphonate based 
inhibitor, 6-phosphonomethylpyridine-2-carboxylate, showed to be a promising 
scaffolding structure since its activity in the cell was not affected by overproduction of 
efflux pumps, at least SmeYZ; however the high concentrations required to inhibit L1, 
limit its use. Interestingly, recently designed rhodanine based inhibitors have shown 
nanomolar potencies (316) and here restored meropenem activity in the mutants 
described in Chapter 3 and 4 but not in those generated in Chapter 5 where 
aztreonam/avibactam and aztreonam/ bicyclic boronate 2 combinations were still 
effective. This highlights the importance of considering the administration of aztreonam 
in combination with a SBL inhibitor in S. maltophilia when β-lactamase hyperproduction 
is suspected as it has occurred in the treatment of infections caused by 
Enterobacteriaceae (340).  
In Chapter 6 we aimed to evaluate the antimicrobial activity of lactivicin 
derivatives against the mutants generated in Chapter 3, 4 and extensively drug 
resistant clinical isolates; and characterise possible emerging lactivicin resistance 
mechanisms. The antimicrobial potency of the lactivicin derivative carrying a catechol-




a collection of extensively drug resistant clinical isolates and the mutants described in 
Chapter 3 and 4. Even though, the lactivicin derivative showed to be hydrolysed by L1 
but not L2, L1 activity is too slow to abolish the antimicrobial activity of the LTV 
derivative. Recently it has been shown that S. maltophilia possesses the machinery to 
synthesize catechol-type siderophores (195, 249) which might explain the increased 
uptake of catechol based antibiotics.  However, it was interesting to find reduced LTV 
susceptibility in the mutants with loss of the TonB energy transducer described in 
Chapter 3. In fact, when selecting mutants with reduced susceptibility in presence of 
the LTV carrying the sideromimic modification, loss of the proline-rich region in the 
TonB energy transducer was found again. Additionally, whole envelope proteomics 
showed, downregulation of TonB energy transducer and increased siderophore 
production. This would add further evidence to the hypothesis stated in Chapter 3 
where loss of TonB energy transducer limits the uptake of myriad substances including 
ceftazidime and catechol-type siderophores involved in iron trafficking, and therefore 
catechol-based antimicrobials. In fact, reports suggest that diminished uptake of 
siderophore conjugated drugs is due to the presence of mutations in the LGP or the 
ferric uptake regulator (Fur) (351, 353). However, since there is no standardized 
breakpoint for lactivicin derivatives, it would be possible to consider that although its 
activity is diminished, still preserves good antimicrobial activity. Nevertheless, this 
finding is worth of consideration when designing siderophore based drugs.  
Future work for additional confirmation of the role on TonB energy transducer in 
ceftazidime resistance and lactivicin reduced susceptibility will include a survey of the 
sequence of smlt0009 in the many ceftazidime resistant clinical isolates identified that 
do not hyper-produce β-lactamase . In the case of levofloxacin resistant mutants and 
moxifloxacin and minocycline mutants with reduced susceptibility, it remains to be 
tested if the mutations found in the glycosyltransferase (encoded by smlt0622) and 
lauroyl acyltransferase (smlt4167) are enough to reduce susceptibility to levofloxacin 
and minocycline, respectively or if they have an interplay with the transcriptional 
regulator SmeT to trigger the upregulation of smeDEF. Testing this will involve the 
knock-out of both genes separately in a wild-type background or alternatively knocking-
out smeE in the mutants. For SmeYZ hyperproducers with reduced aminoglycoside 
susceptibility, it remains to be testes if the rplA mutation seen is enough to trigger 
reduction of aminoglycoside susceptibility or if the phenotype definitely requires the 
overproduction of the SmeYZ efflux-pump. This can be tested with complementation in 
trans with the wild type rplA gene or the mutated version in a background lacking the 




mutation was not sufficient to cause resistance on its own. To perform this it would be 
preferable the use of a vector with a non-ribosomal-acting selection marker which 
could be a tellurite cassette.  Despite applying different methods for analysing the 
genome sequence of the mutants generated in Chapter 5 we could not find an 
explanation for L1 hyperproduction, thus it would be preferable to re-sequence the 
genomes of the mutants and parent strain using long-read technology such as MinION. 
Since the search of a pan β-lactamase inhibitor will continue, it would be important to 
attempt generation and characterisation of mutants against the MBL inhibitors here 
mentioned to contribute to a rational design and propose new alternatives for treatment 
of S. maltophilia infections. It would be also interesting to find analogues of catechol 
conjugated lactivicins or other drugs.  
In conclusion, a lot of important and clinically relevant information has been 
identified about S. maltophilia in this study, and what we have learned will be 
particularly important for the progression of novel and/or current last resort agents 
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